<?xml version="1.0" encoding="UTF-8" ?>
<xliff srcLang="en-US" version="2.1" xmlns:mda="urn:oasis:names:tc:xliff:metadata:2.0" trgLang="it-IT /Volumes/SSD_1_ext/CODING/WeGentic/Weg-Translator-Tauri/weg-translator/Test.xlf" xmlns="urn:oasis:names:tc:xliff:document:2.0">
  <file original="/Volumes/SSD_1_ext/CODING/WeGentic/Weg-Translator-Tauri/weg-translator/Test.docx" id="1">
    <skeleton href="/Volumes/SSD_1_ext/CODING/WeGentic/Weg-Translator-Tauri/weg-translator/Test.docx.skl"/>
    <mda:metadata>
      <mda:metaGroup category="format">
        <mda:meta type="datatype">x-office</mda:meta>
      </mda:metaGroup>
      <mda:metaGroup category="document">
        <mda:meta type="original">word/document.xml</mda:meta>
      </mda:metaGroup>
      <mda:metaGroup category="tool">
        <mda:meta type="tool-id">OpenXLIFF</mda:meta>
        <mda:meta type="tool-name">OpenXLIFF Filters</mda:meta>
        <mda:meta type="tool-version">4.8.0 20250802_1047</mda:meta>
      </mda:metaGroup>
      <mda:metaGroup category="PI">
        <mda:meta type="encoding">UTF-8</mda:meta>
      </mda:metaGroup>
    </mda:metadata>
    <unit id="0">
      <segment id="0">
        <source xml:space="preserve">TRADUZIONE DEL TESTO DEL BREVETTO EUROPEO N. 3619324</source>
      </segment>
    </unit>
    <unit id="1">
      <segment id="1">
        <source xml:space="preserve">“RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THERAPEUTIC USES THEREOF”</source>
      </segment>
    </unit>
    <unit id="2">
      <segment id="2">
        <source xml:space="preserve">* * * * * * * *</source>
      </segment>
    </unit>
    <unit id="3">
      <segment id="3">
        <source xml:space="preserve">DESCRIZIONE</source>
      </segment>
    </unit>
    <unit id="4">
      <segment id="4">
        <source xml:space="preserve">FIELD OF THE INVENTION</source>
      </segment>
    </unit>
    <unit id="5">
      <segment id="5">
        <source xml:space="preserve">Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration of FGFs.</source>
      </segment>
    </unit>
    <unit id="6">
      <segment id="6">
        <source xml:space="preserve">BACKGROUND OF THE INVENTION</source>
      </segment>
    </unit>
    <unit id="7">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0001" w:id="2"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="2"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0002" w:id="3"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="3"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0003" w:id="4"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="4"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0004" w:id="5"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="5"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="7-0">
        <source xml:space="preserve">FGFs are large polypeptides widely expressed in developing and adult tissues (<ph id="ph1"/>Baird et al., Cancer Cells, 3:239-243, 1991<ph id="ph2"/>) and play roles in multiple physiological functions (<ph id="ph3"/>McKeehan et al., Prog.</source>
      </segment>
      <segment id="7-1">
        <source xml:space="preserve"> Nucleic Acid Res. Mol.</source>
      </segment>
      <segment id="7-2">
        <source xml:space="preserve"> Biol. 59:135-176, 1998<ph id="ph4"/>; <ph id="ph5"/>Burgess, W.</source>
      </segment>
      <segment id="7-3">
        <source xml:space="preserve"> H. et al., Annu Rev. Biochem.</source>
      </segment>
      <segment id="7-4">
        <source xml:space="preserve"> 58:575-606 (1989<ph id="ph6"/>).</source>
      </segment>
      <segment id="7-5">
        <source xml:space="preserve"> The FGF family includes at least twenty-two members (<ph id="ph7"/>Reuss et al., Cell Tissue Res. 313:139-157 (2003<ph id="ph8"/>)).</source>
      </segment>
    </unit>
    <unit id="8">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0001" w:id="7"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="7"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="8">
        <source xml:space="preserve">Modified FGFs and methods for using the same to treat or prevent ocular diseases, disorders or conditions in mammals are described in <ph id="ph1"/>WO 2015/048188 A2<ph id="ph2"/>.</source>
      </segment>
    </unit>
    <unit id="9">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0002" w:id="9"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="9"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="9">
        <source xml:space="preserve">Mutant FGF-1 proteins having mitogenic potency are described in <ph id="ph1"/>WO 2015/198175 A1<ph id="ph2"/>.</source>
      </segment>
    </unit>
    <unit id="10">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0003" w:id="11"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="11"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="10">
        <source xml:space="preserve">Synthetic genes which code for mature Human Acidic Fibroblast Growth Factor (aFGF) are described in <ph id="ph1"/>GB 2 223 496 A<ph id="ph2"/>.</source>
      </segment>
    </unit>
    <unit id="11">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="13"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="11">
        <source xml:space="preserve">WO 01/38357 A2<ph id="ph1"/> describes a novel Fibroblast Growth Factor (FGF), "JAFFA".</source>
      </segment>
    </unit>
    <unit id="12">
      <segment id="12">
        <source xml:space="preserve">SUMMARY OF THE INVENTION</source>
      </segment>
    </unit>
    <unit id="13">
      <segment id="13-0">
        <source xml:space="preserve">The invention is defined in the appended claims, and provides a recombinant modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="13-1">
        <source xml:space="preserve"> 1 with (i) an N-terminal methionine residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="13-2">
        <source xml:space="preserve"> 1, and (ii) at least the mutations:</source>
      </segment>
      <segment id="13-3">
        <source xml:space="preserve"> Cys16Ser, Ala66Cys, and Cys117Val with respect to the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="13-4">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="13-5">
        <source xml:space="preserve"> In some embodiments, the polypeptide further comprises an extension peptide positioned between the N-terminal methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="13-6">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="13-7">
        <source xml:space="preserve"> In some embodiments, the extension peptide comprises one or more amino acid residues of SEQ ID NO:</source>
      </segment>
      <segment id="13-8">
        <source xml:space="preserve"> 3.</source>
      </segment>
      <segment id="13-9">
        <source xml:space="preserve"> In some embodiments, the extension peptide comprises any one of the sequences set forth in SEQ ID NOS. 4-8.</source>
      </segment>
      <segment id="13-10">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide is the mature form of the polypeptide.</source>
      </segment>
      <segment id="13-11">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide comprises a sequence selected from SEQ ID NOS:</source>
      </segment>
      <segment id="13-12">
        <source xml:space="preserve"> 14-18.</source>
      </segment>
    </unit>
    <unit id="14">
      <segment id="14-0">
        <source xml:space="preserve">The disclosure also provides a recombinant modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="14-1">
        <source xml:space="preserve"> 1 with one or more mutations, wherein the polypeptide further comprises an extension peptide positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="14-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="14-3">
        <source xml:space="preserve"> The extension peptide may comprise one or more amino acids of SEQ ID NO:</source>
      </segment>
      <segment id="14-4">
        <source xml:space="preserve"> 3.</source>
      </segment>
      <segment id="14-5">
        <source xml:space="preserve"> The extension peptide may comprise any one of the sequences as set forth in SEQ ID NOS. 4-8.</source>
      </segment>
      <segment id="14-6">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be the mature form of the polypeptide.</source>
      </segment>
      <segment id="14-7">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence selected from SEQ ID NOS:</source>
      </segment>
      <segment id="14-8">
        <source xml:space="preserve"> 24-28.</source>
      </segment>
    </unit>
    <unit id="15">
      <segment id="15-0">
        <source xml:space="preserve">The disclosure further provides a recombinant modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="15-1">
        <source xml:space="preserve"> 1 with one or more mutations, wherein the polypeptide further comprises a truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="15-2">
        <source xml:space="preserve"> 1, and wherein the polypeptide comprises an extension peptide at the N-terminus of the polypeptide.</source>
      </segment>
      <segment id="15-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence selected from SEQ ID NOS:</source>
      </segment>
      <segment id="15-4">
        <source xml:space="preserve"> 93-117.</source>
      </segment>
      <segment id="15-5">
        <source xml:space="preserve"> The polypeptide may further comprise a methionine residue N-terminal to the extension peptide.</source>
      </segment>
      <segment id="15-6">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be the mature form of the polypeptide.</source>
      </segment>
      <segment id="15-7">
        <source xml:space="preserve"> In some embodiments of the invention, the modified FGF-1 polypeptide comprises a sequence selected from SEQ ID NOS:</source>
      </segment>
      <segment id="15-8">
        <source xml:space="preserve"> 118-141 and 207.</source>
      </segment>
      <segment id="15-9">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 136 amino acids.</source>
      </segment>
      <segment id="15-10">
        <source xml:space="preserve"> In some embodiments of the invention, the modified FGF-1 polypeptide comprises at least 141 amino acids in its mature form.</source>
      </segment>
    </unit>
    <unit id="16">
      <segment id="16-0">
        <source xml:space="preserve">The disclosure provides a recombinant modified FGF-1 polypeptide comprising a mutation at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="16-1">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="16-2">
        <source xml:space="preserve"> The polypeptide may further comprise a truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="16-3">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="16-4">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence selected from SEQ ID NOS:</source>
      </segment>
      <segment id="16-5">
        <source xml:space="preserve"> 146-149.</source>
      </segment>
      <segment id="16-6">
        <source xml:space="preserve"> The polypeptide may further comprise an extension peptide.</source>
      </segment>
      <segment id="16-7">
        <source xml:space="preserve"> The extension peptide may comprise one or more amino acid residues of SEQ ID NO:</source>
      </segment>
      <segment id="16-8">
        <source xml:space="preserve"> 3.</source>
      </segment>
      <segment id="16-9">
        <source xml:space="preserve"> The extension peptide fragment may comprise any one of the sequences set forth in SEQ ID NOS. 4-8.</source>
      </segment>
      <segment id="16-10">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be the mature form of the polypeptide.</source>
      </segment>
      <segment id="16-11">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence selected from SEQ ID NOS:</source>
      </segment>
      <segment id="16-12">
        <source xml:space="preserve"> 174-204.</source>
      </segment>
    </unit>
    <unit id="17">
      <segment id="17-0">
        <source xml:space="preserve">The disclosure additionally provides a recombinant modified FGF-1 polypeptide comprising a sequence as set forth in SEQ ID NO. 2.</source>
      </segment>
      <segment id="17-1">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be the mature form of the polypeptide.</source>
      </segment>
      <segment id="17-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise one or more mutations selected from the group consisting of:</source>
      </segment>
      <segment id="17-3">
        <source xml:space="preserve"> Cys16Ser, Ala66Cys, and Cys117Val.</source>
      </segment>
    </unit>
    <unit id="18">
      <segment id="18-0">
        <source xml:space="preserve">The disclosure provides a recombinant modified FGF-1 polypeptide, wherein the modified FGF-1 comprises one or more mutations of SEQ ID NO:</source>
      </segment>
      <segment id="18-1">
        <source xml:space="preserve"> 1, said mutation is selected from the group consisting of:</source>
      </segment>
      <segment id="18-2">
        <source xml:space="preserve"> Lys12Val, Cys16Ser, Ala66Cys, Cys117Val, and Pro134Val, and wherein the modified FGF-1 polypeptide further comprises at least one residue of the peptide ALTEK.</source>
      </segment>
    </unit>
    <unit id="19">
      <segment id="19-0">
        <source xml:space="preserve">The disclosure provides a recombinant modified FGF-1 polypeptide, comprising the following mutations of SEQ ID NO:</source>
      </segment>
      <segment id="19-1">
        <source xml:space="preserve"> 1:</source>
      </segment>
      <segment id="19-2">
        <source xml:space="preserve"> Cys16Ser, Ala66Cys, and Cys117Val, wherein the modified FGF-1 polypeptide comprises a methionine residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="19-3">
        <source xml:space="preserve"> 1, and at least one residue of the peptide ALTEK located between the N-terminal methionine and position 1 of SEQ ID NO:</source>
      </segment>
      <segment id="19-4">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="19-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may not be expressed with an extension peptide and may be produced by a method that does not involve a step of removing an extension peptide.</source>
      </segment>
    </unit>
    <unit id="20">
      <segment id="20-0">
        <source xml:space="preserve">In one embodiment of the invention there is provided a pharmaceutical composition comprising the recombinant polypeptide according to the present invention.</source>
      </segment>
      <segment id="20-1">
        <source xml:space="preserve"> In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent.</source>
      </segment>
      <segment id="20-2">
        <source xml:space="preserve"> In some embodiments, the pharmaceutical composition is a liquid ophthalmic formulation.</source>
      </segment>
      <segment id="20-3">
        <source xml:space="preserve"> In some embodiments, the pharmaceutical formulation is administered topically, microneedle into the cornea, or intracamerally.</source>
      </segment>
    </unit>
    <unit id="21">
      <segment id="21-0">
        <source xml:space="preserve">The disclosure provides a method for producing a recombinant modified FGF-1 polypeptide, the method comprising:</source>
      </segment>
      <segment id="21-1">
        <source xml:space="preserve"> expressing the modified FGF-1 polypeptide in a host cell and maturing the expressed polypeptide in the cytoplasm of the host cell, wherein the modified FGF-1 polypeptide comprises one or more mutations of SEQ ID NO:</source>
      </segment>
      <segment id="21-2">
        <source xml:space="preserve"> 1, and is expressed with an N-terminal methionine residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="21-3">
        <source xml:space="preserve"> 1.</source>
      </segment>
    </unit>
    <unit id="22">
      <segment id="22-0">
        <source xml:space="preserve">The disclosure also provides a method for producing a recombinant modified FGF-1 polypeptide, the method comprising:</source>
      </segment>
      <segment id="22-1">
        <source xml:space="preserve"> expressing the modified FGF-1 polypeptide in a host cell and maturing the expressed polypeptide in the cytoplasm of the host cell, wherein the modified FGF-1 polypeptide comprises one or more mutations of SEQ ID NO:</source>
      </segment>
      <segment id="22-2">
        <source xml:space="preserve"> 1, an extension peptide between the N-terminal residue and position 1 of SEQ ID NO:</source>
      </segment>
      <segment id="22-3">
        <source xml:space="preserve"> 1, and is expressed with an N-terminal methionine residue.</source>
      </segment>
    </unit>
    <unit id="23">
      <segment id="23-0">
        <source xml:space="preserve">The disclosure further provides a method for producing a recombinant modified FGF-1 polypeptide, the method comprising:</source>
      </segment>
      <segment id="23-1">
        <source xml:space="preserve"> expressing the modified FGF-1 polypeptide in a host cell and maturing the expressed polypeptide in the cytoplasm of the host cell, wherein the modified FGF-1 polypeptide comprises one or more mutations of SEQ ID NO:</source>
      </segment>
      <segment id="23-2">
        <source xml:space="preserve"> 1, an extension peptide fragment, a truncation of one or more of the first five residues of SEQ ID NO:1, and wherein the polypeptide is expressed with an N-terminal methionine residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="23-3">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="23-4">
        <source xml:space="preserve"> In some embodiments, the N-terminal methionine residue is retained during maturation of the polypeptide.</source>
      </segment>
      <segment id="23-5">
        <source xml:space="preserve"> Alternatively, the N-terminal methionine residue may be cleaved off of the polypeptide, by a cleavage enzyme, during maturation of the polypeptide.</source>
      </segment>
      <segment id="23-6">
        <source xml:space="preserve"> The cleavage enzyme may be methionine aminopeptidase (metAP).</source>
      </segment>
      <segment id="23-7">
        <source xml:space="preserve"> The metAP may be bacterial metAP, yeast metAP, or human metAP.</source>
      </segment>
      <segment id="23-8">
        <source xml:space="preserve"> The cleavage enzyme may be bacterial metAP.</source>
      </segment>
      <segment id="23-9">
        <source xml:space="preserve"> The method may comprise expressing a modified FGF-1 polypeptide comprising a sequence as set forth in SEQ ID NO:</source>
      </segment>
      <segment id="23-10">
        <source xml:space="preserve"> 14 or SEQ ID NO:</source>
      </segment>
      <segment id="23-11">
        <source xml:space="preserve"> 16.</source>
      </segment>
      <segment id="23-12">
        <source xml:space="preserve"> The method may comprise expressing a modified FGF-1 polypeptide comprising a sequence as set forth in SEQ ID NO:</source>
      </segment>
      <segment id="23-13">
        <source xml:space="preserve"> 2.</source>
      </segment>
      <segment id="23-14">
        <source xml:space="preserve"> SEQ ID NO:</source>
      </segment>
      <segment id="23-15">
        <source xml:space="preserve"> 2 may be the sequence of the polypeptide after maturation in the cytoplasm of the host cell.</source>
      </segment>
    </unit>
    <unit id="24">
      <segment id="24-0">
        <source xml:space="preserve">The disclosure provides a method for producing a recombinant modified FGF-1 polypeptide, the method comprising:</source>
      </segment>
      <segment id="24-1">
        <source xml:space="preserve"> expressing the modified FGF-1 polypeptide in a host cell and maturing the expressed polypeptide in the cytoplasm of the host cell, wherein the modified FGF-1 polypeptide comprises a mutation at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="24-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="24-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may further comprise an extension peptide fragment, and a truncation of one or more of the first five residues of SEQ ID NO:1, and the polypeptide may be expressed with an N-terminal methionine residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="24-4">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="24-5">
        <source xml:space="preserve"> The method may comprise cleavage of the N-terminal methionine residue using cyanogen bromide.</source>
      </segment>
    </unit>
    <unit id="25">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="25-0">
        <source xml:space="preserve">The disclosure also provides a method for producing a recombinant modified FGF-1 polypeptide according to any one of the above described embodiments, the method comprising:</source>
      </segment>
      <segment id="25-1">
        <source xml:space="preserve"> expressing the modified FGF-1 polypeptide in a host cell, binding the expressed polypeptide to an affinity material via an affinity tag; cleaving the affinity tag to release the polypeptide, and eluting the polypeptide from the affinity material using an agent.</source>
      </segment>
      <segment id="25-2">
        <source xml:space="preserve"> The affinity tag may comprise poly-histidine, poly-lysine, poly-aspartic acid, or poly-glutamic acid.</source>
      </segment>
      <segment id="25-3">
        <source xml:space="preserve"> The agent may comprise methanol, 2-propanol, or another alcohol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), acetone, or another organic solvent.</source>
      </segment>
      <segment id="25-4">
        <source xml:space="preserve"> The affinity material may be a resin framework.</source>
      </segment>
      <segment id="25-5">
        <source xml:space="preserve"> The affinity material may be an ion exchange resin.</source>
      </segment>
      <segment id="25-6">
        <source xml:space="preserve"> The polypeptide may be expressed in the cytoplasm of the host cell and may not be secreted into the periplasmic space.</source>
      </segment>
      <segment id="25-7">
        <source xml:space="preserve"> The host cell may be microbial.</source>
      </segment>
      <segment id="25-8">
        <source xml:space="preserve"> The microbial expression system may be selected from the group consisting of an <ph id="ph1"/>E. coli<ph id="ph2"/> expression system, a <ph id="ph3"/>Caulobacter crescent<ph id="ph4"/> expression system, and a <ph id="ph5"/>Proteus mirabilis<ph id="ph6"/> expression system.</source>
      </segment>
      <segment id="25-9">
        <source xml:space="preserve"> The microbial expression system may be an <ph id="ph7"/>E. coli<ph id="ph8"/> expression system.</source>
      </segment>
    </unit>
    <unit id="26">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="26-0">
        <source xml:space="preserve">One embodiment provides a recombinant modified FGF-1 according to the invention or a pharmaceutical composition according to the invention for use in a method of treating or preventing an ocular disease, disorder or condition , as set out in the claims.</source>
      </segment>
      <segment id="26-1">
        <source xml:space="preserve"> The ocular disease, disorder or condition may be a disease, disorder, or condition of the cornea or ocular surface.</source>
      </segment>
      <segment id="26-2">
        <source xml:space="preserve"> In some embodiments, the ocular disease, disorder or condition is a disease, disorder, or condition of the corneal endothelium.</source>
      </segment>
      <segment id="26-3">
        <source xml:space="preserve"> In some embodiments, the disease, disorder, or condition of the corneal endothelium is Fuch's dystrophy, bullous keratopathy, congenital hereditary endothelial dystrophy 1, congenital hereditary endothelial dystrophy 2, posterior polymorphous corneal dystrophy, or a dry eye syndrome.</source>
      </segment>
      <segment id="26-4">
        <source xml:space="preserve"> In some embodiments, the ocular disease, disorder or condition is Fuch's dystrophy.</source>
      </segment>
      <segment id="26-5">
        <source xml:space="preserve"> In some embodiments, the ocular disease, disorder or condition is a disease, disorder, or condition of the corneal epithelium.</source>
      </segment>
      <segment id="26-6">
        <source xml:space="preserve"> In some embodiments, the disease, disorder, or condition of the corneal epithelium is a dry eye syndrome or corneal epithelial damage from corneal surgery or transplantation.</source>
      </segment>
      <segment id="26-7">
        <source xml:space="preserve"> In some embodiments, the corneal surgery is photorefractive keratotomy (PRK) or laser-assisted <ph id="ph1"/>in situ<ph id="ph2"/> keratomileusis (LASIK).</source>
      </segment>
      <segment id="26-8">
        <source xml:space="preserve"> In some embodiments, the ocular disease, disorder or condition is a disease, disorder, or condition of the corneal stroma.</source>
      </segment>
      <segment id="26-9">
        <source xml:space="preserve"> In some embodiments, the disease, disorder, or condition of the corneal stroma is keratoconus, lattice corneal dystrophy, granular corneal dystrophy, macular corneal dystrophy, Schnyder crystalline corneal dystrophy, congenital stromal corneal dystrophy, or fleck corneal dystrophy.</source>
      </segment>
    </unit>
    <unit id="27">
      <segment id="27-0">
        <source xml:space="preserve">Also described is a method of transplanting corneal cells to a mammal or enhancing the success of cell transplantation comprising treating the corneal cells to be transplanted with a modified FGF-1 according to any one of the above described embodiments, prior to, during or after transplanting the corneal cells to the mammal.</source>
      </segment>
      <segment id="27-1">
        <source xml:space="preserve"> A method of preventing scarring during tissue regeneration comprising administering a modified FGF-1 according to any one of the above described embodiments is also described.</source>
      </segment>
      <segment id="27-2">
        <source xml:space="preserve"> The modified FGF-1 may be administered to a mammal after undergoing a trabeculectomy.</source>
      </segment>
      <segment id="27-3">
        <source xml:space="preserve"> Methods for treatment of the human or animal body by therapy do not form part of the claimed invention.</source>
      </segment>
    </unit>
    <unit id="28">
      <segment id="28-0">
        <source xml:space="preserve">One embodiment provides a recombinant modified FGF-1 polypeptide according to the invention for use in a method of treating or preventing a chemical or vesicant induced injury in a patient, as set out in the claims.</source>
      </segment>
      <segment id="28-1">
        <source xml:space="preserve"> In some embodiments, the chemical or vesicant induced injury is an ocular injury or a skin injury.</source>
      </segment>
      <segment id="28-2">
        <source xml:space="preserve"> In some embodiments, the ocular injury is a corneal injury.</source>
      </segment>
    </unit>
    <unit id="29">
      <segment id="29-0">
        <source xml:space="preserve">Also described is a method of treatment of corneal injury in a patient, the method comprising administering a modified FGF-1 polypeptide according to this disclosure or a pharmaceutical composition according to this disclosure, wherein the corneal injury is induced by a chemical or a vesicant, and wherein the administering the modified FGF-1 promotes regeneration of cornea, prevents degeneration of the cornea, and prevents long term sequelae to the chemical injury.</source>
      </segment>
      <segment id="29-1">
        <source xml:space="preserve"> The modified FGF-1 may be administered over a period of about 7 days to about 40 years to prevent degeneration of corneal tissue.</source>
      </segment>
      <segment id="29-2">
        <source xml:space="preserve"> The corneal tissue may comprise corneal epithelium, stroma, corneal endothelium, or corneal innervation.</source>
      </segment>
      <segment id="29-3">
        <source xml:space="preserve"> The corneal injury may be a stromal injury.</source>
      </segment>
      <segment id="29-4">
        <source xml:space="preserve"> The stromal injury may comprise stromal scarring and corneal opacity.</source>
      </segment>
    </unit>
    <unit id="30">
      <segment id="30-0">
        <source xml:space="preserve">One embodiment provides a recombinant modified FGF-1 polypeptide according to the invention or a pharmaceutical composition according to the invention for use in a method of preventing long-term corneal injury in a patient wherein the corneal injury is caused by a chemical or a vesicant agent.</source>
      </segment>
      <segment id="30-1">
        <source xml:space="preserve"> In some embodiments, the corneal injury is corneal endothelial injury.</source>
      </segment>
      <segment id="30-2">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide enhances the function of corneal endothelial cells and prevents or reduces long term degeneration of the cornea.</source>
      </segment>
      <segment id="30-3">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide prevents corneal edema and secondary anterior keratopathies.</source>
      </segment>
      <segment id="30-4">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide prevents loss of corneal endothelial cells.</source>
      </segment>
      <segment id="30-5">
        <source xml:space="preserve"> In some embodiments, the corneal injury is a stromal injury.</source>
      </segment>
      <segment id="30-6">
        <source xml:space="preserve"> In some embodiments, the stromal injury comprises stromal scarring and corneal opacity.</source>
      </segment>
      <segment id="30-7">
        <source xml:space="preserve"> In some embodiments, the corneal injury is mustard gas keratopathy (MGK).</source>
      </segment>
      <segment id="30-8">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide results in amelioration of histopathological conditions associated with MGK.</source>
      </segment>
      <segment id="30-9">
        <source xml:space="preserve"> In some embodiments, the histopathological conditions include hyperplasia of corneal epithelial layer and epithelial-stromal cell separation.</source>
      </segment>
      <segment id="30-10">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide results in reduction in edema and elimination of corneal erosions.</source>
      </segment>
      <segment id="30-11">
        <source xml:space="preserve"> In some embodiments, the corneal erosion is characterized by de-epithelialization of the cornea.</source>
      </segment>
      <segment id="30-12">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide reduces the severity of corneal de-epithelialization.</source>
      </segment>
      <segment id="30-13">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide results in faster re-epithelialization of the cornea.</source>
      </segment>
    </unit>
    <unit id="31">
      <segment id="31-0">
        <source xml:space="preserve">Also described is a method of regenerating ocular surface epithelium in a patient exposed to a chemical or a vesicant, the method comprising ocular administration of a modified FGF-1 polypeptide according to any one of the above described embodiments.</source>
      </segment>
      <segment id="31-1">
        <source xml:space="preserve"> The ocular surface epithelium may be corneal epithelium.</source>
      </segment>
    </unit>
    <unit id="32">
      <segment id="32-0">
        <source xml:space="preserve">One embodiment provides a recombinant modified FGF-1 polypeptide according to the invention for use in a method of preventing ocular epithelial injury in a patient exposed to a chemical or a vesicant, the method comprising ocular administration of the modified FGF-1 polypeptide .</source>
      </segment>
      <segment id="32-1">
        <source xml:space="preserve"> In some embodiments, the ocular injury is corneal injury caused by exposure to a vesicant.</source>
      </segment>
      <segment id="32-2">
        <source xml:space="preserve"> In some embodiments, the corneal injury is corneal epithelial detachment.</source>
      </segment>
      <segment id="32-3">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide results in reduction in the severity of corneal epithelial detachment following exposure to the vesicant.</source>
      </segment>
      <segment id="32-4">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide results in reduction in edema and elimination of corneal erosions.</source>
      </segment>
      <segment id="32-5">
        <source xml:space="preserve"> In some embodiments, the corneal erosion is characterized by de-epithelialization of the cornea.</source>
      </segment>
      <segment id="32-6">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide reduces the severity of corneal de-epithelialization.</source>
      </segment>
      <segment id="32-7">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide results in faster re-epithelialization of the cornea.</source>
      </segment>
      <segment id="32-8">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide is administered over a period of up to two weeks or until complete regeneration of the corneal epithelium.</source>
      </segment>
      <segment id="32-9">
        <source xml:space="preserve"> In some embodiments, a first dose of the modified FGF-1 polypeptide is administered within 48 hours after exposure to the vesicant.</source>
      </segment>
      <segment id="32-10">
        <source xml:space="preserve"> In some embodiments, the chemical comprises chlorine gas, phosgene, an alkali, or an acid.</source>
      </segment>
      <segment id="32-11">
        <source xml:space="preserve"> In some embodiments, the vesicant comprises sulfur mustard (SM), nitrogen mustard (NM), lewisite, or half mustard (2-chloroethyl ethyl sulfide (CEES)).</source>
      </segment>
      <segment id="32-12">
        <source xml:space="preserve"> In some embodiments, the vesicant is NM.</source>
      </segment>
      <segment id="32-13">
        <source xml:space="preserve"> In some embodiments, administering the modified FGF-1 polypeptide suppresses NM induced up-regulation of ADAM17.</source>
      </segment>
      <segment id="32-14">
        <source xml:space="preserve"> In some embodiments, the chemical or vesicant induced injury is chemical burn.</source>
      </segment>
      <segment id="32-15">
        <source xml:space="preserve"> In some embodiments, the chemical burn is caused by chlorine gas, phosgene, an alkali, or an acid.</source>
      </segment>
      <segment id="32-16">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprises mutations Cys16Ser, Ala66Cys, and Cys117Val, as set out in the claims.</source>
      </segment>
      <segment id="32-17">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide is less susceptible to oxidation upon exposure to a vesicant.</source>
      </segment>
      <segment id="32-18">
        <source xml:space="preserve"> In some embodiments, the vesicant is NM.</source>
      </segment>
    </unit>
    <unit id="33">
      <segment id="33-0">
        <source xml:space="preserve">One embodiment provides a recombinant modified FGF-1 polypeptide according to the invention or a pharmaceutical composition according to the invention for use in a method of treating herpetic keratopathy, as set out in the claims.</source>
      </segment>
      <segment id="33-1">
        <source xml:space="preserve"> In some embodiments, the herpetic keratopathy is caused by a primary infection by herpes simplex virus.</source>
      </segment>
      <segment id="33-2">
        <source xml:space="preserve"> In some embodiments, the herpetic keratopathy is a chronic herpetic keratopathy.</source>
      </segment>
      <segment id="33-3">
        <source xml:space="preserve"> In some embodiments, the herpetic keratopathy is secondary to an infection by herpes simplex virus.</source>
      </segment>
      <segment id="33-4">
        <source xml:space="preserve"> In some embodiments, the herpetic keratopathy that is secondary to an infection by herpes simplex virus comprises neurotrophic keratopathy.</source>
      </segment>
      <segment id="33-5">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide according to this disclosure or the pharmaceutical composition according to this disclosure is administered twice daily.</source>
      </segment>
      <segment id="33-6">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide according to this disclosure or the pharmaceutical composition according to this disclosure is administered for a duration of 30 days.</source>
      </segment>
      <segment id="33-7">
        <source xml:space="preserve"> In some embodiments, administration of the modified FGF-1 polypeptide according to any this disclosure or the pharmaceutical composition according to this disclosure results in healing of corneal ulcer, reduction of duration of pain and inflammation, reduction in pain and inflammation, reduction in corneal opacity, haze, scarring, or any combinations thereof.</source>
      </segment>
      <segment id="33-8">
        <source xml:space="preserve"> In some embodiments, the corneal ulcer comprises a herpetic corneal ulcer.</source>
      </segment>
      <segment id="33-9">
        <source xml:space="preserve"> In some embodiments, the mammal is a human.</source>
      </segment>
    </unit>
    <unit id="34">
      <segment id="34-0">
        <source xml:space="preserve">The disclosure provides a modified FGF-1 comprising one or more mutations of at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="34-1">
        <source xml:space="preserve"> 1 for use in a method of treating or preventing chemical or vesicant induced injury in a patient The chemical or vesicant induced injury may be an ocular injury or a skin injury.</source>
      </segment>
      <segment id="34-2">
        <source xml:space="preserve"> The ocular injury may be a corneal injury.</source>
      </segment>
    </unit>
    <unit id="35">
      <segment id="35-0">
        <source xml:space="preserve">The disclosure further provides a modified FGF-1 polypeptide comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="35-1">
        <source xml:space="preserve"> 1 for use in a method of treatment of corneal injury in a patient, wherein the corneal injury is induced by a chemical or a vesicant, and wherein the administering the modified FGF-1 promotes regeneration of cornea, prevents degeneration of the cornea, and prevents long term sequelae to the chemical injury.</source>
      </segment>
      <segment id="35-2">
        <source xml:space="preserve"> The modified FGF-1 may be administered over a period of about 7 days to about 40 years to prevent degeneration of corneal tissue.</source>
      </segment>
      <segment id="35-3">
        <source xml:space="preserve"> The corneal tissue may comprise corneal epithelium, stroma, corneal endothelium, or corneal innervation.</source>
      </segment>
      <segment id="35-4">
        <source xml:space="preserve"> The corneal injury may be a stromal injury.</source>
      </segment>
      <segment id="35-5">
        <source xml:space="preserve"> The stromal injury may comprise stromal scarring and corneal opacity.</source>
      </segment>
    </unit>
    <unit id="36">
      <segment id="36-0">
        <source xml:space="preserve">The disclosure additionally provides a modified FGF-1 polypeptide comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="36-1">
        <source xml:space="preserve"> 1 for use a method of preventing long-term corneal injury in a patient, wherein the corneal injury is caused by a chemical or a vesicant agent.</source>
      </segment>
      <segment id="36-2">
        <source xml:space="preserve"> The corneal injury may be a corneal endothelial injury.</source>
      </segment>
      <segment id="36-3">
        <source xml:space="preserve"> Administering the modified FGF-1 polypeptide may enhance the function of the corneal endothelial cells and may prevent or reduce long term degeneration of the cornea.</source>
      </segment>
      <segment id="36-4">
        <source xml:space="preserve"> Administering the modified FGF-1 polypeptide may prevent corneal edema and secondary anterior keratopathies.</source>
      </segment>
      <segment id="36-5">
        <source xml:space="preserve"> Administering the modified FGF-1 polypeptide may prevent loss of corneal endothelial cells.</source>
      </segment>
      <segment id="36-6">
        <source xml:space="preserve"> The corneal injury may be a stromal injury.</source>
      </segment>
      <segment id="36-7">
        <source xml:space="preserve"> The stromal injury may comprise stromal scarring and corneal opacity.</source>
      </segment>
      <segment id="36-8">
        <source xml:space="preserve"> The corneal injury may be mustard gas keratopathy (MGK).</source>
      </segment>
      <segment id="36-9">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may result in amelioration of histopathological conditions associated with MGK.</source>
      </segment>
      <segment id="36-10">
        <source xml:space="preserve"> Histopathological conditions may include hyperplasia of corneal epithelial layer and epithelial-stromal cell separation.</source>
      </segment>
      <segment id="36-11">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may result in reduction in edema and elimination of corneal erosions.</source>
      </segment>
      <segment id="36-12">
        <source xml:space="preserve"> The corneal erosion may be characterized by de-epithelialization of the cornea.</source>
      </segment>
      <segment id="36-13">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may reduce the severity of corneal de-epithelialization.</source>
      </segment>
      <segment id="36-14">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may result in faster re-epithelialization of the cornea.</source>
      </segment>
    </unit>
    <unit id="37">
      <segment id="37-0">
        <source xml:space="preserve">The disclosure provides a modified FGF-1 polypeptide comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="37-1">
        <source xml:space="preserve"> 1 for use in a method of regenerating ocular surface epithelium in a patient exposed to a chemical or a vesicant, the method comprising ocular administration of the modified FGF-1 polypeptide comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="37-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="37-3">
        <source xml:space="preserve"> The ocular surface epithelium is corneal epithelium.</source>
      </segment>
    </unit>
    <unit id="38">
      <segment id="38-0">
        <source xml:space="preserve">The disclosure further provides a modified FGF-1 polypeptide comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="38-1">
        <source xml:space="preserve"> 1 for use in a method of preventing ocular epithelial injury in a patient exposed to a chemical or a vesicant, the method comprising ocular administration of the modified FGF-1 polypeptide comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="38-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="38-3">
        <source xml:space="preserve"> The ocular injury may be corneal injury caused by exposure to a vesicant.</source>
      </segment>
      <segment id="38-4">
        <source xml:space="preserve"> The corneal injury may be corneal epithelial detachment.</source>
      </segment>
      <segment id="38-5">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may result in reduction in the severity of corneal epithelial detachment following exposure to the vesicant.</source>
      </segment>
      <segment id="38-6">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may result in reduction in edema and elimination of corneal erosions.</source>
      </segment>
      <segment id="38-7">
        <source xml:space="preserve"> The corneal erosion may be characterized by de-epithelialization of the cornea.</source>
      </segment>
      <segment id="38-8">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may reduce the severity of corneal de-epithelialization.</source>
      </segment>
      <segment id="38-9">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide may result in faster re-epithelialization of the cornea.</source>
      </segment>
      <segment id="38-10">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be administered over a period of up to two weeks or until complete regeneration of the corneal epithelium.</source>
      </segment>
      <segment id="38-11">
        <source xml:space="preserve"> A first dose of the modified FGF-1 polypeptide may be administered within 48 hours after exposure to the vesicant.</source>
      </segment>
      <segment id="38-12">
        <source xml:space="preserve"> The chemical may comprise chlorine gas, phosgene, an alkali, or an acid.</source>
      </segment>
      <segment id="38-13">
        <source xml:space="preserve"> The vesicant may comprise sulfur mustard (SM), nitrogen mustard (NM), lewisite, or half mustard (2-chloroethyl ethyl sulfide (CEES)).</source>
      </segment>
      <segment id="38-14">
        <source xml:space="preserve"> The vesicant may be NM.</source>
      </segment>
      <segment id="38-15">
        <source xml:space="preserve"> Administration of the modified FGF-1polypeptide may suppress NM induced up-regulation of ADAM17.</source>
      </segment>
      <segment id="38-16">
        <source xml:space="preserve"> The chemical or vesicant induced injury may be chemical burn.</source>
      </segment>
      <segment id="38-17">
        <source xml:space="preserve"> The chemical burn may be caused by chlorine gas, phosgene, an alkali, or an acid.</source>
      </segment>
      <segment id="38-18">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise mutations of positions 16, 66, and 117 of SEQ ID NO:</source>
      </segment>
      <segment id="38-19">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="38-20">
        <source xml:space="preserve"> The mutations may be Cys16Ser, Ala66Cys, and Cys117Val.</source>
      </segment>
      <segment id="38-21">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be less susceptible to oxidation upon exposure to a vesicant.</source>
      </segment>
      <segment id="38-22">
        <source xml:space="preserve"> The vesicant may be NM. the modified FGF-1 polypeptide may comprise a sequence as set forth in any one of SEQ ID NOs:</source>
      </segment>
      <segment id="38-23">
        <source xml:space="preserve"> 2, and 9-206.</source>
      </segment>
      <segment id="38-24">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence as set forth in any one of SEQ ID NOs:</source>
      </segment>
      <segment id="38-25">
        <source xml:space="preserve"> 2, and 9-204.</source>
      </segment>
      <segment id="38-26">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence as set forth in any one of SEQ ID NOs:</source>
      </segment>
      <segment id="38-27">
        <source xml:space="preserve"> 205 and 206.</source>
      </segment>
      <segment id="38-28">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence as set forth in SEQ ID NO:</source>
      </segment>
      <segment id="38-29">
        <source xml:space="preserve"> 2.</source>
      </segment>
      <segment id="38-30">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence as set forth in SEQ ID NO:</source>
      </segment>
      <segment id="38-31">
        <source xml:space="preserve"> 205.</source>
      </segment>
      <segment id="38-32">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence as set forth in SEQ ID NO:</source>
      </segment>
      <segment id="38-33">
        <source xml:space="preserve"> 206.</source>
      </segment>
    </unit>
    <unit id="39">
      <segment id="39-0">
        <source xml:space="preserve">The disclosure provides a modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID NOs:</source>
      </segment>
      <segment id="39-1">
        <source xml:space="preserve"> 205 and 206, or a pharmaceutical composition comprising the same for use in a method of treating herpetic keratopathy comprising administering to a mammal the modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID NOs:</source>
      </segment>
      <segment id="39-2">
        <source xml:space="preserve"> 205 and 206, or the pharmaceutical composition comprising the same.</source>
      </segment>
      <segment id="39-3">
        <source xml:space="preserve"> The herpetic keratopathy may be caused by a primary infection by herpes simplex virus.</source>
      </segment>
      <segment id="39-4">
        <source xml:space="preserve"> The herpetic keratopathy may be a chronic herpetic keratopathy.</source>
      </segment>
      <segment id="39-5">
        <source xml:space="preserve"> The herpetic keratopathy may be secondary to an infection by herpes simplex virus.</source>
      </segment>
      <segment id="39-6">
        <source xml:space="preserve"> The herpetic keratopathy that is secondary to an infection by herpes simplex virus may comprise neurotrophic keratopathy.</source>
      </segment>
      <segment id="39-7">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID Nos:</source>
      </segment>
      <segment id="39-8">
        <source xml:space="preserve"> 205 and 206, or a pharmaceutical composition comprising the same, may be administered twice daily.</source>
      </segment>
      <segment id="39-9">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID Nos:</source>
      </segment>
      <segment id="39-10">
        <source xml:space="preserve"> 205 and 206, or a pharmaceutical composition comprising the same, may be administered for a duration of 30 days.</source>
      </segment>
      <segment id="39-11">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID Nos:</source>
      </segment>
      <segment id="39-12">
        <source xml:space="preserve"> 205 and 206, or a pharmaceutical composition comprising the same, may result in healing of corneal ulcer, reduction of duration of pain and inflammation, reduction in pain and inflammation, reduction in corneal opacity, haze, scarring, or any combinations thereof.</source>
      </segment>
      <segment id="39-13">
        <source xml:space="preserve"> The corneal ulcer may comprise a herpetic corneal ulcer.</source>
      </segment>
    </unit>
    <unit id="40">
      <segment id="40-0">
        <source xml:space="preserve">The disclosure additionally provides a modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID NOs:</source>
      </segment>
      <segment id="40-1">
        <source xml:space="preserve"> 2 and 9-204, or a pharmaceutical composition comprising the same for use in a method of treating herpetic keratopathy comprising administering to a mammal the modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID NOs:</source>
      </segment>
      <segment id="40-2">
        <source xml:space="preserve"> 2 and 9-204, or the pharmaceutical composition comprising the same.</source>
      </segment>
      <segment id="40-3">
        <source xml:space="preserve"> The herpetic keratopathy may be caused by a primary infection by herpes simplex virus.</source>
      </segment>
      <segment id="40-4">
        <source xml:space="preserve"> The herpetic keratopathy may be a chronic herpetic keratopathy.</source>
      </segment>
      <segment id="40-5">
        <source xml:space="preserve"> The herpetic keratopathy may be secondary to an infection by herpes simplex virus.</source>
      </segment>
      <segment id="40-6">
        <source xml:space="preserve"> The herpetic keratopathy that is secondary to an infection by herpes simplex virus may comprise neurotrophic keratopathy.</source>
      </segment>
      <segment id="40-7">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID Nos:</source>
      </segment>
      <segment id="40-8">
        <source xml:space="preserve"> 2 and 9-204, or a pharmaceutical composition comprising the same, may be administered twice daily.</source>
      </segment>
      <segment id="40-9">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID Nos:</source>
      </segment>
      <segment id="40-10">
        <source xml:space="preserve"> 2 and 9-204, or a pharmaceutical composition comprising the same, may be administered for a duration of 30 days.</source>
      </segment>
      <segment id="40-11">
        <source xml:space="preserve"> Administration of the modified FGF-1 polypeptide comprising a sequence as set forth in any one of SEQ ID Nos:</source>
      </segment>
      <segment id="40-12">
        <source xml:space="preserve"> 2 and 9-204, or a pharmaceutical composition comprising the same, may result in healing of corneal ulcer, reduction of duration of pain and inflammation, reduction in pain and inflammation, reduction in corneal opacity, haze, scarring, or any combinations thereof. the corneal ulcer may comprise a herpetic corneal ulcer.</source>
      </segment>
      <segment id="40-13">
        <source xml:space="preserve"> The mammal may be a human.</source>
      </segment>
    </unit>
    <unit id="41">
      <segment id="41">
        <source xml:space="preserve">BRIEF DESCRIPTION OF DRAWINGS</source>
      </segment>
    </unit>
    <unit id="42">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="42">
        <source xml:space="preserve">Figure 1<ph id="ph1"/> illustrates the reaction of mustard gas with cysteine.</source>
      </segment>
    </unit>
    <unit id="43">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="43-0">
        <source xml:space="preserve">Figure 2<ph id="ph1"/> illustrates the effect of exemplary modified FGF-1 polypeptides (TTHX1114 and TTHX1001) according to the present disclosure on the <ph id="ph2"/>in vitro<ph id="ph3"/> proliferation of human corneal endothelial cells.</source>
      </segment>
      <segment id="43-1">
        <source xml:space="preserve"> The dotted line corresponds to TTHX1114 and the dashed line corresponds to TTHX1001.</source>
      </segment>
    </unit>
    <unit id="44">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="44">
        <source xml:space="preserve">Figure 3<ph id="ph1"/> illustrates an exemplary rabbit corneal organ culture model system.</source>
      </segment>
    </unit>
    <unit id="45">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="45">
        <source xml:space="preserve">Figure 4<ph id="ph1"/> shows a time course for vesicant injury to the cornea.</source>
      </segment>
    </unit>
    <unit id="46">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="46">
        <source xml:space="preserve">Figure 5<ph id="ph1"/> illustrates the effect of treatment with an exemplary modified FGF-1 polypeptide (TTHX114), upon vesicant induced injury, assessed by histopathological staining.</source>
      </segment>
    </unit>
    <unit id="47">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="47">
        <source xml:space="preserve">Figure 6<ph id="ph1"/> shows an exemplary histopathological grading scheme for assessing the effects of vesicant induced corneal injury.</source>
      </segment>
    </unit>
    <unit id="48">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="48-0">
        <source xml:space="preserve">Figure 7<ph id="ph1"/> shows histopathological grading of corneal and stromal injury upon vesicant exposure.</source>
      </segment>
      <segment id="48-1">
        <source xml:space="preserve"> The continuous like corresponds to "Epithelium," and the dashed line corresponds to 'Stroma."</source>
      </segment>
    </unit>
    <unit id="49">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="49-0">
        <source xml:space="preserve">Figure 8<ph id="ph1"/> shows reduced histopathological grading of vesicant injury in corneal cells treated with an exemplary modified FGF-1 polypeptide (TTHX1114).</source>
      </segment>
      <segment id="49-1">
        <source xml:space="preserve"> The dashed line corresponds to "NM" and the dotted line corresponds to "NM+ TTHX."</source>
      </segment>
    </unit>
    <unit id="50">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="50">
        <source xml:space="preserve">Figure 9<ph id="ph1"/> demonstrates corneal levels of FGF-1 following exposure to a vesicant.</source>
      </segment>
    </unit>
    <unit id="51">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="51-0">
        <source xml:space="preserve">Figure 10<ph id="ph1"/> illustrates the suppression of ADAM17 activation in corneal cells treated with an exemplary modified FGF-1 polypeptide (TTHX1114) after exposure to a vesicant.</source>
      </segment>
      <segment id="51-1">
        <source xml:space="preserve"> <ph id="ph2"/>Figure 10A<ph id="ph3"/> shows a corneal section which was not exposed to NM, and <ph id="ph4"/>Figure 10B<ph id="ph5"/> shows a comparison of exposed cornea with (lower panel) or without (upper panel) treatment with an exemplary polypeptide (TTHX1114).</source>
      </segment>
    </unit>
    <unit id="52">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="52-0">
        <source xml:space="preserve">Figure 11<ph id="ph1"/> illustrates the proliferation of corneal epithelial cells exposed to a vesicant and treated with an exemplary modified FGF-1 polypeptide (TTHX1114), measured by EdU incorporation.</source>
      </segment>
      <segment id="52-1">
        <source xml:space="preserve"> The dashed line corresponds to "NM" and the solid line corresponds to "NM+TTHX."</source>
      </segment>
    </unit>
    <unit id="53">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="53">
        <source xml:space="preserve">Figure 12<ph id="ph1"/> shows structures of exemplary vesicants.</source>
      </segment>
    </unit>
    <unit id="54">
      <segment id="54">
        <source xml:space="preserve">DETAILED DESCRIPTION</source>
      </segment>
    </unit>
    <unit id="55">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0005" w:id="44"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="44"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="55-0">
        <source xml:space="preserve">Diseases of and injuries to the eyes can be severely debilitating, and occur in a wide variety of forms.</source>
      </segment>
      <segment id="55-1">
        <source xml:space="preserve"> One class of ocular disease is mustard gas keratopathy.</source>
      </segment>
      <segment id="55-2">
        <source xml:space="preserve"> Mustard gas is a vesicant poisonous gas that was first released by the German Army on a battlefield at Ypres in April 1915 during World War I. Exposure to mustard gas can lead to long-term complications, which develop over the years.</source>
      </segment>
      <segment id="55-3">
        <source xml:space="preserve"> The cornea becomes scarred and irregular, and cholesterol and calcium are deposited in its tissues, resulting in progressive impairment of vision.</source>
      </segment>
      <segment id="55-4">
        <source xml:space="preserve"> Slit-lamp examination reveals that the episcleral tissues display a characteristic underglaze.</source>
      </segment>
      <segment id="55-5">
        <source xml:space="preserve"> White porcelain appearance and unusual vascular anomalies are common.</source>
      </segment>
      <segment id="55-6">
        <source xml:space="preserve"> These appear as enlarged, distorted vessels, sometimes with an ampulliform outline accompanied by varicosities and sausage-like vessels.</source>
      </segment>
      <segment id="55-7">
        <source xml:space="preserve"> With the passage of time, dense opacification of the cornea results, being most evident in the central and lower sections, as the upper portion has been protected by the overhanging eyelid.</source>
      </segment>
      <segment id="55-8">
        <source xml:space="preserve"> Predominant histopathological features of MGK include, for example, irregular epithelial thickness, degenerative changes, thickened epithelial basement membrane, keratocytes loss, and destroyed Bowman layer.</source>
      </segment>
      <segment id="55-9">
        <source xml:space="preserve"> (<ph id="ph1"/>Kanavi et al., Chronic and delayed mustard gas keratopathy:</source>
      </segment>
      <segment id="55-10">
        <source xml:space="preserve"> a histopathologic and immunohistochemical study, Eur.</source>
      </segment>
      <segment id="55-11">
        <source xml:space="preserve"> J Ophthalmol.</source>
      </segment>
      <segment id="55-12">
        <source xml:space="preserve"> 2010 Sep-Oct;20(5):839-43<ph id="ph2"/>).</source>
      </segment>
      <segment id="55-13">
        <source xml:space="preserve"> Typically, within one day of corneal vesicant exposure, the corneal epithelium (CE) sloughs from the basement membrane (BM), corneal edema develops in the denuded stroma and full-thickness keratocytosis is apparent within the wound margins.</source>
      </segment>
      <segment id="55-14">
        <source xml:space="preserve"> By five days, an epithelial cap is regenerated and corneal edema begins to subside.</source>
      </segment>
      <segment id="55-15">
        <source xml:space="preserve"> One week after exposure, the CE is partially stratified, with rudimentary hemidesmosomal attachments.</source>
      </segment>
      <segment id="55-16">
        <source xml:space="preserve"> Despite this apparent improvement, corneas develop clinical signatures of chronic injury as soon as three weeks after exposure, including persistently elevated corneal edema, recurring corneal erosions and neovascularization.</source>
      </segment>
      <segment id="55-17">
        <source xml:space="preserve"> By eight weeks, the basement membrane zone undergoes severe degeneration.</source>
      </segment>
      <segment id="55-18">
        <source xml:space="preserve"> Further, MGK affected corneas appear to exhibit delayed wound healing process.</source>
      </segment>
    </unit>
    <unit id="56">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="56">
        <source xml:space="preserve">The present disclosure provides modified FGF-1 polypeptides, pharmaceutical compositions and medicaments that include such modified peptides, and methods of using such modified FGF-1 polypeptides to treat various conditions, such as ocular disease, disorders and conditions (<ph id="ph1"/>e.g.<ph id="ph2"/>, Fuch's dystrophy), vesicant agent induced corneal epithelial and endothelial injuries (<ph id="ph3"/>e.g.,<ph id="ph4"/> Mustard Gas Keratopathy (MGK)), wound healing, cardiovascular diseases (<ph id="ph5"/>e.g.,<ph id="ph6"/> ischemia), and neurological conditions (<ph id="ph7"/>e.g.,<ph id="ph8"/> amylotrophic lateral sclerosis (ALS)).</source>
      </segment>
    </unit>
    <unit id="57">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="57-0">
        <source xml:space="preserve">The disclosure also provides a method of treating a chemical or vesicant induced injury by administering a modified fibroblast growth factors (FGF-1) polypeptides, or pharmaceutical composition or medicaments that include such modified peptides.</source>
      </segment>
      <segment id="57-1">
        <source xml:space="preserve"> The method may comprise treating mustard gas keratopathy (MGK), induced by a chemical injury, <ph id="ph1"/>e.g.,<ph id="ph2"/> a chemical burn, by administering modified FGF-1 polypeptides described herein.</source>
      </segment>
      <segment id="57-2">
        <source xml:space="preserve"> The method may comprise treating mustard gas keratopathy (MGK), induced by a vesicant, <ph id="ph3"/>e.g.,<ph id="ph4"/> nitrogen mustard (NM), by administering modified FGF-1 polypeptides described herein.</source>
      </segment>
      <segment id="57-3">
        <source xml:space="preserve"> The method may comprise treating a chemical or thermal injury caused by a chemical warfare agent, <ph id="ph5"/>e.g.,<ph id="ph6"/> phosgene.</source>
      </segment>
    </unit>
    <unit id="58">
      <segment id="58-0">
        <source xml:space="preserve">In some aspects of the disclosure, where the modified FGF-1 polypeptide is expressed with an N-terminal methionine (N-Met) residue, the polypeptide may be subsequently purified without a step requiring proteolytic cleavage for removal of an N-terminal peptide.</source>
      </segment>
      <segment id="58-1">
        <source xml:space="preserve"> Accordingly, the present disclosure provides a modified FGF-1 polypeptide that is prepared by a rapid purification method, without involving a proteolytic cleavage step for removal of an N-terminal peptide.</source>
      </segment>
      <segment id="58-2">
        <source xml:space="preserve"> This is particularly advantageous for production of the modified FGF-1 polypeptides per good manufacturing practice (GMP) guidelines.</source>
      </segment>
      <segment id="58-3">
        <source xml:space="preserve"> The advantages include the lack of a cleavage step, including eliminating the need for subsequent purification of the cleaved product and removal of the reagents used for cleavage.</source>
      </segment>
      <segment id="58-4">
        <source xml:space="preserve"> The further advantage of this is an increase in yield due to decreased handling and the alleviation of the need to test for residual cleavage reagents and contaminants introduced for the cleavage and subsequent separation of cleaved from uncleaved material.</source>
      </segment>
    </unit>
    <unit id="59">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="59">
        <source xml:space="preserve">The modified FGF-1 polypeptides described herein, can have increased stability (<ph id="ph1"/>e.g.<ph id="ph2"/> thermostability), reduced number of buried free thiols, and/or increased effective heparan sulfate proteoglycan (HSPG) affinity.</source>
      </segment>
    </unit>
    <unit id="60">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="60-0">
        <source xml:space="preserve">Several other advantages are associated with the use of the modified FGF-1 polypeptides in the methods described herein.</source>
      </segment>
      <segment id="60-1">
        <source xml:space="preserve"> For example, the modified FGF-1 polypeptides described herein can be administered without heparin in its pharmaceutical composition or formulation (<ph id="ph1"/>e.g.,<ph id="ph2"/> an ophthalmic formulation), avoiding potential safety issues related to its biologic origin.</source>
      </segment>
      <segment id="60-2">
        <source xml:space="preserve"> In addition, avoidance of heparin allows the use of higher doses of the modified FGF-1 polypeptides without complications resulting from local heparin-induced adverse events or preexisting anti-heparin antibodies.</source>
      </segment>
      <segment id="60-3">
        <source xml:space="preserve"> Furthermore, in the absence of heparin, immediate binding of the modified FGF to tissue is maximized and systemic distribution is significantly reduced.</source>
      </segment>
      <segment id="60-4">
        <source xml:space="preserve"> The modified FGF-1 polypeptides described herein are also advantage of having enhanced local sequestration and reduced redistribution kinetics, thus increasing the elimination half-life and mean residence time (MRT) at the site of delivery, and allowing for a reduced dosing frequency.</source>
      </segment>
      <segment id="60-5">
        <source xml:space="preserve"> This can be the result of modified FGF-1 polypeptides described herein that have increased stability (<ph id="ph3"/>e.g.<ph id="ph4"/> thermostability), reduced number of buried free thiols, and/or increased effective heparan sulfate proteoglycan (HSPG) affinity.</source>
      </segment>
    </unit>
    <unit id="61">
      <segment id="61-0">
        <source xml:space="preserve">The FGF-1 polypeptides of the present disclosure may comprise modifications at the N-terminus of the polypeptide, such as an addition, a truncation, or a combination of additions and truncations.</source>
      </segment>
      <segment id="61-1">
        <source xml:space="preserve"> The modification may be the addition of a single N-terminal methionine residue.</source>
      </segment>
      <segment id="61-2">
        <source xml:space="preserve"> The modification may be the addition of an extension peptide.</source>
      </segment>
      <segment id="61-3">
        <source xml:space="preserve"> The modification may be a truncation of one or more of the first five residues of a FGF-1 polypeptide.</source>
      </segment>
      <segment id="61-4">
        <source xml:space="preserve"> The FGF-1 polypeptides may comprise a sequence as set forth in SEQ ID NO:</source>
      </segment>
      <segment id="61-5">
        <source xml:space="preserve"> 1, with one or more mutations, in addition to the N-terminal modification.</source>
      </segment>
    </unit>
    <unit id="62">
      <segment id="62-0">
        <source xml:space="preserve">Several examples of the modified FGF-1 polypeptides disclosed herein comprise an N-terminal methionine (N-Met) residue in a mature form of the polypeptide.</source>
      </segment>
      <segment id="62-1">
        <source xml:space="preserve"> The retention of biological activity when amino acids are added to the N-terminus of a protein is unpredictable.</source>
      </segment>
      <segment id="62-2">
        <source xml:space="preserve"> Some proteins are tolerant of this and some are not, and the retention of biological activity and the potential for changes in stability are only determined empirically.</source>
      </segment>
      <segment id="62-3">
        <source xml:space="preserve"> The present disclosure identifies that the addition of N-terminal Met residues are tolerated with retention of biological activity and stability.</source>
      </segment>
    </unit>
    <unit id="63">
      <segment id="63">
        <source xml:space="preserve">Certain Terminology</source>
      </segment>
    </unit>
    <unit id="64">
      <segment id="64-0">
        <source xml:space="preserve">It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed.</source>
      </segment>
      <segment id="64-1">
        <source xml:space="preserve"> In this application, the use of the singular includes the plural unless specifically stated otherwise.</source>
      </segment>
      <segment id="64-2">
        <source xml:space="preserve"> It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.</source>
      </segment>
      <segment id="64-3">
        <source xml:space="preserve"> In this application, the use of "or" means "and/or" unless stated otherwise.</source>
      </segment>
      <segment id="64-4">
        <source xml:space="preserve"> Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting.</source>
      </segment>
    </unit>
    <unit id="65">
      <segment id="65-0">
        <source xml:space="preserve">The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.</source>
      </segment>
      <segment id="65-1">
        <source xml:space="preserve"> Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood to which the claimed subject matter belongs.</source>
      </segment>
      <segment id="65-2">
        <source xml:space="preserve"> In the event that there is a plurality of definitions for terms herein, those in this section prevail.</source>
      </segment>
      <segment id="65-3">
        <source xml:space="preserve"> Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet.</source>
      </segment>
      <segment id="65-4">
        <source xml:space="preserve"> Reference thereto evidences the availability and public dissemination of such information.</source>
      </segment>
    </unit>
    <unit id="66">
      <segment id="66-0">
        <source xml:space="preserve">As used herein, the term "Percent (%) amino acid sequence identity" with respect to a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.</source>
      </segment>
      <segment id="66-1">
        <source xml:space="preserve"> Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer softwares such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software.</source>
      </segment>
      <segment id="66-2">
        <source xml:space="preserve"> Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.</source>
      </segment>
    </unit>
    <unit id="67">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0006" w:id="56"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="56"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0007" w:id="57"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="57"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="67-0">
        <source xml:space="preserve">Definition of standard chemistry terms may be found in reference works, including but not limited to, <ph id="ph1"/>Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4TH ED."</source>
      </segment>
      <segment id="67-1">
        <source xml:space="preserve"> Vols.</source>
      </segment>
      <segment id="67-2">
        <source xml:space="preserve"> A (2000<ph id="ph2"/>) and <ph id="ph3"/>B (2001), Plenum Press, New York<ph id="ph4"/>.</source>
      </segment>
      <segment id="67-3">
        <source xml:space="preserve"> Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology.</source>
      </segment>
    </unit>
    <unit id="68">
      <segment id="68-0">
        <source xml:space="preserve">Unless specific definitions are provided, the nomenclature employed in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those recognized in the field.</source>
      </segment>
      <segment id="68-1">
        <source xml:space="preserve"> Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.</source>
      </segment>
      <segment id="68-2">
        <source xml:space="preserve"> Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection).</source>
      </segment>
      <segment id="68-3">
        <source xml:space="preserve"> Reactions and purification techniques can be performed e.g., using kits of manufacturer's specifications or as commonly accomplished in the art or as described herein.</source>
      </segment>
      <segment id="68-4">
        <source xml:space="preserve"> The foregoing techniques and procedures can be generally performed of conventional methods and as described in various general and more specific references that are cited and discussed throughout the present specification.</source>
      </segment>
    </unit>
    <unit id="69">
      <segment id="69-0">
        <source xml:space="preserve">It is to be understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein and as such may vary.</source>
      </segment>
      <segment id="69-1">
        <source xml:space="preserve"> It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods, compounds, compositions described herein.</source>
      </segment>
    </unit>
    <unit id="70">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="70-0">
        <source xml:space="preserve">The terms "treat," "treating" or "treatment" include alleviating, abating or ameliorating a disease, disorder or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease, disorder, or condition, <ph id="ph1"/>e.g.,<ph id="ph2"/> arresting the development of the disease, disorder or condition, relieving the disease, disorder or condition, causing regression of the disease, disorder or condition, relieving a condition caused by the disease, disorder or condition, or stopping the symptoms of the disease, disorder or condition.</source>
      </segment>
      <segment id="70-1">
        <source xml:space="preserve"> The terms "treat," "treating" or "treatment", include, but are not limited to, prophylactic and/or therapeutic treatments.</source>
      </segment>
    </unit>
    <unit id="71">
      <segment id="71">
        <source xml:space="preserve">The term "acceptable" or "pharmaceutically acceptable", with respect to a formulation, composition or ingredient, refers to having no persistent detrimental effect on the general health of the subject being treated or does not abrogate the biological activity or properties of the modified FGF described herein, and is relatively nontoxic.</source>
      </segment>
    </unit>
    <unit id="72">
      <segment id="72">
        <source xml:space="preserve">The term "amelioration" of the symptoms of a particular disease, disorder or condition by administration of a particular modified FGF or pharmaceutical composition refers to any lessening of severity, delay in onset, slowing of progression, or shortening of duration, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the modified FGF or pharmaceutical composition.</source>
      </segment>
    </unit>
    <unit id="73">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="73-0">
        <source xml:space="preserve">The term "combination" or "pharmaceutical combination" as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.</source>
      </segment>
      <segment id="73-1">
        <source xml:space="preserve"> The term "fixed combination" means that one active ingredient (<ph id="ph1"/>e.g.,<ph id="ph2"/> a modified FGF) and a co-agent are both administered to a patient simultaneously in the form of a single entity or dosage.</source>
      </segment>
      <segment id="73-2">
        <source xml:space="preserve"> The term "non-fixed combination" means that one active ingredient (<ph id="ph3"/>e.g.,<ph id="ph4"/> a modified FGF) and a co-agent are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two agents in the body of the patient.</source>
      </segment>
      <segment id="73-3">
        <source xml:space="preserve"> The latter also applies to cocktail therapy, <ph id="ph5"/>e.g.,<ph id="ph6"/> the administration of three or more active ingredients.</source>
      </segment>
    </unit>
    <unit id="74">
      <segment id="74-0">
        <source xml:space="preserve">The term "pharmaceutical composition" as used herein refers to one or more modified FGF-1 polypeptides with one or more other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.</source>
      </segment>
      <segment id="74-1">
        <source xml:space="preserve"> The pharmaceutical composition facilitates administration of the modified FGF-1 polypeptides to an organism.</source>
      </segment>
      <segment id="74-2">
        <source xml:space="preserve"> Multiple techniques of administering a modified FGF-1 polypeptide exist in the art including, but not limited to:</source>
      </segment>
      <segment id="74-3">
        <source xml:space="preserve"> topical, ophthalmic, intraocular, periocular, intravenous, oral, aerosol, parenteral, and administration.</source>
      </segment>
    </unit>
    <unit id="75">
      <segment id="75">
        <source xml:space="preserve">The term "carrier," as used herein, refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of an agent of interest (e.g., a modified FGF) into cells or tissues.</source>
      </segment>
    </unit>
    <unit id="76">
      <segment id="76-0">
        <source xml:space="preserve">The term "diluent" refers to chemical compounds that are used to dilute the agent of interest (e.g., a modified FGF) prior to delivery.</source>
      </segment>
      <segment id="76-1">
        <source xml:space="preserve"> Diluents can also be used to stabilize agents because they can provide a more stable environment.</source>
      </segment>
      <segment id="76-2">
        <source xml:space="preserve"> Salts dissolved in buffered solutions (which also can provide pH control or maintenance) are utilized as diluents in the art, including, but not limited to a phosphate buffered saline solution.</source>
      </segment>
    </unit>
    <unit id="77">
      <segment id="77">
        <source xml:space="preserve">The terms "co-administration" or the like, are meant to encompass administration of the selected agents (e.g., a modified FGF or composition thereof and a co-agent) to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.</source>
      </segment>
    </unit>
    <unit id="78">
      <segment id="78-0">
        <source xml:space="preserve">The terms "effective amount" or "therapeutically effective amount," refer to a sufficient amount of a modified FGF-1 polypeptide, agent, combination or pharmaceutical composition described herein administered which will relieve to some extent one or more of the symptoms of the disease, disorder or condition being treated.</source>
      </segment>
      <segment id="78-1">
        <source xml:space="preserve"> The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.</source>
      </segment>
      <segment id="78-2">
        <source xml:space="preserve"> For example, an "effective amount" for therapeutic uses is the amount of the modified FGF, agent, combination or pharmaceutical composition required to provide a desired pharmacologic effect, therapeutic improvement, or clinically significant decrease in disease symptoms without undue adverse side effects.</source>
      </segment>
      <segment id="78-3">
        <source xml:space="preserve"> An appropriate "effective amount" in any individual case may be determined using techniques, such as a dose escalation study.</source>
      </segment>
      <segment id="78-4">
        <source xml:space="preserve"> The term "therapeutically effective amount" includes, for example, a prophylactically effective amount.</source>
      </segment>
      <segment id="78-5">
        <source xml:space="preserve"> It is understood that "an effect amount" can vary from subject to subject due to variation in metabolism of the modified FGF, combination, or pharmaceutical composition, age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician.</source>
      </segment>
      <segment id="78-6">
        <source xml:space="preserve"> By way of example only, therapeutically effective amounts may be determined by routine experimentation, including but not limited to a dose escalation clinical trial.</source>
      </segment>
    </unit>
    <unit id="79">
      <segment id="79-0">
        <source xml:space="preserve">The term "prophylactically effective amount," refers that amount of a modified FGF, compound, agent, combination or pharmaceutical composition described herein applied to a patient which will relieve to some extent one or more of the symptoms of a disease, condition or disorder being treated.</source>
      </segment>
      <segment id="79-1">
        <source xml:space="preserve"> In such prophylactic applications, such amounts may depend on the patient's state of health, weight, and the like.</source>
      </segment>
      <segment id="79-2">
        <source xml:space="preserve"> It is considered well within the skill of the art for one to determine such prophylactically effective amounts by routine experimentation, including, but not limited to, a dose escalation clinical trial.</source>
      </segment>
    </unit>
    <unit id="80">
      <segment id="80-0">
        <source xml:space="preserve">The term "subject" or "patient" as used herein, refers to an animal, which is the object of treatment, observation or experiment.</source>
      </segment>
      <segment id="80-1">
        <source xml:space="preserve"> By way of example only, a subject may be, but is not limited to, a mammal including, but not limited to, a human.</source>
      </segment>
    </unit>
    <unit id="81">
      <segment id="81-0">
        <source xml:space="preserve">The terms "enhance" or "enhancing" means to increase or prolong either in potency or duration a desired effect.</source>
      </segment>
      <segment id="81-1">
        <source xml:space="preserve"> By way of example, "enhancing" the effect of therapeutic agents singly or in combination refers to the ability to increase or prolong, either in potency, duration and/or magnitude, the effect of the agents on the treatment of a disease, disorder or condition.</source>
      </segment>
      <segment id="81-2">
        <source xml:space="preserve"> When used in a patient, amounts effective for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.</source>
      </segment>
    </unit>
    <unit id="82">
      <segment id="82-0">
        <source xml:space="preserve">The term "modulate," means to interact with a target (e.g., a FGF receptor) either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit or antagonize the activity of the target, to limit the activity of the target, or to extend the activity of the target.</source>
      </segment>
      <segment id="82-1">
        <source xml:space="preserve"> In some embodiments, modified FGF-1 polypeptides and pharmaceutical compositions described herein can modulate the activity of one or more respective targets (e.g., one or more FGF receptors).</source>
      </segment>
      <segment id="82-2">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptides described herein modulate (e.g., increase) the activity of one or more FGF receptors on a cell (e.g., a corneal endothelial cell), resulting, e.g., in cell migration and/or cell proliferation.</source>
      </segment>
    </unit>
    <unit id="83">
      <segment id="83-0">
        <source xml:space="preserve">As used herein, the term "target" or refers to a biological molecule (e.g., a target protein or protein complex), such as an FGF receptor, or a portion of a biological molecule capable of being bound by a selective binding agent (e.g., a modified FGF) or pharmaceutical composition described herein.</source>
      </segment>
      <segment id="83-1">
        <source xml:space="preserve"> As used herein, the term "non-target" refers to a biological molecule or a portion of a biological molecule that is not selectively bound by a selective binding agent or pharmaceutical composition described herein.</source>
      </segment>
    </unit>
    <unit id="84">
      <segment id="84-0">
        <source xml:space="preserve">The term "target activity" or "cell response" refers to a biological activity capable of being modulated by a modified FGF or any cellular response that results from the binding of a modified FGF to a FGF receptor.</source>
      </segment>
      <segment id="84-1">
        <source xml:space="preserve"> Certain exemplary target activities and cell responses include, but are not limited to, binding affinity, signal transduction, gene expression, cell migration, cell proliferation, cell differentiation, and amelioration of one or more symptoms associated with an ocular disease, disorder or condition.</source>
      </segment>
    </unit>
    <unit id="85">
      <segment id="85">
        <source xml:space="preserve">The terms "herpetic keratitis", "herpes simplex keratitis", "HSK", "herpetic keratopathy", "herpes corneae", and "herpetic keratoconjunctivitis" refer to an ocular disease, disorder, or condition that is typically caused by herpes simplex virus (HSV).</source>
      </segment>
    </unit>
    <unit id="86">
      <segment id="86">
        <source xml:space="preserve">Expressed and Mature Forms of the Modified FGF-1 Polypeptides</source>
      </segment>
    </unit>
    <unit id="87">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0008" w:id="77"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="77"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0009" w:id="78"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="78"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0010" w:id="79"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="79"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="87-0">
        <source xml:space="preserve">FGFs stimulate a family seven FGF receptor isoforms, and each FGF stimulates a different pattern of receptors to achieve its specific effect.</source>
      </segment>
      <segment id="87-1">
        <source xml:space="preserve"> <ph id="ph1"/>See, e.g.,<ph id="ph2"/> <ph id="ph3"/>Ornitz et al. (1996) The Journal of biological chemistry, 1996, 271(25):15292-7<ph id="ph4"/>; <ph id="ph5"/>Zhang et al. (2006) The Journal of biological chemistry, 2006, 281(23):15694-700<ph id="ph6"/>).</source>
      </segment>
      <segment id="87-2">
        <source xml:space="preserve"> Modified FGF-1 polypeptide is preferable because it binds to and stimulates all seven FGF receptor isoforms.</source>
      </segment>
      <segment id="87-3">
        <source xml:space="preserve"> <ph id="ph7"/>See<ph id="ph8"/> <ph id="ph9"/>Ornitz et al. (1996) The Journal of biological chemistry, 1996, 271(25):15292-7<ph id="ph10"/>.</source>
      </segment>
    </unit>
    <unit id="88">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="88-0">
        <source xml:space="preserve">Aspects of the disclosure relate to a modified FGF-1 polypeptide or a pharmaceutical composition (e.g., an ophthalmic formulation) comprising a modified FGF-1 polypeptide.</source>
      </segment>
      <segment id="88-1">
        <source xml:space="preserve"> Further aspects of the disclosure relate to a modified FGF-1 polypeptide or a pharmaceutical composition <ph id="ph1"/>(e.g.,<ph id="ph2"/> an ophthalmic formulation) comprising a modified FGF-1 polypeptide for use in a method of treating a chemical or a vesicant injury.</source>
      </segment>
      <segment id="88-2">
        <source xml:space="preserve"> A modified FGF-polypeptide, as used herein, refers to a recombinant FGF that includes a substitution or mutation of one or more different amino acid residues and/or one or more deletions of one or more amino acid residues and/or one or more additions of one or more amino acid residues of SEQ ID NO:</source>
      </segment>
      <segment id="88-3">
        <source xml:space="preserve"> 1.</source>
      </segment>
    </unit>
    <unit id="89">
      <segment id="89-0">
        <source xml:space="preserve">The disclosure provides, in a first aspect, a modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="89-1">
        <source xml:space="preserve"> 1, with one or more mutations, wherein the modified polypeptide further comprises a methionine residue upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="89-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="89-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising the N-terminal methionine (N-Met) residue is a mature form of the polypeptide.</source>
      </segment>
      <segment id="89-4">
        <source xml:space="preserve"> The modified FGF-1 polypeptide, according to the first aspect of the disclosure, may comprise one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="89-5">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="89-6">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a host cell with a methionine residue upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="89-7">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="89-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may not be subject to N-terminal processing for removal of the N-Met residue during maturation.</source>
      </segment>
      <segment id="89-9">
        <source xml:space="preserve"> The mature form of a modified FGF-1 may comprise an N-Met residue and one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="89-10">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="89-11">
        <source xml:space="preserve"> An exemplary modified FGF-1 sequence, comprising an N-Met residue, is disclosed as SEQ ID NO:</source>
      </segment>
      <segment id="89-12">
        <source xml:space="preserve"> 2.</source>
      </segment>
    </unit>
    <unit id="90">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="90-0">
        <source xml:space="preserve">The present disclosure identifies that a modified FGF-1 as described herein, comprising an N-Met residue in its mature form, has similar biological activity as a version without the N-Met residue.</source>
      </segment>
      <segment id="90-1">
        <source xml:space="preserve"> N-terminal methionine removal, or excision, is a co-translational process that occurs as soon as a polypeptide emerges from the ribosome.</source>
      </segment>
      <segment id="90-2">
        <source xml:space="preserve"> The removal of the N-terminal methionine involves the substrate specificities of a cleavage enzyme, methionine aminopeptidase (metAP), which recognizes a methionine residue which is followed by an amino acid residue with a small side chain, such as alanine, glycine, proline, serine, threonine, or valine.</source>
      </segment>
      <segment id="90-3">
        <source xml:space="preserve"> Due to this substrate sequence specificity, the modified FGF-1 of the first aspect of the disclosure, which comprises an N-Met residue followed by phenylalanine, <ph id="ph1"/>see<ph id="ph2"/> position 1 of SEQ ID NO:</source>
      </segment>
      <segment id="90-4">
        <source xml:space="preserve"> 1, may not be processed by metAP.</source>
      </segment>
      <segment id="90-5">
        <source xml:space="preserve"> Thus, by expressing the modified FGF-1 with a methionine residue directly upstream of SEQ ID NO:</source>
      </segment>
      <segment id="90-6">
        <source xml:space="preserve"> 1, a mature modified FGF-1, comprising methionine as its N-terminal residue, can be obtained.</source>
      </segment>
      <segment id="90-7">
        <source xml:space="preserve"> The modified FGF-1 according to the first aspect of the disclosure is not expressed with an N-terminal peptide and therefore may not be subject to proteolytic cleavage for removal of the same, during subsequent purification.</source>
      </segment>
    </unit>
    <unit id="91">
      <segment id="91-0">
        <source xml:space="preserve">Provided herein, in a second aspect of the disclosure, is a modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="91-1">
        <source xml:space="preserve"> 1, with one or more mutations, wherein the modified polypeptide further comprises a methionine residue upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-2">
        <source xml:space="preserve"> 1, and one or more amino acids of the peptide set forth as SEQ ID NO:</source>
      </segment>
      <segment id="91-3">
        <source xml:space="preserve"> 3.</source>
      </segment>
      <segment id="91-4">
        <source xml:space="preserve"> A peptide comprising one or more residues of SEQ ID NO:</source>
      </segment>
      <segment id="91-5">
        <source xml:space="preserve"> 3 is herein referred to as an "extension peptide."</source>
      </segment>
      <segment id="91-6">
        <source xml:space="preserve"> Thus, the modified FGF-1 according to the second aspect of the disclosure comprises the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="91-7">
        <source xml:space="preserve"> 1, with one or more mutations, a methionine residue upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-8">
        <source xml:space="preserve"> 1, and an extension peptide positioned between the methionine residue and the first residue of SEQ ID NO:1.</source>
      </segment>
      <segment id="91-9">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising the N-terminal methionine and an extension peptide, positioned between the methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-10">
        <source xml:space="preserve"> 1, may be a mature form of the polypeptide.</source>
      </segment>
      <segment id="91-11">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="91-12">
        <source xml:space="preserve"> 1, which polypeptide may be expressed in a host cell with a methionine residue upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-13">
        <source xml:space="preserve"> 1, and further an extension peptide positioned between the methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-14">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="91-15">
        <source xml:space="preserve"> The modified FGF-1 polypeptide according to the second embodiment may be expressed with an extension peptide comprising five residues of SEQ ID NO:</source>
      </segment>
      <segment id="91-16">
        <source xml:space="preserve"> 3, positioned between the methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-17">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="91-18">
        <source xml:space="preserve"> The modified FGF-1 polypeptide according to the second aspect of the disclosure may be expressed with four residues of SEQ ID NO:</source>
      </segment>
      <segment id="91-19">
        <source xml:space="preserve"> 3, positioned between the methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-20">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="91-21">
        <source xml:space="preserve"> The modified FGF-1 polypeptide according to the second aspect of the disclosure may be expressed with three residues of SEQ ID NO:</source>
      </segment>
      <segment id="91-22">
        <source xml:space="preserve"> 3, positioned between the methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-23">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="91-24">
        <source xml:space="preserve"> The modified FGF-1 polypeptide according to the second aspect of the disclosure may be expressed with two residues of SEQ ID NO:</source>
      </segment>
      <segment id="91-25">
        <source xml:space="preserve"> 3, positioned between the methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-26">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="91-27">
        <source xml:space="preserve"> The modified FGF-1 polypeptide according to the second aspect of the disclosure may be expressed with one residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-28">
        <source xml:space="preserve"> 3, positioned between the methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="91-29">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="91-30">
        <source xml:space="preserve"> Exemplary sequences of the extension peptide include SEQ ID NOS:</source>
      </segment>
      <segment id="91-31">
        <source xml:space="preserve"> 4-8.</source>
      </segment>
    </unit>
    <unit id="92">
      <segment id="92-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide of the second aspect of the disclosure, comprising an extension peptide and an N-terminal methionine residue, may not be subject to N-terminal processing for removal of the methionine residue, whereas in some instances the methionine is excised by a cleavage enzyme.</source>
      </segment>
      <segment id="92-1">
        <source xml:space="preserve"> Typically, the cleavage enzyme is methionine aminopeptidase (metAP).</source>
      </segment>
      <segment id="92-2">
        <source xml:space="preserve"> Thus, in some examples, the mature form of the modified FGF-1 polypeptide according to the second aspect of the disclosure comprises an N-Met residue followed by an extension peptide as described herein.</source>
      </segment>
      <segment id="92-3">
        <source xml:space="preserve"> Exemplary sequences of mature forms of modified FGF-1 polypeptides according to the second aspect of the disclosure, comprising an N-terminal methionine, and one or more residues of the extension peptide, positioned between the methionine residue and the first residue of SEQ ID NO:1, are set forth as SEQ ID NOS:</source>
      </segment>
      <segment id="92-4">
        <source xml:space="preserve"> 9-13, wherein the sequences may further comprise one or more mutations at amino acids corresponding to positions12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="92-5">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="92-6">
        <source xml:space="preserve"> Additional exemplar sequences of mature modified FGF-1 polypeptides comprising an N-terminal methionine, and an extension peptide are set forth as SEQ ID NOS:</source>
      </segment>
      <segment id="92-7">
        <source xml:space="preserve"> 14-18.</source>
      </segment>
      <segment id="92-8">
        <source xml:space="preserve"> In some other examples, the mature form of the modified FGF-1 polypeptide according to the second aspect of the disclosure may not comprise an N-Met residue but may include only an extension peptide.</source>
      </segment>
      <segment id="92-9">
        <source xml:space="preserve"> Exemplary sequences of mature forms of modified FGF-1 polypeptides according to the second aspect of the disclosure, comprising an extension peptide, positioned upstream to the first residue of SEQ ID NO:1 are set forth as SEQ ID NOS:</source>
      </segment>
      <segment id="92-10">
        <source xml:space="preserve"> 19-23, wherein the sequences may further comprise one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="92-11">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="92-12">
        <source xml:space="preserve"> Additional exemplar sequences of mature modified FGF-1 polypeptides comprising one or more residues of the extension peptide are set forth as SEQ ID NOS:</source>
      </segment>
      <segment id="92-13">
        <source xml:space="preserve"> 24-28.</source>
      </segment>
      <segment id="92-14">
        <source xml:space="preserve"> The methionine residue may be cleaved by metAP when the extension peptide starts with an alanine (as in SEQ ID NO:</source>
      </segment>
      <segment id="92-15">
        <source xml:space="preserve"> 4) or with a threonine (as in SEQ ID NO:</source>
      </segment>
      <segment id="92-16">
        <source xml:space="preserve"> 5).</source>
      </segment>
      <segment id="92-17">
        <source xml:space="preserve"> In those instance, the mature FGF-1 polypeptide may not comprise an N-terminal methionine residue, e.g., SEQ ID NOS:</source>
      </segment>
      <segment id="92-18">
        <source xml:space="preserve"> 19, 21, 24, and 26.</source>
      </segment>
    </unit>
    <unit id="93">
      <segment id="93-0">
        <source xml:space="preserve">Provided herein, in a third aspect of the disclosure, is a modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="93-1">
        <source xml:space="preserve"> 1, with one or more mutations, wherein the modified polypeptide further comprises an extension peptide positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="93-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="93-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising an extension peptide may be a mature form of the polypeptide.</source>
      </segment>
      <segment id="93-4">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="93-5">
        <source xml:space="preserve"> 1, which polypeptide may be expressed in a host cell with one or more amino acid residues of the extension peptide positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="93-6">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="93-7">
        <source xml:space="preserve"> Exemplary sequences of the modified FGF-1 polypeptides comprising an extension peptide, expressed without an N-terminal methionine residue, are set forth as SEQ ID NOS:</source>
      </segment>
      <segment id="93-8">
        <source xml:space="preserve"> 19-23, wherein the sequences may further comprise one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="93-9">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="93-10">
        <source xml:space="preserve"> Additional exemplar sequences of mature modified FGF-1 polypeptides comprising one or more residues of the extension peptide, and expressed without an N-terminal methionine residue, are set forth as SEQ ID NOS:</source>
      </segment>
      <segment id="93-11">
        <source xml:space="preserve"> 24-28.</source>
      </segment>
    </unit>
    <unit id="94">
      <segment id="94-0">
        <source xml:space="preserve">Provided herein, in a fourth aspect of the disclosure, is a modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="94-1">
        <source xml:space="preserve"> 1, with one or more mutations, wherein the modified polypeptide further comprises a truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="94-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="94-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising the truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="94-4">
        <source xml:space="preserve"> 1 may be the mature form of the polypeptide.</source>
      </segment>
      <segment id="94-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="94-6">
        <source xml:space="preserve"> 1, wherein one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="94-7">
        <source xml:space="preserve"> 1 may be deleted.</source>
      </segment>
      <segment id="94-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide comprising truncations may be expressed with an N-terminal methionine residue.</source>
      </segment>
      <segment id="94-9">
        <source xml:space="preserve"> For instance, the modified FGF-1 polypeptide, according to the fourth aspect of the disclosure, can have a sequence wherein the N-Met residue is followed by the second residue, asparagine, of SEQ ID NO:</source>
      </segment>
      <segment id="94-10">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="94-11">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise an N-Met residue followed by the third residue, leucine, of SEQ ID NO:</source>
      </segment>
      <segment id="94-12">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="94-13">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise an N-Met residue followed by the fourth residue, proline, of SEQ ID NO:</source>
      </segment>
      <segment id="94-14">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="94-15">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise an N-Met residue followed by the fifth residue, proline, of SEQ ID NO:1.</source>
      </segment>
      <segment id="94-16">
        <source xml:space="preserve"> An extension peptide can be positioned in between the N-Met residue and the first, second, third, fourth, or fifth residue of SEQ ID NO:</source>
      </segment>
      <segment id="94-17">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="94-18">
        <source xml:space="preserve"> Examples of a mature form of the modified FGF-1 polypeptide according to the fourth aspect of the disclosure wherein an N-Met residue is followed by the second, third, fourth, or fifth residue of SEQ ID NO:</source>
      </segment>
      <segment id="94-19">
        <source xml:space="preserve"> 1 are shown in SEQ ID NOS:</source>
      </segment>
      <segment id="94-20">
        <source xml:space="preserve"> 37-40, wherein the sequences further comprise one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="94-21">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="94-22">
        <source xml:space="preserve"> Additional examples of modified FGF-1 polypeptides comprising truncations and an N-Met residue, are provided in SEQ ID NOS:</source>
      </segment>
      <segment id="94-23">
        <source xml:space="preserve"> 41-44.</source>
      </segment>
    </unit>
    <unit id="95">
      <segment id="95-0">
        <source xml:space="preserve">The present disclosure also relates to modified FGF-1 polypeptides comprising one or more mutations of SEQ ID NO:</source>
      </segment>
      <segment id="95-1">
        <source xml:space="preserve"> 1, wherein the polypeptides are expressed with an N-Met residue followed by an extension peptide, and the extension peptide is followed by truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="95-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="95-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="95-4">
        <source xml:space="preserve"> 1, wherein the polypeptide may be expressed with an N-Met residue followed by an extension peptide, and the extension peptide may be followed by truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="95-5">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="95-6">
        <source xml:space="preserve"> Examples of such sequences expressed with an N-Met residue followed by an extension peptide, which extension peptide is followed by truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="95-7">
        <source xml:space="preserve"> 1 are disclosed as SEQ ID NOS:</source>
      </segment>
      <segment id="95-8">
        <source xml:space="preserve"> 45-68, wherein the sequences further comprise one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="95-9">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="95-10">
        <source xml:space="preserve"> The N-terminal methionine may be cleaved off by N-terminal processing and accordingly the mature form of the modified FGF-1 polypeptide may comprise only one or more residues of the leader fragment followed by truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="95-11">
        <source xml:space="preserve"> 1, as exemplified in SEQ ID NOS:</source>
      </segment>
      <segment id="95-12">
        <source xml:space="preserve"> 69-92, wherein the exemplary sequences further comprise one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="95-13">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="95-14">
        <source xml:space="preserve"> Additional examples of sequences without N-Met residue but including an extension peptide and truncations of N-terminal residues, are provided in SEQ ID NO:</source>
      </segment>
      <segment id="95-15">
        <source xml:space="preserve"> 93-117.</source>
      </segment>
    </unit>
    <unit id="96">
      <segment id="96-0">
        <source xml:space="preserve">The N-Met residue may be retained in the mature modified FGF-1 polypeptide sequence, and accordingly the mature forms may comprise sequences as exemplified in SEQ ID NO:</source>
      </segment>
      <segment id="96-1">
        <source xml:space="preserve"> 45-68, further comprising one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="96-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="96-3">
        <source xml:space="preserve"> Additional examples of sequences comprising an N-Met residue, an extension peptide and truncations of N-terminal residues, are provided in SEQ ID NO:</source>
      </segment>
      <segment id="96-4">
        <source xml:space="preserve"> 118-141 and 207.</source>
      </segment>
    </unit>
    <unit id="97">
      <segment id="97-0">
        <source xml:space="preserve">The truncated versions of the modified FGF-1 polypeptides comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="97-1">
        <source xml:space="preserve"> 1, may be, in a fifth aspect of the disclosure, expressed without an N-terminal methionine residue, and further without an extension peptide.</source>
      </segment>
      <segment id="97-2">
        <source xml:space="preserve"> In some examples, mature modified FGF-1 polypeptides according to the fifth aspect of the disclosure may comprise a sequence as set forth in SEQ ID NOS:</source>
      </segment>
      <segment id="97-3">
        <source xml:space="preserve"> 29-32, wherein the sequences may further comprise one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="97-4">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="97-5">
        <source xml:space="preserve"> In some examples, the modified FGF-1 polypeptides according to the fifth aspect of the disclosure may comprise a sequence selected from the group consisting of SEQ ID NOS:</source>
      </segment>
      <segment id="97-6">
        <source xml:space="preserve"> 33-36.</source>
      </segment>
    </unit>
    <unit id="98">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="98-0">
        <source xml:space="preserve">In instances where the modified FGF-1 polypeptide, or its truncated version, comprising one or more mutations at positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="98-1">
        <source xml:space="preserve"> 1, is expressed with an N-terminal methionine followed by an extension peptide, the methionine residue may either be retained or cleaved off of the N-terminus during maturation of the polypeptide after expression.</source>
      </segment>
      <segment id="98-2">
        <source xml:space="preserve"> Where the modified FGF-1 polypeptide is expressed with an alanine next to the N-Met residue, <ph id="ph1"/>e.g.,<ph id="ph2"/> SEQ ID NO:</source>
      </segment>
      <segment id="98-3">
        <source xml:space="preserve"> 14, the methionine may be cleaved, to yield a mature FGF-1 polypeptide that does not comprise an N-Met residue, <ph id="ph3"/>e.g.,<ph id="ph4"/> SEQ ID NO:</source>
      </segment>
      <segment id="98-4">
        <source xml:space="preserve"> 19.</source>
      </segment>
      <segment id="98-5">
        <source xml:space="preserve"> Where the modified FGF-1 polypeptide is expressed with a threonine next to the N-Met residue, <ph id="ph5"/>e.g.,<ph id="ph6"/> SEQ ID NO:</source>
      </segment>
      <segment id="98-6">
        <source xml:space="preserve"> 16, the methionine may be cleaved, to yield a mature FGF-1 polypeptide that does not comprise an N-Met residue, <ph id="ph7"/>e.g.,<ph id="ph8"/> SEQ ID NO:</source>
      </segment>
      <segment id="98-7">
        <source xml:space="preserve"> 20.</source>
      </segment>
      <segment id="98-8">
        <source xml:space="preserve"> Where the modified FGF-1 polypeptide is expressed with a glutamic acid next to the N-Met residue, <ph id="ph9"/>e.g.,<ph id="ph10"/> SEQ ID NO:</source>
      </segment>
      <segment id="98-9">
        <source xml:space="preserve"> 17, the methionine may not be cleaved, to yield a mature FGF-1 that comprise an N-terminal methionine and has the same sequence as the expressed form.</source>
      </segment>
    </unit>
    <unit id="99">
      <segment id="99-0">
        <source xml:space="preserve">Provided herein, in a sixth aspect of the disclosure, is a modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="99-1">
        <source xml:space="preserve"> 1, comprising a mutation at position 67.</source>
      </segment>
      <segment id="99-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a mutation at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="99-3">
        <source xml:space="preserve"> 1, one or more further mutations at positions 12, 16, 66, 117, and 134, and may be expressed with an N-Met residue.</source>
      </segment>
      <segment id="99-4">
        <source xml:space="preserve"> The internal methionine at position 67 may be be replaced, for example, with an alanine residue.</source>
      </segment>
      <segment id="99-5">
        <source xml:space="preserve"> In absence of the internal methionine at position 67, the N-terminal methionine of the modified FGF-1 polypeptide can be cleaved, post-expression; using cyanogen bromide (CNBr), an agent that specifically cleaves the amide bond after methionine residues.</source>
      </segment>
      <segment id="99-6">
        <source xml:space="preserve"> The modified FGF-1 polypeptides according to the sixth aspect of the disclosure may be expressed with an extension peptide.</source>
      </segment>
      <segment id="99-7">
        <source xml:space="preserve"> In some other cases, modified FGF-1 polypeptides according to the sixth aspect of the disclosure may be expressed in a form comprising truncations of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="99-8">
        <source xml:space="preserve"> 1, as exemplified in SEQ ID NOS:</source>
      </segment>
      <segment id="99-9">
        <source xml:space="preserve"> 142-149, wherein the sequences further comprise one or more mutations at amino acids corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="99-10">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="99-11">
        <source xml:space="preserve"> The modified FGF-1 polypeptides according to the sixth aspect of the disclosure may be expressed in a form comprising an extension peptide and truncations of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="99-12">
        <source xml:space="preserve"> 1, as exemplified in SEQ ID NOS:</source>
      </segment>
      <segment id="99-13">
        <source xml:space="preserve"> 151-175.</source>
      </segment>
      <segment id="99-14">
        <source xml:space="preserve"> Additional examples of the modified FGF-1 polypeptides according to the sixth aspect of the disclosure, in their mature forms, are set forth in SEQ ID NOS:</source>
      </segment>
      <segment id="99-15">
        <source xml:space="preserve"> 174-204.</source>
      </segment>
      <segment id="99-16">
        <source xml:space="preserve"> Among the modified FGF-1 polypeptides expressed in a form that comprises an internal methionine mutation, in cases where the polypeptide is expressed with an N-terminal methionine followed by an alanine or a threonine residue from the extension peptide, e.g., SEQ ID NO:</source>
      </segment>
      <segment id="99-17">
        <source xml:space="preserve"> 175 and SEQ ID NO:</source>
      </segment>
      <segment id="99-18">
        <source xml:space="preserve"> 177, respectively, the N-terminal methionine can be cleaved off during maturation of the polypeptide either by metAP or using CNBr.</source>
      </segment>
    </unit>
    <unit id="100">
      <segment id="100-0">
        <source xml:space="preserve">Provided herein, in a seventh aspect of the disclosure, is a modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="100-1">
        <source xml:space="preserve"> 205, for use in a method as described herein.</source>
      </segment>
      <segment id="100-2">
        <source xml:space="preserve"> Provided herein, in an eighth aspect of the disclosure, is a modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="100-3">
        <source xml:space="preserve"> 206, for use in a method as described herein</source>
      </segment>
    </unit>
    <unit id="101">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="101-0">
        <source xml:space="preserve">The present disclosure further relates to modified FGF-1 polypeptides comprising any combination of deletion, insertion, and substitution of SEQ ID NO:</source>
      </segment>
      <segment id="101-1">
        <source xml:space="preserve"> 1, provided that said modified polypeptide comprises one or more mutations of SEQ ID NO:</source>
      </segment>
      <segment id="101-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="101-3">
        <source xml:space="preserve"> Amino acid substitutions may be introduced into a modified FGF-1 polypeptide and the products screened for a desired activity, <ph id="ph1"/>e.g.,<ph id="ph2"/> retained/improved effectivity in treating ocular disorders, increased potency in amelioration of Fuch's dystrophy, improved treatment of mustard gas keratopathy.</source>
      </segment>
      <segment id="101-4">
        <source xml:space="preserve"> Amino acid substitutions may also be introduced into a modified FGF-1 polypeptide and the products screened for a desired physicochemical property, <ph id="ph3"/>e.g.,<ph id="ph4"/> less prone to aggregation, improved solubility, prolonged half-life, ease of formulating as an ophthalmic pharmaceutical, enhanced stability, improved shelf-life.</source>
      </segment>
      <segment id="101-5">
        <source xml:space="preserve"> Both conservative and non-conservative amino acid substitutions are contemplated.</source>
      </segment>
    </unit>
    <unit id="102">
      <segment id="102-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide, as in any of the above aspects of the disclosure, may be expressed in a form that comprises at least 136 amino acids.</source>
      </segment>
      <segment id="102-1">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 137 amino acids.</source>
      </segment>
      <segment id="102-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 138 amino acids.</source>
      </segment>
      <segment id="102-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 139 amino acids.</source>
      </segment>
      <segment id="102-4">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 140 amino acids.</source>
      </segment>
      <segment id="102-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 141 amino acids.</source>
      </segment>
      <segment id="102-6">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 142 amino acids.</source>
      </segment>
      <segment id="102-7">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 143 amino acids.</source>
      </segment>
      <segment id="102-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 144 amino acids.</source>
      </segment>
      <segment id="102-9">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 145 amino acids.</source>
      </segment>
      <segment id="102-10">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may be expressed in a form that comprises 146 amino acids.</source>
      </segment>
    </unit>
    <unit id="103">
      <segment id="103-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide, as in any of the above aspects of the disclosure, may comprise at least 136 amino acids in the mature form.</source>
      </segment>
      <segment id="103-1">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 137 amino acids in the mature form.</source>
      </segment>
      <segment id="103-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 138 amino acids in the mature form.</source>
      </segment>
      <segment id="103-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 139 amino acids in the mature form.</source>
      </segment>
      <segment id="103-4">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 140 amino acids in the mature form.</source>
      </segment>
      <segment id="103-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 141 amino acids in the mature form.</source>
      </segment>
      <segment id="103-6">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 142 amino acids in the mature form.</source>
      </segment>
      <segment id="103-7">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 143 amino acids in the mature form.</source>
      </segment>
      <segment id="103-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 144 amino acids in the mature form.</source>
      </segment>
      <segment id="103-9">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 145 amino acids in the mature form.</source>
      </segment>
      <segment id="103-10">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise 146 amino acids in the mature form.</source>
      </segment>
    </unit>
    <unit id="104">
      <segment id="104-0">
        <source xml:space="preserve">The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="104-1">
        <source xml:space="preserve"> 1, provided that said polypeptide comprises an N-Met residue in the mature form of the polypeptide.</source>
      </segment>
      <segment id="104-2">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-3">
        <source xml:space="preserve"> 9-13, provided that said polypeptide comprises the N-Met residue in its mature form, and the polypeptide comprises one or more mutations at amino acid positions corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="104-4">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="104-5">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-6">
        <source xml:space="preserve"> 14-18, provided that said polypeptide comprises the N-Met residue in its mature form.</source>
      </segment>
      <segment id="104-7">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-8">
        <source xml:space="preserve"> 19 -23, provided that said polypeptide does not comprise the N-Met residue in its mature form, and the polypeptide comprises one or more mutations at amino acid positions corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="104-9">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="104-10">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-11">
        <source xml:space="preserve"> 24-28, provided that said polypeptide does not comprise an N-Met residue in its mature form.</source>
      </segment>
      <segment id="104-12">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-13">
        <source xml:space="preserve"> 19-23, provided that said polypeptide does not comprise an N-Met residue in its mature form, and the polypeptide comprises one or more mutations at amino acid positions corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="104-14">
        <source xml:space="preserve"> 1. the sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-15">
        <source xml:space="preserve"> 37-40, provided that said polypeptide comprises an N-Met residue in its mature form, and the polypeptide comprises one or more mutations at amino acid positions corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="104-16">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="104-17">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-18">
        <source xml:space="preserve"> 41-44, provided that said polypeptide comprises an N-Met residue in its mature form.</source>
      </segment>
      <segment id="104-19">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-20">
        <source xml:space="preserve"> 45-68, provided that said polypeptide comprises one or more mutations at amino acid positions corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="104-21">
        <source xml:space="preserve"> 1, and said polypeptide does not comprise an N-Met residue in its mature form.</source>
      </segment>
      <segment id="104-22">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-23">
        <source xml:space="preserve"> 69-92, may comprise one or more mutations at amino acid positions corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="104-24">
        <source xml:space="preserve"> 1, and said polypeptide may comprise an N-Met residue in its mature form.</source>
      </segment>
      <segment id="104-25">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-26">
        <source xml:space="preserve"> 93-117, provided that said polypeptide does not comprise an N-Met residue in its mature form.</source>
      </segment>
      <segment id="104-27">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NO:</source>
      </segment>
      <segment id="104-28">
        <source xml:space="preserve"> 118-141 and 207, provided that said polypeptide comprises an N-Met residue in its mature form.</source>
      </segment>
      <segment id="104-29">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NOS:</source>
      </segment>
      <segment id="104-30">
        <source xml:space="preserve"> 29-32, provided that said polypeptide comprises one or more mutations at amino acid positions corresponding to positions 12, 16, 66, 117, and 134 of SEQ ID NO:</source>
      </segment>
      <segment id="104-31">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="104-32">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NOS:</source>
      </segment>
      <segment id="104-33">
        <source xml:space="preserve"> 33-36.</source>
      </segment>
    </unit>
    <unit id="105">
      <segment id="105-0">
        <source xml:space="preserve">The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences selected from SEQ ID NOS:</source>
      </segment>
      <segment id="105-1">
        <source xml:space="preserve"> 142-204.</source>
      </segment>
    </unit>
    <unit id="106">
      <segment id="106-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="106-1">
        <source xml:space="preserve"> 1 mutated at position 12 with, for example, the mutation Lys12Val, and wherein said modified FGF-1 polypeptide comprises an N-terminal methionine in its mature form.</source>
      </segment>
      <segment id="106-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 12 of SEQ ID NO:</source>
      </segment>
      <segment id="106-3">
        <source xml:space="preserve"> 1, for example the mutation Lys12Val, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="106-4">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N-Met residue in its mature form.</source>
      </segment>
      <segment id="106-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 12 of SEQ ID NO:</source>
      </segment>
      <segment id="106-6">
        <source xml:space="preserve"> 1, for example the mutation Lys12Val, with an extension peptide, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="106-7">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="106-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with mutations at position 12 of SEQ ID NO:</source>
      </segment>
      <segment id="106-9">
        <source xml:space="preserve"> 1, for example the mutation Lys12Val, wherein the polypeptide further comprises a mutation of the methionine at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="106-10">
        <source xml:space="preserve"> 1, and is expressed with a methionine at the N-terminus, which methionine is cleaved off of the polypeptide in its mature form.</source>
      </segment>
    </unit>
    <unit id="107">
      <segment id="107-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="107-1">
        <source xml:space="preserve"> 1 mutated at position 16 with, for example, the mutation Cys16Ser, and wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="107-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 16 of SEQ ID NO:</source>
      </segment>
      <segment id="107-3">
        <source xml:space="preserve"> 1, for example the mutation Cys16Ser, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="107-4">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="107-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 16 of SEQ ID NO:</source>
      </segment>
      <segment id="107-6">
        <source xml:space="preserve"> 16, for example the mutation Cys16Ser, with an extension peptide, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="107-7">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue.</source>
      </segment>
      <segment id="107-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with mutations at position 16 of SEQ ID NO:</source>
      </segment>
      <segment id="107-9">
        <source xml:space="preserve"> 1, for example the mutation Cys16Ser, wherein the polypeptide further comprises a mutation of the methionine at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="107-10">
        <source xml:space="preserve"> 1, and is expressed with a methionine at the N-terminus, which methionine is cleaved off of the polypeptide in its mature form.</source>
      </segment>
    </unit>
    <unit id="108">
      <segment id="108-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="108-1">
        <source xml:space="preserve"> 1 mutated at position 66 with, for example, the mutation Ala66Cys, and wherein said modified FGF-1 polypeptide comprises an N-terminal methionine in its mature form.</source>
      </segment>
      <segment id="108-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 66 of SEQ ID NO:</source>
      </segment>
      <segment id="108-3">
        <source xml:space="preserve"> 1, for example the mutation Ala66Cys, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="108-4">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="108-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 66 of SEQ ID NO:</source>
      </segment>
      <segment id="108-6">
        <source xml:space="preserve"> 1, for example the mutation Ala66Cys, with an extension peptide, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="108-7">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide is expressed with an N-Met residue.</source>
      </segment>
      <segment id="108-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprises a sequence with mutations at position 66 of SEQ ID NO:</source>
      </segment>
      <segment id="108-9">
        <source xml:space="preserve"> 1, for example the mutation Ala66Cys, wherein the polypeptide further comprises a mutation of the methionine at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="108-10">
        <source xml:space="preserve"> 1, and is expressed with a methionine at the N-terminus, which methionine is cleaved off of the polypeptide in its mature form.</source>
      </segment>
    </unit>
    <unit id="109">
      <segment id="109-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="109-1">
        <source xml:space="preserve"> 1 mutated at position 117 with, for example, the mutation Cys117Val, and wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="109-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 117 of SEQ ID NO:</source>
      </segment>
      <segment id="109-3">
        <source xml:space="preserve"> 1, for example the mutation Cys117Val, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="109-4">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="109-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 117 of SEQ ID NO:</source>
      </segment>
      <segment id="109-6">
        <source xml:space="preserve"> 1, for example the mutation Cys117Val, with an extension peptide, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="109-7">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="109-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with mutations at position 117 of SEQ ID NO:</source>
      </segment>
      <segment id="109-9">
        <source xml:space="preserve"> 1, for example the mutation Cys117Val, wherein the polypeptide further comprises a mutation of the methionine at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="109-10">
        <source xml:space="preserve"> 1, and is expressed with a methionine at the N-terminus, which methionine is cleaved off of the polypeptide in its mature form.</source>
      </segment>
    </unit>
    <unit id="110">
      <segment id="110-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="110-1">
        <source xml:space="preserve"> 1 mutated at position 134 with, for example, the mutation Pro134Val, and wherein said modified FGF-1 polypeptide comprises an N-terminal methionine in its mature form.</source>
      </segment>
      <segment id="110-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 134 of SEQ ID NO:</source>
      </segment>
      <segment id="110-3">
        <source xml:space="preserve"> 1, for example the mutation Pro134Val, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="110-4">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="110-5">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with a mutation at position 134 of SEQ ID NO:</source>
      </segment>
      <segment id="110-6">
        <source xml:space="preserve"> 1, for example the mutation Pro134Val, with an extension peptide, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="110-7">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue in its mature form.</source>
      </segment>
      <segment id="110-8">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise a sequence with mutations at position 134 of SEQ ID NO:</source>
      </segment>
      <segment id="110-9">
        <source xml:space="preserve"> 1, for example the mutation Pro134Val, wherein the polypeptide further comprises a mutation of the methionine at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="110-10">
        <source xml:space="preserve"> 1, and is expressed with a methionine at the N-terminus, which methionine is cleaved off of the polypeptide in its mature form.</source>
      </segment>
    </unit>
    <unit id="111">
      <segment id="111-0">
        <source xml:space="preserve">In the present invention, the recombinant modified FGF-1 polypeptide comprises SEQ ID NO:</source>
      </segment>
      <segment id="111-1">
        <source xml:space="preserve"> 1 mutated at positions 16, 66, and 117 of SEQ ID NO:</source>
      </segment>
      <segment id="111-2">
        <source xml:space="preserve"> 1, with the mutations Cys16Ser, Ala66Cys, and Cys117Val, and wherein said modified FGF-1 polypeptide comprises an N- met residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="111-3">
        <source xml:space="preserve"> 1, as set out in the claims.</source>
      </segment>
      <segment id="111-4">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide comprises a sequence with mutations at positions 16, 66, and 117 of SEQ ID NO:</source>
      </segment>
      <segment id="111-5">
        <source xml:space="preserve"> 1, with the mutations Cys16Ser, Ala66Cys, and Cys117Val, and with truncation of one or more of the first five residues of SEQ ID NO:</source>
      </segment>
      <segment id="111-6">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="111-7">
        <source xml:space="preserve"> 1 in its mature form.</source>
      </segment>
      <segment id="111-8">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide comprises a sequence with mutations at positions 16, 66, and 117 of SEQ ID NO:</source>
      </segment>
      <segment id="111-9">
        <source xml:space="preserve"> 1, with the mutation Cys16Ser, Ala66Cys, and Cys117Val, with an extension peptide, and with truncation of one or more of the first five residue of SEQ ID NO:</source>
      </segment>
      <segment id="111-10">
        <source xml:space="preserve"> 1, wherein said modified FGF-1 polypeptide comprises an N- met residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="111-11">
        <source xml:space="preserve"> 1.</source>
      </segment>
      <segment id="111-12">
        <source xml:space="preserve"> In some embodiments, the modified FGF-1 polypeptide comprises a sequence with mutations at positions 16, 66, and 117 of SEQ ID NO:</source>
      </segment>
      <segment id="111-13">
        <source xml:space="preserve"> 1, with the mutation Cys16Ser, Ala66Cys, and Cys117Val, wherein the polypeptide further comprises a mutation of the methionine at position 67 of SEQ ID NO:</source>
      </segment>
      <segment id="111-14">
        <source xml:space="preserve"> 1, and is expressed with a methionine at the N-terminus positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="111-15">
        <source xml:space="preserve"> 1, which methionine is cleaved off of the polypeptide in its mature form.</source>
      </segment>
    </unit>
    <unit id="112">
      <segment id="112-0">
        <source xml:space="preserve">The sequence of the modified FGF-1 polypeptide described herein may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence selected from SEQ ID NOs:</source>
      </segment>
      <segment id="112-1">
        <source xml:space="preserve"> 2 and 9-204.</source>
      </segment>
      <segment id="112-2">
        <source xml:space="preserve"> The sequence of the modified FGF-1 polypeptide may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="112-3">
        <source xml:space="preserve"> 205 or 206.</source>
      </segment>
    </unit>
    <unit id="113">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0005" w:id="106"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="106"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0006" w:id="107"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="107"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0007" w:id="108"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="108"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph11">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0008" w:id="109"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph12">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="109"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph13">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0009" w:id="110"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph14">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="110"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph15">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0010" w:id="111"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph16">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="111"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph17">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0011" w:id="112"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph18">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="112"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph19">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0012" w:id="113"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph20">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="113"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph21">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0013" w:id="114"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph22">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="114"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph23">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0014" w:id="115"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph24">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="115"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph25">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0015" w:id="116"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph26">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="116"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph27">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0011" w:id="117"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph28">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="117"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="113-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may be thermostable.</source>
      </segment>
      <segment id="113-1">
        <source xml:space="preserve"> As used herein, a thermostable FGF (<ph id="ph1"/>e.g.,<ph id="ph2"/> a thermostable FGF-1) refers to an FGF having a modified amino acid sequence relative to SEQ ID NO:</source>
      </segment>
      <segment id="113-2">
        <source xml:space="preserve"> 1 that is also more stable than the polypeptide of SEQ ID NO:</source>
      </segment>
      <segment id="113-3">
        <source xml:space="preserve"> 1 under the same conditions.</source>
      </segment>
      <segment id="113-4">
        <source xml:space="preserve"> Examples of mutations capable of conferring thermostability to FGF (<ph id="ph3"/>e.g.,<ph id="ph4"/> FGF-1) and methods for assessing thermostability are described, for example, in <ph id="ph5"/>U.S.</source>
      </segment>
      <segment id="113-5">
        <source xml:space="preserve"> Patent Nos. 7,790,682<ph id="ph6"/>; <ph id="ph7"/>7,595,296<ph id="ph8"/>; <ph id="ph9"/>7,696,171<ph id="ph10"/>; <ph id="ph11"/>7,776,825<ph id="ph12"/>; <ph id="ph13"/>7,659,379<ph id="ph14"/>; <ph id="ph15"/>8,119,776<ph id="ph16"/>; <ph id="ph17"/>8,153,770<ph id="ph18"/>; <ph id="ph19"/>8,153,771<ph id="ph20"/>; and <ph id="ph21"/>8,461,111<ph id="ph22"/>; <ph id="ph23"/>U.S.</source>
      </segment>
      <segment id="113-6">
        <source xml:space="preserve"> Patent Application Publication Nos. 2011/0224404<ph id="ph24"/> and <ph id="ph25"/>2013/0130983<ph id="ph26"/>; and in <ph id="ph27"/>Xia et al.</source>
      </segment>
      <segment id="113-7">
        <source xml:space="preserve"> PloS one. (2012) 7(11):e48210<ph id="ph28"/>.</source>
      </segment>
      <segment id="113-8">
        <source xml:space="preserve"> In some embodiments, positions 12 and/or 134 are mutated in FGF-1 to generate a modified FGF-1 that is thermostable.</source>
      </segment>
    </unit>
    <unit id="114">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0016" w:id="119"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="119"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0017" w:id="120"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="120"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0018" w:id="121"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="121"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0019" w:id="122"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="122"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph11">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0020" w:id="123"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph12">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="123"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph13">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0021" w:id="124"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph14">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="124"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph15">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0022" w:id="125"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph16">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="125"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph17">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0023" w:id="126"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph18">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="126"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph19">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0024" w:id="127"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph20">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="127"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph21">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0025" w:id="128"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph22">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="128"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph23">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0026" w:id="129"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph24">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="129"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph25">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0012" w:id="130"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph26">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="130"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="114-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may include one or more modifications that reduce the number of reactive thiols (<ph id="ph1"/>e.g.,<ph id="ph2"/> free cysteines).</source>
      </segment>
      <segment id="114-1">
        <source xml:space="preserve"> Examples such modifications in FGF-1 are described, for example, in <ph id="ph3"/>U.S.</source>
      </segment>
      <segment id="114-2">
        <source xml:space="preserve"> Patent Nos. 7,790,682<ph id="ph4"/>; <ph id="ph5"/>7,595,296<ph id="ph6"/>; <ph id="ph7"/>7,696,171<ph id="ph8"/>; <ph id="ph9"/>7,776,825<ph id="ph10"/>; <ph id="ph11"/>7,659,379<ph id="ph12"/>; <ph id="ph13"/>8,119,776<ph id="ph14"/>; <ph id="ph15"/>8,153,770<ph id="ph16"/>; <ph id="ph17"/>8,153,771<ph id="ph18"/>; and <ph id="ph19"/>8,461,111<ph id="ph20"/>; <ph id="ph21"/>U.S.</source>
      </segment>
      <segment id="114-3">
        <source xml:space="preserve"> Patent Application Publication Nos. 2011/0224404<ph id="ph22"/> and <ph id="ph23"/>2013/0130983<ph id="ph24"/>; and in <ph id="ph25"/>Xia et al.</source>
      </segment>
      <segment id="114-4">
        <source xml:space="preserve"> PloS one. (2012) 7(11):e48210<ph id="ph26"/>.</source>
      </segment>
      <segment id="114-5">
        <source xml:space="preserve"> Positions 83 and/or 117 may be mutated in SEQ ID NO:</source>
      </segment>
      <segment id="114-6">
        <source xml:space="preserve"> 1 to generate a modified FGF-1 that reduces the number of reactive thiols.</source>
      </segment>
    </unit>
    <unit id="115">
      <segment id="115-0">
        <source xml:space="preserve">The modified FGF may include one or more modifications that enable formation of an internal disulfide linkage.</source>
      </segment>
      <segment id="115-1">
        <source xml:space="preserve"> Position 66 may be mutated in SEQ ID NO:</source>
      </segment>
      <segment id="115-2">
        <source xml:space="preserve"> 1 to generate a modified FGF-1 that comprises an internal disulfide linkage.</source>
      </segment>
    </unit>
    <unit id="116">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="116-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides described herein can be administered without exogenous heparin in the formulation for stability, they can be formulated and applied without heparin and thus are more able to bind to the tissue heparans.</source>
      </segment>
      <segment id="116-1">
        <source xml:space="preserve"> Such modified FGF-1 polypeptides have a high affinity for tissue heparans that are exposed in a surgical, traumatic or dystrophic conditions and disease-states and so bind to diseased tissue on application.</source>
      </segment>
      <segment id="116-2">
        <source xml:space="preserve"> In addition, the modified FGF-1 polypeptides being more thermally stable are suitable for formulation and storage at room temperature.</source>
      </segment>
      <segment id="116-3">
        <source xml:space="preserve"> The stability of the modified FGF-1 polypeptides also makes them suitable for administration in both solution (<ph id="ph1"/>e.g.,<ph id="ph2"/> immediate release) and sustained-release formulations.</source>
      </segment>
    </unit>
    <unit id="117">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="117-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide may be SEQ ID NO:</source>
      </segment>
      <segment id="117-1">
        <source xml:space="preserve"> 1 that has been modified at one or more of positions 12, 16, 66, 117, and 134.</source>
      </segment>
      <segment id="117-2">
        <source xml:space="preserve"> The modified FGF may be SEQ ID NO:</source>
      </segment>
      <segment id="117-3">
        <source xml:space="preserve"> 1 that has been modified at positions 16, 66, and 117.</source>
      </segment>
      <segment id="117-4">
        <source xml:space="preserve"> The amino acid positions can be substituted with, <ph id="ph1"/>e.g.,<ph id="ph2"/> Ser, Cys, Val, or other amino acids to create disulfide linkages between modified amino acids and wild-type amino acids.</source>
      </segment>
      <segment id="117-5">
        <source xml:space="preserve"> The modified FGF may comprise the amino acid sequence of SEQ ID NO:</source>
      </segment>
      <segment id="117-6">
        <source xml:space="preserve"> 2, also referred to as N-Met THX1114.</source>
      </segment>
      <segment id="117-7">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise one or more mutations selected from the group consisting of:</source>
      </segment>
      <segment id="117-8">
        <source xml:space="preserve"> Lys12Val, Pro134Val, Ala66Cys, Cys117Val, and Pro134Val.</source>
      </segment>
      <segment id="117-9">
        <source xml:space="preserve"> The modified FGF-1 polypeptide may comprise the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="117-10">
        <source xml:space="preserve"> 2.</source>
      </segment>
    </unit>
    <unit id="118">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="118-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides or compositions described herein may be prepared as prodrugs.</source>
      </segment>
      <segment id="118-1">
        <source xml:space="preserve"> A "prodrug" refers to an agent that is converted into the parent drug <ph id="ph1"/>in vivo.</source>
      </segment>
      <ignorable>
        <source xml:space="preserve"><ph id="ph2"/></source>
      </ignorable>
      <segment id="118-2">
        <source xml:space="preserve"> Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug.</source>
      </segment>
      <segment id="118-3">
        <source xml:space="preserve"> They may, for instance, be bioavailable by oral administration whereas the parent is not.</source>
      </segment>
      <segment id="118-4">
        <source xml:space="preserve"> The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.</source>
      </segment>
    </unit>
    <unit id="119">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="119">
        <source xml:space="preserve">The modified FGF-1 polypeptides described herein may be labeled isotopically (<ph id="ph1"/>e.g.,<ph id="ph2"/> with a radioisotope) or by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, photoactivatable or chemiluminescent labels.</source>
      </segment>
    </unit>
    <unit id="120">
      <segment id="120-0">
        <source xml:space="preserve">The present disclosure further relates to modified FGF polypeptides comprising N-terminal modification(s), wherein the modified FGF polypeptide can be any member of the FGF family, including FGF-1 (SEQ ID NO:</source>
      </segment>
      <segment id="120-1">
        <source xml:space="preserve"> 1), FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, and FGF-23, and FGF-24.</source>
      </segment>
    </unit>
    <unit id="121">
      <segment id="121">
        <source xml:space="preserve">The synthesis of modified FGF-1 polypeptides as described herein may be accomplished using means described in the art, using the methods described herein, or by a combination thereof.</source>
      </segment>
    </unit>
    <unit id="122">
      <segment id="122-0">
        <source xml:space="preserve">The sequence of the modified FGF may comprise 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:</source>
      </segment>
      <segment id="122-1">
        <source xml:space="preserve"> 1 mutated at one or more positions 16, 66, and 117 with, for example, the mutations Cys16Ser, Ala66Cys, and Cys117Val.</source>
      </segment>
      <segment id="122-2">
        <source xml:space="preserve"> The modified FGF may comprise the wild-type human FGF-1 sequence with a mutation at positions 16, 66 and 117, for example the mutations Cys16Ser, Ala66Cys, and Cys117Val.</source>
      </segment>
    </unit>
    <unit id="123">
      <segment id="123">
        <source xml:space="preserve">Recombinant Techniques for Preparation of Modified FGF-1 Polypeptides</source>
      </segment>
    </unit>
    <unit id="124">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph11">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph12">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph13">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph14">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph15">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph16">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="124-0">
        <source xml:space="preserve">A variety of host-expression vector systems may be utilized to produce the modified FGF-1 polypeptides described herein.</source>
      </segment>
      <segment id="124-1">
        <source xml:space="preserve"> Such host-expression systems represent vehicles by which the modified FGF-1 polypeptides may be produced and subsequently purified, but also represent cells that may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the modified gene product <ph id="ph1"/>in situ.</source>
      </segment>
      <segment id="124-2">
        <source xml:space="preserve"><ph id="ph2"/> Examples of host-expression systems include but are not limited to, bacteria, insect, plant, mammalian, including human host systems, such as, but not limited to, insect cell systems infected with recombinant virus expression vectors (<ph id="ph3"/>e.g.,<ph id="ph4"/> baculovirus) containing nucleotide sequences coding for the modified FGF-1 polypeptides; plant cell systems infected with recombinant virus expression vectors (<ph id="ph5"/>e.g.,<ph id="ph6"/> cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (<ph id="ph7"/>e.g.,<ph id="ph8"/> Ti plasmid) containing coding sequences for the modified FGF-1 polypeptides; or mammalian cell systems, including human cell systems, <ph id="ph9"/>e.g.,<ph id="ph10"/> HT1080, COS, CHO, BHK, 293, 3T3, harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells, e.g., metallothionein promoter, or from mammalian viruses, e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter, or from yeast-derived plasmids <ph id="ph11"/>e.g.,<ph id="ph12"/> pSH19 and pSH15, or from bacteriophages such as lambda phase and derivatives thereof.</source>
      </segment>
      <segment id="124-3">
        <source xml:space="preserve"> Examples of bacterial expression systems include but are not limited to Escherichia coli-derived plasmids (<ph id="ph13"/>e.g.,<ph id="ph14"/> pBR322, pBR325, pUC12, pUC13, and pET-3); Bacillus subtilis-derived plasmids (<ph id="ph15"/>e.g.,<ph id="ph16"/> PUB110, pTP5, and pC194).</source>
      </segment>
    </unit>
    <unit id="125">
      <segment id="125-0">
        <source xml:space="preserve">A host cell strain may be chosen such that it modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired.</source>
      </segment>
      <segment id="125-1">
        <source xml:space="preserve"> Such modifications and processing of protein products may be important for the function of the protein.</source>
      </segment>
      <segment id="125-2">
        <source xml:space="preserve"> Different host cells have specific mechanisms for the post-translational processing and modification of proteins and gene products.</source>
      </segment>
      <segment id="125-3">
        <source xml:space="preserve"> Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.</source>
      </segment>
      <segment id="125-4">
        <source xml:space="preserve"> To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.</source>
      </segment>
      <segment id="125-5">
        <source xml:space="preserve"> Such mammalian host cells, including human host cells, include but are not limited to HT1080, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, and WI38.</source>
      </segment>
    </unit>
    <unit id="126">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="126-0">
        <source xml:space="preserve">For long-term, high-yield production of recombinant peptides, stable expression is desired.</source>
      </segment>
      <segment id="126-1">
        <source xml:space="preserve"> For example, cell lines that stably express the recombinant modified FGF-1 polypeptides may be engineered.</source>
      </segment>
      <segment id="126-2">
        <source xml:space="preserve"> Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements, <ph id="ph1"/>e.g.,<ph id="ph2"/> promoter, enhancer, sequences, transcription terminators, polyadenylation sites, and the like, and a selectable marker.</source>
      </segment>
      <segment id="126-3">
        <source xml:space="preserve"> Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.</source>
      </segment>
      <segment id="126-4">
        <source xml:space="preserve"> The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci that in turn can be cloned and expanded into cell lines.</source>
      </segment>
      <segment id="126-5">
        <source xml:space="preserve"> In some examples, this method may advantageously be used to engineer cell lines that express the modified FGF-1 polypeptide product.</source>
      </segment>
      <segment id="126-6">
        <source xml:space="preserve"> Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the biological of the gene product.</source>
      </segment>
    </unit>
    <unit id="127">
      <segment id="127">
        <source xml:space="preserve">Disulfide Bond Formation in Modified FGF-1 Polypeptides</source>
      </segment>
    </unit>
    <unit id="128">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0013" w:id="143"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="143"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0014" w:id="144"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="144"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="128-0">
        <source xml:space="preserve">The modified FGF-1 polypeptide of the present disclosure may comprise the following mutations in SEQ ID NO:</source>
      </segment>
      <segment id="128-1">
        <source xml:space="preserve"> 1- Cys16Ser, Ala66Cys, and Cys117Val, wherein the polypeptide includes an internal disulfide bond between the cysteine residues at positions 66 and 83.</source>
      </segment>
      <segment id="128-2">
        <source xml:space="preserve"> For many recombinant proteins, the formation of correct disulfide bonds is vital for attaining their biologically active three-dimensional conformation.</source>
      </segment>
      <segment id="128-3">
        <source xml:space="preserve"> The formation of erroneous disulfide bonds can lead to protein misfolding and aggregation into inclusion bodies.</source>
      </segment>
      <segment id="128-4">
        <source xml:space="preserve"> In <ph id="ph1"/>E. coli,<ph id="ph2"/> cysteine oxidation typically takes places in the periplasm, where disulfide bonds are formed in disulfide exchange reactions catalyzed by a myriad of enzymes, mainly from the Dsb family (<ph id="ph3"/>Rosano, G.</source>
      </segment>
      <segment id="128-5">
        <source xml:space="preserve"> L., &amp; Ceccarelli, E.</source>
      </segment>
      <segment id="128-6">
        <source xml:space="preserve"> A. (2014).</source>
      </segment>
      <segment id="128-7">
        <source xml:space="preserve"> Recombinant protein expression in Escherichia coli:</source>
      </segment>
      <segment id="128-8">
        <source xml:space="preserve"> advances and challenges.</source>
      </segment>
      <segment id="128-9">
        <source xml:space="preserve"> Frontiers in Microbiology, 5, 172<ph id="ph4"/>).</source>
      </segment>
      <segment id="128-10">
        <source xml:space="preserve"> By contrast, disulfide bond formation in the cytoplasm is rare.</source>
      </segment>
      <segment id="128-11">
        <source xml:space="preserve"> This situation affects the production of recombinant proteins with disulfide bonds that are produced in the cytoplasm, such as a modified FGF-1 polypeptide comprising an internal disulfide linkage between Cys66 and Cys83.</source>
      </segment>
      <segment id="128-12">
        <source xml:space="preserve"> Accordingly, in some examples, an engineered <ph id="ph5"/>E. coli<ph id="ph6"/> strain that possess an oxidative cytoplasmic environment that favors disulfide bond formation is selected as a host cell for expression of the modified FGF-1 polypeptides (<ph id="ph7"/>Rosano, G.</source>
      </segment>
      <segment id="128-13">
        <source xml:space="preserve"> L., &amp; Ceccarelli, E.</source>
      </segment>
      <segment id="128-14">
        <source xml:space="preserve"> A. (2014).</source>
      </segment>
      <segment id="128-15">
        <source xml:space="preserve"> Recombinant protein expression in Escherichia coli:</source>
      </segment>
      <segment id="128-16">
        <source xml:space="preserve"> advances and challenges.</source>
      </segment>
      <segment id="128-17">
        <source xml:space="preserve"> Frontiers in Microbiology, 5, 172<ph id="ph8"/>).</source>
      </segment>
      <segment id="128-18">
        <source xml:space="preserve"> Examples of such strains include but are not limited to Origami (Novagen), which has a trxB- gor- genotype in the K-12 background, and SHuffle<ph id="ph9"/>®<ph id="ph10"/> T7 Express strain (NEB), which has a trxB-gor-genotype in a BL21(DE3) background and constitutively expresses a chromosomal copy of the disulfide bond isomerase DsbC.</source>
      </segment>
      <segment id="128-19">
        <source xml:space="preserve"> It has been shown that DsbC promotes the correction of mis-oxidized proteins into their correct form and is also a chaperone that can assist in the folding of proteins that do not require disulfide bonds.</source>
      </segment>
      <segment id="128-20">
        <source xml:space="preserve"> Without being bound by a particular theory, it is contemplated that due to the action of DsbC, less target protein, such as the modified FGF-1 polypeptide comprising an internal disulfide linkage between Cys66 and Cys83, aggregates into inclusion bodies.</source>
      </segment>
      <segment id="128-21">
        <source xml:space="preserve"> Thus, the present disclosure identifies an improved method for cytoplasmic production of a modified FGF-1 polypeptide comprising internal disulfide linkage between Cys16 and Cys83.</source>
      </segment>
    </unit>
    <unit id="129">
      <segment id="129-0">
        <source xml:space="preserve">Where the modified FGF-1 polypeptide is expressed with an N-Met residue, the polypeptide may be subsequently purified without a step requiring proteolytic cleavage for removal of an N-terminal peptide.</source>
      </segment>
      <segment id="129-1">
        <source xml:space="preserve"> Accordingly, the present disclosure provides a method of rapid purification of the modified FGF-1 polypeptides described herein, without involving a proteolytic cleavage step for removal of an N-terminal peptide.</source>
      </segment>
      <segment id="129-2">
        <source xml:space="preserve"> This is particularly advantageous for production of the modified FGF-1 polypeptides per good manufacturing practice (GMP) guidelines.</source>
      </segment>
      <segment id="129-3">
        <source xml:space="preserve"> The advantages include the lack of a cleavage step, including eliminating the need for subsequent purification of the cleaved product and removal of the reagents used for cleavage.</source>
      </segment>
      <segment id="129-4">
        <source xml:space="preserve"> The further advantage of this is an increase in yield due to decreased handling and the alleviation of the need to test for residual cleavage reagents and contaminants introduced for the cleavage and subsequent separation of cleaved from uncleaved material.</source>
      </segment>
    </unit>
    <unit id="130">
      <segment id="130">
        <source xml:space="preserve">Methods of Use</source>
      </segment>
    </unit>
    <unit id="131">
      <segment id="131-0">
        <source xml:space="preserve">Described herein is a modified FGF-1 polypeptide as described in the above disclosure for use in a method of treating an ocular disease, disorder or condition in a mammal.</source>
      </segment>
      <segment id="131-1">
        <source xml:space="preserve"> In some instances, the modified FGF-1 polypeptide for use in the methods described herein comprises a sequence selected from SEQ ID NOs:</source>
      </segment>
      <segment id="131-2">
        <source xml:space="preserve"> 2, and 9-204.</source>
      </segment>
      <segment id="131-3">
        <source xml:space="preserve"> Described herein is a modified FGF-1 polypeptide comprising a sequence as set forth in SEQ ID NO:</source>
      </segment>
      <segment id="131-4">
        <source xml:space="preserve"> 205 or 206 for use in a method of treating an ocular disease, disorder or condition in a mammal.</source>
      </segment>
    </unit>
    <unit id="132">
      <segment id="132-0">
        <source xml:space="preserve">The ocular disease, disorder or condition to be treated may be a disease, disorder, or condition of the corneal endothelial layer.</source>
      </segment>
      <segment id="132-1">
        <source xml:space="preserve"> Diseases, disorders, or conditions of the corneal endothelial layer include, but are not limited to, Fuch's dystrophy, bullous keratopathy, congenital hereditary endothelial dystrophy 1, congenital hereditary endothelial dystrophy 2, posterior polymorphous corneal dystrophy, and dry eye syndromes.</source>
      </segment>
    </unit>
    <unit id="133">
      <segment id="133-0">
        <source xml:space="preserve">Without being bound by theory, it is believed a solution of a modified FGF-1 polypeptide injected intracamerally into the aqueous humor of the eye binds to the endothelial surface and especially any areas of the cornea that are not covered by a healthy endothelial layer.</source>
      </segment>
      <segment id="133-1">
        <source xml:space="preserve"> The modified FGF stimulates the growth and migration of the endothelial cells.</source>
      </segment>
      <segment id="133-2">
        <source xml:space="preserve"> This reduces the corneal edema associated with the endothelial dystrophy and reduces the likelihood for a need for a corneal or endothelial transplant.</source>
      </segment>
      <segment id="133-3">
        <source xml:space="preserve"> The action of the modified FGF can occur at a site other than the site of greatest dystrophy (typically at the corneal center) and also results in stimulation of endothelial cells in the corneal periphery and endothelial progenitor pools in the trabecular meshwork (TM).</source>
      </segment>
    </unit>
    <unit id="134">
      <segment id="134-0">
        <source xml:space="preserve">The ocular disease, disorder or condition to be treated may be a disease, disorder, or condition of the corneal epithelium.</source>
      </segment>
      <segment id="134-1">
        <source xml:space="preserve"> Diseases, disorders or conditions of the corneal epithelium include, but are not limited to, dry eye syndromes, inflammatory conditions such as Stevens-Johnson syndrome, and corneal epithelial defects.</source>
      </segment>
    </unit>
    <unit id="135">
      <segment id="135-0">
        <source xml:space="preserve">The ocular disease, disorder or condition to be treated may be herpetic keratopathy.</source>
      </segment>
      <segment id="135-1">
        <source xml:space="preserve"> Herpetic keratopathy typically is an infection of the cornea caused by Herpes Simplex virus (HSV).</source>
      </segment>
      <segment id="135-2">
        <source xml:space="preserve"> Primary infection can be the result of direct exposure of the host's mucous membranes to infectious HSV.</source>
      </segment>
      <segment id="135-3">
        <source xml:space="preserve"> Following primary infection and the establishment of latency in the sensory ganglia, the virus can be stimulated to enter an infectious cycle, from which it returns to the cornea.</source>
      </segment>
      <segment id="135-4">
        <source xml:space="preserve"> Once there, this recurrent infection can cause various complications, in particular an inflammatory response, which if strong enough can compromise the integrity of the cornea, leading to corneal ulcer, opacity, haze, scarring and in severe cases blindness.</source>
      </segment>
      <segment id="135-5">
        <source xml:space="preserve"> Secondary to herpes infection, there can be development of chronic herpetic keratopathy, neurotrophic keratopathy, or both.</source>
      </segment>
      <segment id="135-6">
        <source xml:space="preserve"> For example, stromal infections, which are immune-mediated and are the leading cause of corneal blindness in developed countries occur as a result of chronic viral reactivation, and lead to neurotrophic keratopathy, a degenerative condition.</source>
      </segment>
      <segment id="135-7">
        <source xml:space="preserve"> A normal cornea is densely innervated, but lacks blood vessels.</source>
      </segment>
      <segment id="135-8">
        <source xml:space="preserve"> Subsequent episodes following primary viral infection can not only damage nerves, leading to decreased corneal sensation (corneal hypoesthesia), but also lead to angiogenesis, and neovascularization.</source>
      </segment>
    </unit>
    <unit id="136">
      <segment id="136">
        <source xml:space="preserve">The modified FGF-1 polypeptides described herein can be used to treat epithelial basement membrane dystrophy, Meesmann juvenile epithelial corneal dystrophy, gelatinous drop-like corneal dystrophy, Lisch epithelial corneal dystrophy, subepithelial mucinous corneal dystrophy, Reis-Bucklers corneal dystrophy, or Thiel-Behnke dystrophy, and recurrent corneal erosions.</source>
      </segment>
    </unit>
    <unit id="137">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="137">
        <source xml:space="preserve">The ocular condition may include damage to the cornea (<ph id="ph1"/>e.g.<ph id="ph2"/>, the corneal surface or endothelial layer at the interface of the cornea and aqueous humor) or surgical disruption caused by corneal surgeries, including PRK, LASIK, and any penetrating corneal surgery or keratoplasty.</source>
      </segment>
    </unit>
    <unit id="138">
      <segment id="138">
        <source xml:space="preserve">Also described herein is a method of treating a chemical or vesicant agent induced injury by administering a modified fibroblast growth factors (FGF-1) polypeptides, or pharmaceutical composition or medicaments that include such modified peptides.</source>
      </segment>
    </unit>
    <unit id="139">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="139-0">
        <source xml:space="preserve">Also described herein is a modified FGF-1 polypeptide as described herein for use in a method of treating a chemical or vesicant injury.</source>
      </segment>
      <segment id="139-1">
        <source xml:space="preserve"> The method may comprise treating a skin injury or an ocular injury caused by a chemical or a vesicant agent.</source>
      </segment>
      <segment id="139-2">
        <source xml:space="preserve"> The method may comprise treating mustard gas keratopathy, induced by a vesicant, <ph id="ph1"/>e.g.,<ph id="ph2"/> nitrogen mustard (NM), by administering modified FGF-1 as polypeptides described herein.</source>
      </segment>
      <segment id="139-3">
        <source xml:space="preserve"> Treating MGK with a modified FGF-1 polypeptide, as described herein, may result in amelioration of histopathological conditions associated with MGK, such as hyperplasia of corneal epithelial layer, epithelial-stromal cell separation edema, corneal erosions.</source>
      </segment>
      <segment id="139-4">
        <source xml:space="preserve"> The administration of modified FGF-1 of the present disclosure, may result in reduction in edema and elimination of corneal erosions.</source>
      </segment>
      <segment id="139-5">
        <source xml:space="preserve"> Corneal erosion is typically characterized by de-epithelialization of the cornea and in some examples; administration of the modified FGF-1 results in faster re-epithelialization of the cornea or reduces the severity of corneal de-epithelialization.</source>
      </segment>
      <segment id="139-6">
        <source xml:space="preserve"> Described herein is a method of regenerating ocular surface epithelium in a patient exposed to a chemical or a vesicant, by administering a modified FGF-1 as described herein.</source>
      </segment>
      <segment id="139-7">
        <source xml:space="preserve"> The method may promote regeneration of cornea, prevent degeneration of the cornea, and prevent long term sequelae to the chemical injury.</source>
      </segment>
      <segment id="139-8">
        <source xml:space="preserve"> In some examples, the method may comprise treating a corneal endothelial injury, a corneal epithelial injury, or a corneal stromal injury.</source>
      </segment>
      <segment id="139-9">
        <source xml:space="preserve"> In instances where the method treats corneal endothelial injuries, administering a modified FGF-1, as described herein, enhances the function of corneal endothelial cells and prevents long term degeneration of the cornea.</source>
      </segment>
      <segment id="139-10">
        <source xml:space="preserve"> In some instances, where the method treats corneal endothelial injuries, administering a modified FGF-1, as described herein, prevents corneal edema and secondary anterior keratopathies.</source>
      </segment>
      <segment id="139-11">
        <source xml:space="preserve"> In some instances, where the method treats corneal endothelial injuries, administering a modified FGF-1, as described herein, prevents loss of corneal endothelial cells.</source>
      </segment>
      <segment id="139-12">
        <source xml:space="preserve"> The method may result in reduction of the severity of corneal epithelial detachment.</source>
      </segment>
      <segment id="139-13">
        <source xml:space="preserve"> The method may comprise treating a stromal injury such as stromal scarring and corneal opacity.</source>
      </segment>
    </unit>
    <unit id="140">
      <segment id="140-0">
        <source xml:space="preserve">The ocular condition may include accidental trauma or chemical or thermal injury to the cornea.</source>
      </segment>
      <segment id="140-1">
        <source xml:space="preserve"> In some examples, the chemical or thermal injury is a chemical burn.</source>
      </segment>
      <segment id="140-2">
        <source xml:space="preserve"> In some examples, the chemical or thermal injury is caused by a vesicant agent.</source>
      </segment>
      <segment id="140-3">
        <source xml:space="preserve"> In some examples, the chemical or thermal injury is caused by a chemical warfare agent.</source>
      </segment>
    </unit>
    <unit id="141">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="141-0">
        <source xml:space="preserve">A multitude of household and occupational compounds have the potential to induce chemical burns to the eye and skin.</source>
      </segment>
      <segment id="141-1">
        <source xml:space="preserve"> Without prompt intervention, irreversible visual loss and disfigurement may prevail.</source>
      </segment>
      <segment id="141-2">
        <source xml:space="preserve"> Agents that rapidly neutralize both acid and alkali agents without heat release and limit diffusion, are contemplated to be effective in treating chemical injuries.</source>
      </segment>
      <segment id="141-3">
        <source xml:space="preserve"> Exemplary chemical injuries include, but are not limited to, alkali injuries, acid injuries.</source>
      </segment>
      <segment id="141-4">
        <source xml:space="preserve"> Common sources of chemical burns include sulfuric acid (H<ph id="ph1"/>2<ph id="ph2"/>SO<ph id="ph3"/>4<ph id="ph4"/>), hydrochloric acid (HCl), sodium hydroxide (NaOH), lime (CaO), silver nitrate (AgNO<ph id="ph5"/>3<ph id="ph6"/>), hydrogen peroxide (H<ph id="ph7"/>2<ph id="ph8"/>O<ph id="ph9"/>2<ph id="ph10"/>), chlorine gas and any strong oxidant.</source>
      </segment>
    </unit>
    <unit id="142">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0015" w:id="158"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="158"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="142-0">
        <source xml:space="preserve">Exemplary chemical warfare agent that can cause the chemical or thermal injury described herein, is phosgene, an urticant, or a nettle agent.</source>
      </segment>
      <segment id="142-1">
        <source xml:space="preserve"> Phosgene is a highly toxic, colorless gas at room temperature and standard pressure that condenses at 0 °C to a fuming liquid.</source>
      </segment>
      <segment id="142-2">
        <source xml:space="preserve"> Its molecular formula is COCl<ph id="ph1"/>2<ph id="ph2"/>.</source>
      </segment>
      <segment id="142-3">
        <source xml:space="preserve"> Phosgene is extremely toxic by acute (short-term) inhalation exposure.</source>
      </segment>
      <segment id="142-4">
        <source xml:space="preserve"> Severe respiratory effects, including pulmonary edema, pulmonary emphysema, and death have been reported in humans.</source>
      </segment>
      <segment id="142-5">
        <source xml:space="preserve"> Severe ocular irritation and dermal burns may result following eye or skin exposure.</source>
      </segment>
      <segment id="142-6">
        <source xml:space="preserve"> Chronic (long-term) inhalation exposure to phosgene may also cause irreversible pulmonary changes, such as emphysema and fibrosis.</source>
      </segment>
      <segment id="142-7">
        <source xml:space="preserve"> Its exposure can result in widespread and devastating effects including high mortality due to its fast penetration and ability to cause immediate severe cutaneous injury.</source>
      </segment>
      <segment id="142-8">
        <source xml:space="preserve"> Results from a recent study show that topical cutaneous exposure to phosgene vapor causes blanching of exposed skin with an erythematous ring, necrosis, edema, mild urticaria and erythema within minutes after exposure out to 8h post-exposure, in a mouse model.</source>
      </segment>
      <segment id="142-9">
        <source xml:space="preserve"> These clinical skin manifestations are accompanied with increases in skin thickness, apoptotic cell death, mast cell degranulation, myeloperoxidase activity indicating neutrophil infiltration, p53 phosphorylation and accumulation, and an increase in COX-2 and TNFα levels.</source>
      </segment>
      <segment id="142-10">
        <source xml:space="preserve"> Topical phosgene-exposure also resulted in the dilatation of the peripheral vessels with a robust increase in RBCs in vessels of the liver, spleen, kidney, lungs and heart tissues.</source>
      </segment>
      <segment id="142-11">
        <source xml:space="preserve"> It is contemplated that these events could cause a drop in blood pressure leading to shock, hypoxia and death.</source>
      </segment>
      <segment id="142-12">
        <source xml:space="preserve"> See, <ph id="ph3"/>Tewari-Singh N, Goswami DG, Kant R, Croutch CR, Casillas RP, Orlicky DJ, Agarwal R, Cutaneous exposure to vesicant phosgene oxime:</source>
      </segment>
      <segment id="142-13">
        <source xml:space="preserve"> Acute effects on the skin and systemic toxicity, Toxicol Appl Pharmacol.</source>
      </segment>
      <segment id="142-14">
        <source xml:space="preserve"> 2017 Feb 15; 317:25-32<ph id="ph4"/>.</source>
      </segment>
    </unit>
    <unit id="143">
      <segment id="143">
        <source xml:space="preserve">The modified FGF-1 polypeptide described herein may be for use in a method of treating, preventing, or ameliorating the various skin injuries caused by vesicant exposure.</source>
      </segment>
    </unit>
    <unit id="144">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0016" w:id="161"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="161"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="144-0">
        <source xml:space="preserve">Vesicants, or vesicant agents, or blistering agents are toxic compounds that produce skin injuries resembling those caused by burns.</source>
      </segment>
      <segment id="144-1">
        <source xml:space="preserve"> These agents on inhalation affect the upper respiratory tract as well as the lungs, producing pulmonary edema.</source>
      </segment>
      <segment id="144-2">
        <source xml:space="preserve"> <ph id="ph1"/>See, e.g.,<ph id="ph2"/> <ph id="ph3"/>Ganesan, K., S.</source>
      </segment>
      <segment id="144-3">
        <source xml:space="preserve"> K. Raza, and R. Vijayaraghavan (2010) Chemical Warfare Agents, Journal of Pharmacy and Bioallied Sciences 2.3:</source>
      </segment>
      <segment id="144-4">
        <source xml:space="preserve"> 166-178<ph id="ph4"/>.</source>
      </segment>
      <segment id="144-5">
        <source xml:space="preserve"> These agents can also cause severe eye injuries.</source>
      </segment>
      <segment id="144-6">
        <source xml:space="preserve"> There are two forms of vesicants:</source>
      </segment>
      <segment id="144-7">
        <source xml:space="preserve"> mustards and arsenicals.</source>
      </segment>
      <segment id="144-8">
        <source xml:space="preserve"> The most important substance in this class of chemical warfare agents is sulfur mustard.</source>
      </segment>
      <segment id="144-9">
        <source xml:space="preserve"> Other members include nitrogen mustards (HN1, HN2 and HN3), and arsenic vesicants such as lewisites (L1, L2 and L3), ethyldichloroarsine, methyldichloroarsine, phenyldichloriarsine.</source>
      </segment>
      <segment id="144-10">
        <source xml:space="preserve"> <ph id="ph5"/>Fig. 12<ph id="ph6"/> shows some example structures of vesicant agents.</source>
      </segment>
      <segment id="144-11">
        <source xml:space="preserve"> Specific examples of vesicant agents include but are not limited to sulfur mustard (SM), bis-(2-chloroethyl) sulfide, chloroethylethyl sulfide (CEES), lewisite, and 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride, a member of the family of nitrogen mustard (NM).</source>
      </segment>
      <segment id="144-12">
        <source xml:space="preserve"> As used throughout this disclosure, the terms vesicant, vesication-causing agent or chemical, vesicating agent, and the like, are taken to mean vesicants as specifically enumerated herein, and other compounds, such as toxins and/or chemical warfare agents.</source>
      </segment>
      <segment id="144-13">
        <source xml:space="preserve"> Sulfur mustard is the vesicant with the highest military significance since its use in WWI.</source>
      </segment>
      <segment id="144-14">
        <source xml:space="preserve"> The nitrogen mustards were synthesized in the 1930s but were not produced in large amounts for warfare.</source>
      </segment>
      <segment id="144-15">
        <source xml:space="preserve"> Mechlorethamine (HN2, Mustargen) has found more peaceful applications as a cancer chemotherapeutic agent and has remained the standard compound for this purpose for many years.</source>
      </segment>
      <segment id="144-16">
        <source xml:space="preserve"> Lewisite (L) was synthesized in 1918 for military purpose due to its non-flammable property and toxicity similar to mustard, but has probably not been used on a battlefield.</source>
      </segment>
      <segment id="144-17">
        <source xml:space="preserve"> The mustards are radiomimetic and are extremely toxic to dividing cells.</source>
      </segment>
      <segment id="144-18">
        <source xml:space="preserve"> Mustards are lipophilic and readily penetrate the skin, most textiles and rubber.</source>
      </segment>
      <segment id="144-19">
        <source xml:space="preserve"> After passing through the cellular membrane, sulfur mustard is converted to highly reactive sulphonium ion.</source>
      </segment>
      <segment id="144-20">
        <source xml:space="preserve"> It irreversibly alkylates DNA, RNA and protein, causing cell death; the most important target is DNA.</source>
      </segment>
      <segment id="144-21">
        <source xml:space="preserve"> Mustard alkylates the purine bases of DNA and damages them.</source>
      </segment>
      <segment id="144-22">
        <source xml:space="preserve"> Lewisite is absorbed by the skin much faster, and it causes immediate pain and irritation in the affected organ and produces more systematic symptoms.</source>
      </segment>
      <segment id="144-23">
        <source xml:space="preserve"> It directly binds to the sulfhydryl groups and inactivates them.</source>
      </segment>
    </unit>
    <unit id="145">
      <segment id="145-0">
        <source xml:space="preserve">The use of sulfur mustard (SM), and other vesicating agents in chemical warfare has been long known.</source>
      </segment>
      <segment id="145-1">
        <source xml:space="preserve"> More recently, in August 2015, SM was used by ISIS in an attack on Kurdish forces in Iraq, as well as an attack in Syria.</source>
      </segment>
      <segment id="145-2">
        <source xml:space="preserve"> Mustard agents injure the eyes, the skin, and the lungs, with the eyes being the most sensitive.</source>
      </segment>
      <segment id="145-3">
        <source xml:space="preserve"> Because symptoms do not manifest until 2 to 4 hours after exposure, exposed persons do not immediately know they are exposed to mustard.</source>
      </segment>
      <segment id="145-4">
        <source xml:space="preserve"> This delay has contributed to confusion and panic when symptoms of exposure finally develop.</source>
      </segment>
      <segment id="145-5">
        <source xml:space="preserve"> For the eyes, these consist of blepharospasm, lacrimation, irritation, pain, and photophobia.</source>
      </segment>
      <segment id="145-6">
        <source xml:space="preserve"> Corneal injuries resulting from ocular exposure to sulfur mustard (SM) vapor are the most prevalent chemical warfare injury.</source>
      </segment>
      <segment id="145-7">
        <source xml:space="preserve"> Ocular exposures exhibit three distinct, dose-dependent clinical trajectories:</source>
      </segment>
      <segment id="145-8">
        <source xml:space="preserve"> complete injury resolution, immediate transition to a chronic injury, or apparent recovery followed by the subsequent development of persistent ocular manifestations.</source>
      </segment>
      <segment id="145-9">
        <source xml:space="preserve"> These latter two trajectories include a constellation of corneal symptoms that are collectively known as mustard gas keratopathy (MGK).</source>
      </segment>
      <segment id="145-10">
        <source xml:space="preserve"> Tissue-specific damage during the acute injury can decrement the regenerative capacities of corneal endothelium and limbal stem cells, thereby predisposing the cornea to the chronic or delayed forms of MGK.</source>
      </segment>
    </unit>
    <unit id="146">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="146-0">
        <source xml:space="preserve">For some patients MGK occurs a few weeks after exposure; in others it took years to manifest.</source>
      </segment>
      <segment id="146-1">
        <source xml:space="preserve"> This keratopathy is characterized by corneal conjunctivalization and limbal stem cell deficiency.</source>
      </segment>
      <segment id="146-2">
        <source xml:space="preserve"> It has been shown that in the human corneal endothelium, gaps due to CEC loss are typically filled by spreading of proximal CECs.</source>
      </segment>
      <segment id="146-3">
        <source xml:space="preserve"> These morphological changes compensate for endothelial loss until the barrier between the cornea and aqueous humor can no longer be maintained, resulting in persistent corneal edema and secondary anterior keratopathies.</source>
      </segment>
      <segment id="146-4">
        <source xml:space="preserve"> Because adult human CECs do not proliferate <ph id="ph1"/>in vivo,<ph id="ph2"/> any loss of CECs therefore potentially represents a permanent reduction in endothelial capacity.</source>
      </segment>
      <segment id="146-5">
        <source xml:space="preserve"> Thus, while endothelial function can be restored after a mild injury by CEC spreading, more severe injuries may exceed the repair capacity of the human endothelium.</source>
      </segment>
      <segment id="146-6">
        <source xml:space="preserve"> Rabbits are distinct from humans in that they can undergo limited CEC proliferation, giving them an improved capacity to recover from CEC loss.</source>
      </segment>
      <segment id="146-7">
        <source xml:space="preserve"> However, as in humans, sufficiently severe injury to the rabbit endothelium also results in irreversible corneal decompensation and secondary keratopathies.</source>
      </segment>
    </unit>
    <unit id="147">
      <segment id="147-0">
        <source xml:space="preserve">Based on the above studies, it has been hypothesized that vesicant-induced endothelial failure may be the causal mechanism underlying MGK pathogenesis.</source>
      </segment>
      <segment id="147-1">
        <source xml:space="preserve"> This hypothesis is consistent with the dose dependence between SM and the development of MGK that has been observed in humans and rabbits, as well as the different clinical trajectories (resolved chronic MGK and delayed-onset MGK) that have been reported in human casualties.</source>
      </segment>
      <segment id="147-2">
        <source xml:space="preserve"> According to this hypothesis, cornea exposure to low doses of vesicant may result in an acute epithelial lesion, with minimal endothelial toxicity, and corneas recover without long-term complications.</source>
      </segment>
      <segment id="147-3">
        <source xml:space="preserve"> Alternatively, exposure to doses of a vesicant that cause irreparable injury to the corneal endothelium could result in endothelial barrier failure, producing a persistent edema with secondary anterior keratopathies.</source>
      </segment>
      <segment id="147-4">
        <source xml:space="preserve"> Following a severe injury, there may be no apparent delay between the acute injury and MGK onset.</source>
      </segment>
    </unit>
    <unit id="148">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="148-0">
        <source xml:space="preserve">Hence, a composition and method for minimizing or preventing injury due to sulfur mustard and similarly acting chemical toxicants, particularly chemical warfare agents, is an important pursuit for scientists working for the U.S.</source>
      </segment>
      <segment id="148-1">
        <source xml:space="preserve"> Department of Defense.</source>
      </segment>
      <segment id="148-2">
        <source xml:space="preserve"> Recent studies have shown that as vesicating agents, mustard compounds lead to a loss of epithelial-stromal attachment.</source>
      </segment>
      <segment id="148-3">
        <source xml:space="preserve"> In the cornea, microbullae are formed, and once enough have accrued, the corneal epithelium is unable to hold fast to the basement membrane, causing the epithelial tissue to slough.</source>
      </segment>
      <segment id="148-4">
        <source xml:space="preserve"> Thus, an effective post-exposure therapy for SM is desired to enhance the ability of the corneal epithelium to remain attached to the stroma.</source>
      </segment>
      <segment id="148-5">
        <source xml:space="preserve"> Without being bound by a theory, it is contemplated that the ability of the corneal epithelium to remain attached to the stroma might allow some basal epithelia the opportunity to recover <ph id="ph1"/>in situ,<ph id="ph2"/> maintaining their connections with their basement membrane and stroma.</source>
      </segment>
      <segment id="148-6">
        <source xml:space="preserve"> It has also been hypothesized that one of the key players in the epithelial-stromal integrity is collagen XVII (<ph id="ph3"/>i.e.,<ph id="ph4"/> BP180), a transmembranous component of the hemidesmosome.</source>
      </segment>
      <segment id="148-7">
        <source xml:space="preserve"> Cleavage of collagen XVII by ADAM ("A Disintegrin And Metalloproteinase") family of proteins, including ADAM9, ADAM10, and/or ADAM17 after injury releases epithelial cells from their basement membrane, and this cleavage allows them to migrate.</source>
      </segment>
    </unit>
    <unit id="149">
      <segment id="149-0">
        <source xml:space="preserve">ADAM17, also known as TNF-a converting enzyme or TACE, is a general response to injury as well as a "sheddase" for releasing collagen XVII.</source>
      </segment>
      <segment id="149-1">
        <source xml:space="preserve"> It was postulated that corneal microblistering, induced by vesicant agent exposure, is in part due to activation of ADAM17, which is capable of cleaving collagen XVII.</source>
      </segment>
      <segment id="149-2">
        <source xml:space="preserve"> Experimental data confirmed the induction of ADAM17 expression at the basement membrane zone of corneas exposed to vesicant agent NM.</source>
      </segment>
      <segment id="149-3">
        <source xml:space="preserve"> Thus, agents that are able to inhibit the post-exposure upregulation of ADAM17 expression are contemplated to be useful for attenuation of corneal injuries caused by vesicant agents.</source>
      </segment>
    </unit>
    <unit id="150">
      <segment id="150-0">
        <source xml:space="preserve">The present disclosure provides modified FGF-1 polypeptides that treat, reduce the adverse effects or, and otherwise aid in the healing of exposure to vesicant agents, such as SM and NM.</source>
      </segment>
      <segment id="150-1">
        <source xml:space="preserve"> The modified FGF-1 polypeptides disclosed herein are capable of preventing the overexpression of ADAM17 following exposure to a vesicant agent, such as SM and/or NM.</source>
      </segment>
    </unit>
    <unit id="151">
      <segment id="151-0">
        <source xml:space="preserve">The present disclosure also provides a modified FGF-1 polypeptide for use in a method of treating, preventing, reducing the adverse effects of, and otherwise aiding the healing of exposure to chemical or vesicant induced injury.</source>
      </segment>
      <segment id="151-1">
        <source xml:space="preserve"> The methods disclosed herein may further prevent the overexpression of ADAM17 following exposure to a vesicant agent, such as SM and/or NM.</source>
      </segment>
    </unit>
    <unit id="152">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="152-0">
        <source xml:space="preserve">Wild type FGF-1 proteins, e.g., SEQ ID NO:</source>
      </segment>
      <segment id="152-1">
        <source xml:space="preserve"> 1, which have unpaired cysteine residues that are susceptible to oxidation and alkylation.</source>
      </segment>
      <segment id="152-2">
        <source xml:space="preserve"> <ph id="ph1"/>See<ph id="ph2"/> <ph id="ph3"/>Fig. 1.</source>
      </segment>
      <ignorable>
        <source xml:space="preserve"><ph id="ph4"/></source>
      </ignorable>
      <segment id="152-3">
        <source xml:space="preserve"> Where the modified FGF-1 polypeptides do not comprise unpaired cysteine residues, such modified FGF-1 polypeptides are less susceptible to oxidation and/or alkylation by vesicant agents.</source>
      </segment>
      <segment id="152-4">
        <source xml:space="preserve"> Experimental data has also indicated reduction in levels of FGF-1 and its mRNA are known to result from exposure to mustard agents and it is hypothesized that this loss may play a role in the slow healing of mustard-induced lesions in the cornea.</source>
      </segment>
      <segment id="152-5">
        <source xml:space="preserve"> In some embodiments of the present disclosure, the modified FGF-1 polypeptides, which do not comprise free cysteine residues and accordingly are less or not susceptible to cysteine modification, are effective in accelerating the healing of corneal mustard lesions.</source>
      </segment>
    </unit>
    <unit id="153">
      <segment id="153-0">
        <source xml:space="preserve">In the present disclosure, the method may comprise administering a modified FGF-1 polypeptide that do not comprise unpaired cysteine residues, which modified FGF-1 polypeptides are less susceptible to oxidation and/or alkylation by vesicant agents.</source>
      </segment>
      <segment id="153-1">
        <source xml:space="preserve"> In the present disclosure, the method may comprise administering a modified FGF-1 polypeptides, which do not comprise free cysteine residues and accordingly are less or not susceptible to cysteine modification.</source>
      </segment>
      <segment id="153-2">
        <source xml:space="preserve"> The method disclosed herein may be effective in accelerating the healing of corneal lesions associated with MGK.</source>
      </segment>
    </unit>
    <unit id="154">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0017" w:id="171"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="171"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="154-0">
        <source xml:space="preserve">Exposure to vesicant agents, such as sulfur mustard (SM) and nitrogen mustard (NM) can cause severe skin injury with delayed blistering.</source>
      </segment>
      <segment id="154-1">
        <source xml:space="preserve"> Depending upon the dose and time of their exposure, edema and erythema can potentially develop into blisters, ulceration, necrosis, desquamation, and pigmentation changes, which persist weeks and even years after exposure.</source>
      </segment>
      <segment id="154-2">
        <source xml:space="preserve"> <ph id="ph1"/>See, e.g.,<ph id="ph2"/> <ph id="ph3"/>Tewari-Singh N, Agarwal R, Mustard vesicating agent-induced toxicity in the skin tissue and silibinin as a potential countermeasure, Ann N Y Acad Sci. 2016 Jun;1374(1):184-92<ph id="ph4"/>.</source>
      </segment>
      <segment id="154-3">
        <source xml:space="preserve"> Another exemplary vesicant agent Phosgene Oxime (CX), an urticant or nettle agent, is also a potential chemical warfare and terrorist weapon.</source>
      </segment>
    </unit>
    <unit id="155">
      <segment id="155-0">
        <source xml:space="preserve">The ocular disease, disorder or condition to be treated may be a disease, disorder, or condition of the corneal stroma.</source>
      </segment>
      <segment id="155-1">
        <source xml:space="preserve"> Diseases, disorders or conditions of the corneal stroma include, but are not limited to, keratoconus, lattice corneal dystrophy, granular corneal dystrophy, macular corneal dystrophy, Schnyder crystalline corneal dystrophy, congenital stromal corneal dystrophy, fleck corneal dystrophy, trauma or chemical or thermal injury, or injury secondary to infections such as trachoma.</source>
      </segment>
    </unit>
    <unit id="156">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="156">
        <source xml:space="preserve">The modified FGF-1 polypeptides described herein can be applied before, during, or after corneal transplantations procedures (<ph id="ph1"/>e.g.,<ph id="ph2"/> corneal transplantation or procedures involving Descemet's membrane) that involve disruption of the cornea (<ph id="ph3"/>e.g.,<ph id="ph4"/> corneal endothelial structure) where acceleration of healing of corneal or ocular surface cells and/or improving the cellular response (<ph id="ph5"/>e.g.,<ph id="ph6"/> by increasing the viability and/or longevity of the transplanted cells) to insult would result in a therapeutic benefit.</source>
      </segment>
    </unit>
    <unit id="157">
      <segment id="157-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides described herein can be used to increase the viability and health of corneal cells or corneal progenitors being prepared for transplantation.</source>
      </segment>
      <segment id="157-1">
        <source xml:space="preserve"> Modified FGF-1 polypeptides described herein added to the organ culture medium for donated corneas or other donated corneal tissue stimulate the corneal cells and increase the length of time the corneas can be stored before transplantation, as well as increasing the probability that a cornea will have sufficient healthy cells to be useful for transplantation.</source>
      </segment>
      <segment id="157-2">
        <source xml:space="preserve"> Also, the modified FGF-1 polypeptides described herein can be used in culture media when culturing corneal progenitor cells to stimulate growth of those cells.</source>
      </segment>
    </unit>
    <unit id="158">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="158-0">
        <source xml:space="preserve">The disclosure further relates to methods of modulating the activity of one or more fibroblast growth factor receptors (FGFRs) in a corneal endothelial cell comprising contacting said corneal endothelial cell with a modified FGF (<ph id="ph1"/>e.g.,<ph id="ph2"/> a modified FGF-1, such as one comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="158-1">
        <source xml:space="preserve"> 2).</source>
      </segment>
      <segment id="158-2">
        <source xml:space="preserve"> Such methods can be used to increase or stimulate the activity of one or more FGFRs, which can result in increased cell migration and/or cell proliferation.</source>
      </segment>
    </unit>
    <unit id="159">
      <segment id="159-0">
        <source xml:space="preserve">Described herein are methods of treating a metabolic disease by administering a modified FGF-1 polypeptide according to the present disclosure.</source>
      </segment>
      <segment id="159-1">
        <source xml:space="preserve"> Exemplary metabolic diseases that can be treated with the disclosed modified FGF-1 polypeptides include but are not limited to:</source>
      </segment>
      <segment id="159-2">
        <source xml:space="preserve"> (1) glucose utilization disorders and the sequelae associated therewith, including diabetes mellitus (Type I and Type-2), gestational diabetes, hyperglycemia, insulin resistance, abnormal glucose metabolism, "pre-diabetes" (Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)), and other physiological disorders associated with, or that result from, the hyperglycemic condition, including, for example, histopathological changes such as pancreatic β-cell destruction; (2) dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary artery disease, cerebrovascular disorders and the like; (3) other conditions which may be associated with the metabolic syndrome, such as obesity and elevated body mass (including the co-morbid conditions thereof such as, but not limited to, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS)), and also include thromboses, hypercoagulable and prothrombotic states (arterial and venous), hypertension, cardiovascular disease, stroke and heart failure; (4) disorders or conditions in which inflammatory reactions are involved, including atherosclerosis, chronic inflammatory bowel diseases (e.g., Crohn's disease and ulcerative colitis), asthma, lupus erythematosus, arthritis, or other inflammatory rheumatic disorders; (5) disorders of cell cycle or cell differentiation processes such as adipose cell tumors, lipomatous carcinomas including, for example, liposarcomas, solid tumors, and neoplasms; (6) neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinfiammatory processes and/or other peripheral neuropathies, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, progressive multifocal leukoencephalopathy and Guillian-Barre syndrome; (7) skin and dermatological disorders and/or disorders of wound healing processes, including erythemato-squamous dermatoses; and (8) other disorders such as syndrome X, osteoarthritis, and acute respiratory distress syndrome.</source>
      </segment>
      <segment id="159-3">
        <source xml:space="preserve"> Also described are methods of reducing fed and fasting blood glucose, improving insulin sensitivity and glucose tolerance, reducing systemic chronic inflammation, ameliorating hepatic steatosis in a mammal, reducing food intake, or combinations thereof, by administering a therapeutically effective amount of a disclosed modified FGF-1 polypeptide (or nucleic acid molecules encoding such).</source>
      </segment>
    </unit>
    <unit id="160">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="160-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides may be administered for wound healing.</source>
      </segment>
      <segment id="160-1">
        <source xml:space="preserve"> Examples of wounds include, but are not limited to, abrasions, avulsions, blowing wounds (<ph id="ph1"/>e.g.,<ph id="ph2"/> open pneumothorax), burn wounds, contusions, gunshot wounds, incised wounds, open wounds, penetrating wounds, perforating wounds, puncture wounds, séton wounds, stab wounds, surgical wounds, subcutaneous wounds, diabetic lesions, or tangential wounds.</source>
      </segment>
      <segment id="160-2">
        <source xml:space="preserve"> Additional examples of wounds that can be treated by the compounds and compositions described herein include acute conditions or wounds, such as thermal burns, chemical burns, radiation burns, burns caused by excess exposure to ultraviolet radiation (<ph id="ph3"/>e.g.,<ph id="ph4"/> sunburn); damage to bodily tissues, such as the perineum as a result of labor and childbirth; injuries sustained during medical procedures, such as episiotomies; trauma-induced injuries including cuts, incisions, excoriations; injuries sustained from accidents; post-surgical injuries, as well as chronic conditions, such as pressure sores, bedsores, conditions related to diabetes and poor circulation, and all types of acne.</source>
      </segment>
      <segment id="160-3">
        <source xml:space="preserve"> In addition, the wound can include dermatitis, such as impetigo, intertrigo, folliculitis and eczema, wounds following dental surgery; periodontal disease; wounds following trauma; and tumor-associated wounds.</source>
      </segment>
      <segment id="160-4">
        <source xml:space="preserve"> Yet other examples of wounds include animal bites, arterial disease, insect stings and bites, bone infections, compromised skin/muscle grafts, gangrene, skin tears or lacerations, skin aging, surgical incisions, including slow or non-healing surgical wounds, intracerebral hemorrhage, aneurysm, dermal asthenia, and post-operation infections.</source>
      </segment>
    </unit>
    <unit id="161">
      <segment id="161-0">
        <source xml:space="preserve">A therapeutic peptide of the present disclosure may also be used to treat external wounds caused by, but not limited to scrapes, cuts, lacerated wounds, bite wounds, bullet wounds, stab wounds, burn wounds, sun burns, chemical burns, surgical wounds, bed sores, radiation injuries, all kinds of acute and chronic wounds, wounds or lesions created by cosmetic skin procedures.</source>
      </segment>
      <segment id="161-1">
        <source xml:space="preserve"> The peptide may also be used to ameliorate the effects of skin aging.</source>
      </segment>
      <segment id="161-2">
        <source xml:space="preserve"> The peptide may accelerate wound healing in an external wound and/or improve the cosmetic appearance of wounded areas, or skin subject to aging and disease.</source>
      </segment>
      <segment id="161-3">
        <source xml:space="preserve"> The peptide may be used to treat internal injury caused by, but not limited to, disease, surgery, gunshots, stabbing, accidents, infarcts, ischemic injuries, to organs and tissues including but not limited to heart, bone, brain, spinal cord, retina, peripheral nerves and other tissues and organs commonly subject to acute and chronic injury, disease, congenital and developmental malformation and aging processes.</source>
      </segment>
    </unit>
    <unit id="162">
      <segment id="162-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides of the present disclosure may be administered for treating burn injury.</source>
      </segment>
      <segment id="162-1">
        <source xml:space="preserve"> Exemplary burn wounds include, but are not limited to, "burn ulcers" including, for example, ulceration that occur as a result of a burn injury, including a first degree burn (i.e., superficial, reddened area of skin); a second degree burn (a blistered injury site which may heal spontaneously after the blister fluid has been removed); a third degree burn (burn through the entire skin and usually require surgical intervention for wound healing); scalding (may occur from scalding hot water, grease or radiator fluid); a thermal burn (may occur from flames, usually deep burns); a chemical burn (may come from acid and alkali, usually deep burns); an electrical burn (either low voltage around a house or high voltage at work); an explosion flash (usually superficial injuries); and contact burns (usually deep and may occur from muffler tail pipes, hot irons, and stoves).</source>
      </segment>
      <segment id="162-2">
        <source xml:space="preserve"> As used herein, a delayed or difficult to heal wound may include, for example, a wound that is characterized at least in part by 1) a prolonged inflammatory phase, 2) a slow forming extracellular matrix (ECM), and 3) a decreased rate of epithelialization.</source>
      </segment>
    </unit>
    <unit id="163">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0018" w:id="180"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="180"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0019" w:id="181"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="181"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="163-0">
        <source xml:space="preserve">It has been shown that growth factors, e.g. FGF-1, play an important role in nerve regeneration and nerve healing.</source>
      </segment>
      <segment id="163-1">
        <source xml:space="preserve"> FGF-1 has been suggested for use in regenerating nervous system tissue following spinal cord injury or trauma, such as brachial plexus injury, neuroimmunologic disorders, such as acute or idiopathic transverse myelitis (TM), or any other disease or condition where regeneration and/or protection of neurons or neural tissue is desired, since FGF-1 is believed to stimulate neural proliferation and growth and may be neuroprotective.</source>
      </segment>
      <segment id="163-2">
        <source xml:space="preserve"> <ph id="ph1"/>See, e.g.,<ph id="ph2"/> <ph id="ph3"/>Cheng, H. et al., "Spinal Cord Repair with Acidic Fibroblast Growth Factor as a Treatment for a Patient with Chronic Paraplegia," SPINE 29(14):E284-E288 (2004<ph id="ph4"/>); and <ph id="ph5"/>Lin, P-H., "Functional recovery of chronic complete idiopathic transverse myelitis after administration of neurotrophic factors," Spinal Cord 44:254-257 (2006<ph id="ph6"/>).</source>
      </segment>
      <segment id="163-3">
        <source xml:space="preserve"> FGF-1 is known to have a neurotrophic activity, promote axonal growth, and exert beneficial effects in models of spinal cord injury and axon regeneration.</source>
      </segment>
      <segment id="163-4">
        <source xml:space="preserve"> Accordingly, the modified FGF-1 polypeptide of the present disclosure promotes neural regeneration and can be used in methods of treating conditions that benefit from neural regeneration.</source>
      </segment>
      <segment id="163-5">
        <source xml:space="preserve"> In some example methods, the neurological condition may be amyotrophic lateral sclerosis (ALS).</source>
      </segment>
      <segment id="163-6">
        <source xml:space="preserve"> In some example methods, the neurological condition may be acute or idiopathic transverse myelitis (TM).</source>
      </segment>
      <segment id="163-7">
        <source xml:space="preserve"> In certain instances, the modified FGF-1 polypeptide can be administered in combination with other growth factors, as well as other pharmaceutically active components, for treating conditions that benefit from neural; regeneration.</source>
      </segment>
    </unit>
    <unit id="164">
      <segment id="164">
        <source xml:space="preserve">Pharmaceutical Compositions, Methods of Administration, and Dosing</source>
      </segment>
    </unit>
    <unit id="165">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0020" w:id="183"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="183"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0021" w:id="184"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="184"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0022" w:id="185"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="185"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0023" w:id="186"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="186"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="165-0">
        <source xml:space="preserve">Pharmaceutical compositions comprising a modified FGF-polypeptide as described herein may be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.</source>
      </segment>
      <segment id="165-1">
        <source xml:space="preserve"> Proper formulation is dependent upon the route of administration chosen.</source>
      </segment>
      <segment id="165-2">
        <source xml:space="preserve"> Additional details about suitable excipients for pharmaceutical compositions described herein may be found, for example, in <ph id="ph1"/>Remington:</source>
      </segment>
      <segment id="165-3">
        <source xml:space="preserve"> The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.:</source>
      </segment>
      <segment id="165-4">
        <source xml:space="preserve"> Mack Publishing Company, 1995<ph id="ph2"/>); <ph id="ph3"/>Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975<ph id="ph4"/>; <ph id="ph5"/>Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980<ph id="ph6"/>; and <ph id="ph7"/>Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams &amp; Wilkins1999<ph id="ph8"/>).</source>
      </segment>
    </unit>
    <unit id="166">
      <segment id="166-0">
        <source xml:space="preserve">A pharmaceutical composition, as used herein, refers to a mixture of a modified FGF with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients, and, optionally, other therapeutic and/or prophylactic ingredients.</source>
      </segment>
      <segment id="166-1">
        <source xml:space="preserve"> The pharmaceutical composition facilitates administration of the modified FGF to an organism.</source>
      </segment>
      <segment id="166-2">
        <source xml:space="preserve"> In practicing the methods of treatment or use described herein, therapeutically effective amounts of modified FGF-1 polypeptides described herein are administered in a pharmaceutical composition to a mammal having an ocular disease, disorder, or condition to be treated.</source>
      </segment>
      <segment id="166-3">
        <source xml:space="preserve"> The mammal may be a human.</source>
      </segment>
      <segment id="166-4">
        <source xml:space="preserve"> A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.</source>
      </segment>
      <segment id="166-5">
        <source xml:space="preserve"> A pharmaceutically acceptable or suitable composition includes an ophthalmologically suitable or acceptable composition.</source>
      </segment>
    </unit>
    <unit id="167">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="167-0">
        <source xml:space="preserve">A pharmaceutical composition (<ph id="ph1"/>e.g.,<ph id="ph2"/> for delivery by injection or for application as an eye drop) may be in the form of a liquid or solid.</source>
      </segment>
      <segment id="167-1">
        <source xml:space="preserve"> A liquid pharmaceutical composition may include, for example, one or more of the following:</source>
      </segment>
      <segment id="167-2">
        <source xml:space="preserve"> sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils that may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents; antioxidants; chelating agents; buffers and agents for the adjustment of tonicity such as sodium chloride or dextrose.</source>
      </segment>
      <segment id="167-3">
        <source xml:space="preserve"> A parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.</source>
      </segment>
      <segment id="167-4">
        <source xml:space="preserve"> Physiological saline is commonly used as an excipient, and an injectable pharmaceutical composition or a composition that is delivered ocularly (for example, as an eye drop) is preferably sterile.</source>
      </segment>
    </unit>
    <unit id="168">
      <segment id="168-0">
        <source xml:space="preserve">A modified FGF-polypeptide or pharmaceutical composition described herein can be delivered to a subject by any suitable means, including, for example, topically, intraocularly, intracamerally, orally, parenterally, intravenously, intraperitoneally, intranasally (or other delivery methods to the mucous membranes, for example, of the nose, throat, and bronchial tubes), or by local administration to the eye, or by an intraocular or periocular device.</source>
      </segment>
      <segment id="168-1">
        <source xml:space="preserve"> Modes of local administration can include, for example, topical application, eye drops, intraocular injection or periocular injection.</source>
      </segment>
      <segment id="168-2">
        <source xml:space="preserve"> Periocular injection typically involves injection of the compound under the conjunctiva or into the Tennon's space (beneath the fibrous tissue overlying the eye).</source>
      </segment>
      <segment id="168-3">
        <source xml:space="preserve"> Intraocular injection typically involves injection of the modified FGF or pharmaceutical composition into the vitreous.</source>
      </segment>
      <segment id="168-4">
        <source xml:space="preserve"> The administration may be non-invasive, such as by topical application or eye drops.</source>
      </segment>
      <segment id="168-5">
        <source xml:space="preserve"> The administration may be via a combination of topical and intracameral method.</source>
      </segment>
    </unit>
    <unit id="169">
      <segment id="169-0">
        <source xml:space="preserve">A modified FGF or pharmaceutical composition described herein can be formulated for administration using pharmaceutically acceptable (suitable) carriers or vehicles as well as techniques routinely used in the art.</source>
      </segment>
      <segment id="169-1">
        <source xml:space="preserve"> A pharmaceutically acceptable or suitable carrier includes an ophthalmologically suitable or acceptable carrier.</source>
      </segment>
      <segment id="169-2">
        <source xml:space="preserve"> A carrier is selected according to the solubility of the particular modified FGF.</source>
      </segment>
      <segment id="169-3">
        <source xml:space="preserve"> Suitable ophthalmological compositions and formulations include those that are administrable locally to the eye, such as by eye drops, injection or the like.</source>
      </segment>
      <segment id="169-4">
        <source xml:space="preserve"> In the case of eye drops, the formulation can also optionally include, for example, ophthalmologically compatible agents such as isotonizing agents such as sodium chloride, concentrated glycerin, and the like; buffering agents such as sodium phosphate, sodium acetate, and the like; surfactants such as polyoxyethylene sorbitan mono-oleate (also referred to as Polysorbate 80), polyoxyl stearate 40, polyoxyethylene hydrogenated castor oil, and the like; stabilization agents such as sodium citrate, sodium edentate, and the like; preservatives such as benzalkonium chloride, parabens, and the like; and other ingredients.</source>
      </segment>
      <segment id="169-5">
        <source xml:space="preserve"> Preservatives can be employed, for example, at a level of from about 0.001 to about 1.0% weight/volume.</source>
      </segment>
      <segment id="169-6">
        <source xml:space="preserve"> The pH of the formulation is usually within the range acceptable to ophthalmologic formulations, such as within the range of about pH 4 to 8.</source>
      </segment>
    </unit>
    <unit id="170">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0024" w:id="192"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="192"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="170-0">
        <source xml:space="preserve">For injection, the modified FGF or pharmaceutical composition can be provided in an injection grade saline solution, in the form of an injectable liposome solution, slow-release polymer system or the like.</source>
      </segment>
      <segment id="170-1">
        <source xml:space="preserve"> Intraocular and periocular injections are known to those skilled in the art and are described in numerous publications including, for example, <ph id="ph1"/>Spaeth, Ed., Ophthalmic Surgery:</source>
      </segment>
      <segment id="170-2">
        <source xml:space="preserve"> Principles of Practice, W.</source>
      </segment>
      <segment id="170-3">
        <source xml:space="preserve"> B. Sanders Co., Philadelphia, Pa., 85-87, 1990<ph id="ph2"/>.</source>
      </segment>
    </unit>
    <unit id="171">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0025" w:id="194"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="194"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="171-0">
        <source xml:space="preserve">The modified FGF or pharmaceutical composition (e.g., an ophthalmic formulation) described herein may be administered via microneedles into the cornea (<ph id="ph1"/>Jiang et al. (2007).</source>
      </segment>
      <segment id="171-1">
        <source xml:space="preserve"> Invest Ophthalmol Vis Sci 48(9):</source>
      </segment>
      <segment id="171-2">
        <source xml:space="preserve"> 4038-4043<ph id="ph2"/>).</source>
      </segment>
      <segment id="171-3">
        <source xml:space="preserve"> A microneedle array is coated with the modified FGF or pharmaceutical composition and pressed against the cornea such that the microneedles penetrate into the corneal stroma but do not penetrate the entire cornea.</source>
      </segment>
      <segment id="171-4">
        <source xml:space="preserve"> It is then removed, and the modified FGF or pharmaceutical composition is left behind in the corneal stroma.</source>
      </segment>
      <segment id="171-5">
        <source xml:space="preserve"> This modified FGF or pharmaceutical composition can stimulate the corneal cells to proliferate and migrate, and suppresses the scarring response that the stromal cells normally have.</source>
      </segment>
    </unit>
    <unit id="172">
      <segment id="172-0">
        <source xml:space="preserve">For delivery of a composition comprising at least one of the modified FGF-1 polypeptides described herein via a mucosal route, which includes delivery to the nasal passages, throat, and airways, the composition may be delivered in the form of an aerosol.</source>
      </segment>
      <segment id="172-1">
        <source xml:space="preserve"> The compound may be in a liquid or powder form for intramucosal delivery.</source>
      </segment>
      <segment id="172-2">
        <source xml:space="preserve"> For example, the composition may be delivered via a pressurized aerosol container with a suitable propellant, such as a hydrocarbon propellant (e.g., propane, butane, isobutene).</source>
      </segment>
      <segment id="172-3">
        <source xml:space="preserve"> The composition may be delivered via a non-pressurized delivery system such as a nebulizer or atomizer.</source>
      </segment>
    </unit>
    <unit id="173">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0026" w:id="197"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="197"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="173-0">
        <source xml:space="preserve">Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract.</source>
      </segment>
      <segment id="173-1">
        <source xml:space="preserve"> Suitable nontoxic solid carriers can be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. (<ph id="ph1"/>See, e.g.,<ph id="ph2"/> <ph id="ph3"/>Remington:</source>
      </segment>
      <segment id="173-2">
        <source xml:space="preserve"> The Science and Practice of Pharmacy (Gennaro, 21st Ed.</source>
      </segment>
      <segment id="173-3">
        <source xml:space="preserve"> Mack Pub.</source>
      </segment>
      <segment id="173-4">
        <source xml:space="preserve"> Co., Easton, PA (2005<ph id="ph4"/>)).</source>
      </segment>
    </unit>
    <unit id="174">
      <segment id="174-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides or pharmaceutical compositions described herein may be formulated for sustained or slow-release.</source>
      </segment>
      <segment id="174-1">
        <source xml:space="preserve"> Such compositions may generally be prepared using well known technology and administered by, for example, periocular, intraocular, rectal, oral or subcutaneous implantation, or by implantation at the desired target site, or by topical application.</source>
      </segment>
      <segment id="174-2">
        <source xml:space="preserve"> Sustained-release formulations may contain an agent dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane.</source>
      </segment>
      <segment id="174-3">
        <source xml:space="preserve"> Excipients for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release.</source>
      </segment>
      <segment id="174-4">
        <source xml:space="preserve"> The amount of active compound contained within a sustained-release formulation depends upon the site of implantation, the rate and expected duration of release, and the nature of the condition to be treated or prevented.</source>
      </segment>
    </unit>
    <unit id="175">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0027" w:id="200"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:lastRenderedPageBreak&gt;&lt;/w:lastRenderedPageBreak &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="200"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0028" w:id="201"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="201"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="175-0">
        <source xml:space="preserve">Systemic drug absorption of a drug or composition administered via an ocular route is known to those skilled in the art (<ph id="ph1"/>see, e.g.,<ph id="ph2"/> <ph id="ph3"/>Lee et al., Int.</source>
      </segment>
      <segment id="175-1">
        <source xml:space="preserve"> J. Pharm.</source>
      </segment>
      <segment id="175-2">
        <source xml:space="preserve"> 233:1-18 (2002<ph id="ph4"/>)).</source>
      </segment>
      <segment id="175-3">
        <source xml:space="preserve"> In one embodiment, a compound described herein is delivered by a topical ocular delivery method (<ph id="ph5"/>see, e.g.,<ph id="ph6"/> <ph id="ph7"/>Curr.</source>
      </segment>
      <segment id="175-4">
        <source xml:space="preserve"> Drug Metab.</source>
      </segment>
      <segment id="175-5">
        <source xml:space="preserve"> 4:213-22 (2003<ph id="ph8"/>)).</source>
      </segment>
      <segment id="175-6">
        <source xml:space="preserve"> The composition may be in the form of an eye drop, salve, or ointment or the like, such as, aqueous eye drops, aqueous ophthalmic suspensions, non-aqueous eye drops, and non-aqueous ophthalmic suspensions, gels, ophthalmic ointments, etc. For preparing a gel, for example, carboxyvinyl polymer, methyl cellulose, sodium alginate, hydroxypropyl cellulose, ethylene maleic anhydride polymer and the like can be used.</source>
      </segment>
    </unit>
    <unit id="176">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="176">
        <source xml:space="preserve">The modified FGF solution or pharmaceutical composition (<ph id="ph1"/>e.g.,<ph id="ph2"/> an ophthalmic formulation) described herein may contain hyaluronic acid, carboxymethyl cellulose, or other polysaccharides that provide increased ocular tolerability, viscosity and osmolality to produce a comfortable ocular solution.</source>
      </segment>
    </unit>
    <unit id="177">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="177-0">
        <source xml:space="preserve">The dose of the modified FGF or pharmaceutical composition comprising at least one of the modified FGF-1 polypeptides described herein may differ, depending upon the patient's (<ph id="ph1"/>e.g.,<ph id="ph2"/> human) condition, that is, stage of the ocular disease, disorder, or condition, general health status, age, and other factors that a person skilled in the medical art will use to determine dose.</source>
      </segment>
      <segment id="177-1">
        <source xml:space="preserve"> When the composition is used as eye drops, for example, one to several drops per unit dose, preferably 1 or 2 drops (about 50 µl per 1 drop), may be applied about 1 to about 6 times daily.</source>
      </segment>
    </unit>
    <unit id="178">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="178-0">
        <source xml:space="preserve">Pharmaceutical compositions may be administered in a manner appropriate to the disease, disorder, or condition to be treated (or prevented) as determined by persons skilled in the medical arts.</source>
      </segment>
      <segment id="178-1">
        <source xml:space="preserve"> An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, disorder, or condition, the particular form of the active ingredient, and the method of administration.</source>
      </segment>
      <segment id="178-2">
        <source xml:space="preserve"> In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (<ph id="ph1"/>e.g.,<ph id="ph2"/> an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free, or a lessening of symptom severity).</source>
      </segment>
      <segment id="178-3">
        <source xml:space="preserve"> For prophylactic use, a dose should be sufficient to prevent, delay the onset of, or diminish the severity of an ocular disease, disorder, or condition.</source>
      </segment>
      <segment id="178-4">
        <source xml:space="preserve"> Optimal doses may generally be determined using experimental models and/or clinical trials.</source>
      </segment>
      <segment id="178-5">
        <source xml:space="preserve"> The optimal dose may depend upon the body mass, weight, or blood volume of the patient.</source>
      </segment>
    </unit>
    <unit id="179">
      <segment id="179-0">
        <source xml:space="preserve">A modified FGF-1 polypeptide of the present disclosure may be administered as a daily dose over a period of time to a subject.</source>
      </segment>
      <segment id="179-1">
        <source xml:space="preserve"> A modified FGF-1 polypeptide of the present disclosure may be administered chronically or long-term.</source>
      </segment>
      <segment id="179-2">
        <source xml:space="preserve"> A modified FGF-1 polypeptide of the present disclosure may be administered for a period of days, weeks, months, years or continued therapy over the lifetime of a subject.</source>
      </segment>
      <segment id="179-3">
        <source xml:space="preserve"> In some embodiments, a modified FGF-1 polypeptide of the present disclosure may be administered for a period of about 7 days, 15 days, about 21 days, about 30 days, about 3 months, about 6 months, about 12 months, about 18 months, about 2 years, about 5 years, about 7 years, about 10 years, about 15 years, about 20 years, about 25 years, about 30 years, about 35 years, or about 40 years.</source>
      </segment>
      <segment id="179-4">
        <source xml:space="preserve"> A treatment regime may be determined for an individual subject dependent on various factors.</source>
      </segment>
      <segment id="179-5">
        <source xml:space="preserve"> In some examples, the treatment regimen may be dependent on the level of exposure to a compound causing a chemical or thermal injury, such as a vesicant compound.</source>
      </segment>
      <segment id="179-6">
        <source xml:space="preserve"> The treatment regimen may be about 2 weeks for an acute exposure and several months to a year for a long term exposure.</source>
      </segment>
      <segment id="179-7">
        <source xml:space="preserve"> The treatment regimen may be chronic.</source>
      </segment>
      <segment id="179-8">
        <source xml:space="preserve"> In some examples, a factor may include, but not be limited to, a determination of the change in the extent of degeneration of corneal tissue in response to administration of a modified FGF-1 polypeptide of the present disclosure.</source>
      </segment>
      <segment id="179-9">
        <source xml:space="preserve"> In some examples, a factor may include, but not be limited to, amelioration of MGK sequelae in response to administration of a modified FGF-1 polypeptide of the present disclosure.</source>
      </segment>
      <segment id="179-10">
        <source xml:space="preserve"> In some examples, a factor may include, but not be limited to, healing of corneal endothelial lesions in response to administration of a modified FGF-1 polypeptide of the present disclosure.</source>
      </segment>
      <segment id="179-11">
        <source xml:space="preserve"> In some examples, a factor may include, but not be limited to, corneal epithelial cell proliferation in response to administration of a modified FGF-1 polypeptide of the present disclosure.</source>
      </segment>
      <segment id="179-12">
        <source xml:space="preserve"> In some examples, a factor may include, but not be limited to, reduction of symptoms associated with Fuch's dystrophy in response to administration of a modified FGF-1 polypeptide of the present disclosure.</source>
      </segment>
      <segment id="179-13">
        <source xml:space="preserve"> In embodiments, a subject exhibiting an immediate response to the composition, for example, an immediate reduction in symptoms associated with Fuch's dystrophy, may require less frequent doses than a subject exhibiting a response to the composition at a later time or after several doses.</source>
      </segment>
    </unit>
    <unit id="180">
      <segment id="180-0">
        <source xml:space="preserve">The doses of the modified FGF-1 polypeptides or pharmaceutical compositions can be suitably selected depending on the clinical status, condition and age of the subject, dosage form and the like.</source>
      </segment>
      <segment id="180-1">
        <source xml:space="preserve"> In the case of eye drops, a modified FGF described herein can be administered, for example, from about 10ug/ml to about 100mg/ml of the modified FGF one to seven times per week.</source>
      </segment>
    </unit>
    <unit id="181">
      <segment id="181-0">
        <source xml:space="preserve">Also described are methods of manufacturing the modified FGF-1 polypeptides and pharmaceutical compositions described herein.</source>
      </segment>
      <segment id="181-1">
        <source xml:space="preserve"> A composition comprising a pharmaceutically acceptable excipient or carrier and at least one of the modified FGF-1 polypeptides described herein may be prepared by synthesizing the modified FGF according to any one of the methods described herein or practiced in the art and then formulating the compound with a pharmaceutically acceptable carrier.</source>
      </segment>
      <segment id="181-2">
        <source xml:space="preserve"> Formulation of the composition will be appropriate and dependent on several factors, including but not limited to, the delivery route, dose, and stability of the compound.</source>
      </segment>
    </unit>
    <unit id="182">
      <segment id="182-0">
        <source xml:space="preserve">At least one modified FGF described herein can be administered to human or other nonhuman vertebrates.</source>
      </segment>
      <segment id="182-1">
        <source xml:space="preserve"> In certain embodiments, the modified FGF is substantially pure, in that it contains less than about 5% or less than about 1%, or less than about 0.1%, of other organic molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.</source>
      </segment>
      <segment id="182-2">
        <source xml:space="preserve"> In other embodiments, a combination of one or more modified FGF-1 polypeptides described herein can be administered.</source>
      </segment>
    </unit>
    <unit id="183">
      <segment id="183-0">
        <source xml:space="preserve">The compositions described herein can be administered for prophylactic and/or therapeutic treatments.</source>
      </segment>
      <segment id="183-1">
        <source xml:space="preserve"> In therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition.</source>
      </segment>
      <segment id="183-2">
        <source xml:space="preserve"> Amounts effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician.</source>
      </segment>
    </unit>
    <unit id="184">
      <segment id="184-0">
        <source xml:space="preserve">In prophylactic applications, compositions described herein may be administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition.</source>
      </segment>
      <segment id="184-1">
        <source xml:space="preserve"> Such an amount is defined to be a "prophylactically effective amount or dose."</source>
      </segment>
      <segment id="184-2">
        <source xml:space="preserve"> In this use, the precise amounts also depend on the patient's state of health, weight, and the like.</source>
      </segment>
    </unit>
    <unit id="185">
      <segment id="185">
        <source xml:space="preserve">In the case wherein the patient's condition does not improve, upon the doctor's discretion the administration of the compositions may be administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.</source>
      </segment>
    </unit>
    <unit id="186">
      <segment id="186">
        <source xml:space="preserve">In the case wherein the patient's status does improve, upon the doctor's discretion the administration of the compositions may be given continuously; alternatively, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday").</source>
      </segment>
    </unit>
    <unit id="187">
      <segment id="187-0">
        <source xml:space="preserve">Once improvement of the patient's conditions has occurred, a maintenance dose may be administered if necessary.</source>
      </segment>
      <segment id="187-1">
        <source xml:space="preserve"> Subsequently, the dosage or the frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained.</source>
      </segment>
      <segment id="187-2">
        <source xml:space="preserve"> Patients can, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.</source>
      </segment>
    </unit>
    <unit id="188">
      <segment id="188">
        <source xml:space="preserve">The desired dose may conveniently be presented in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.</source>
      </segment>
    </unit>
    <unit id="189">
      <segment id="189-0">
        <source xml:space="preserve">The pharmaceutical composition described herein may be in unit dosage forms suitable for single administration of precise dosages.</source>
      </segment>
      <segment id="189-1">
        <source xml:space="preserve"> In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more modified FGF-1 polypeptides.</source>
      </segment>
      <segment id="189-2">
        <source xml:space="preserve"> The unit dosage may be in the form of a package containing discrete quantities of the formulation.</source>
      </segment>
      <segment id="189-3">
        <source xml:space="preserve"> Non-limiting examples are packaged tablets or capsules, and powders in vials or ampoules.</source>
      </segment>
      <segment id="189-4">
        <source xml:space="preserve"> Aqueous suspension compositions can be packaged in single-dose non-reclosable containers.</source>
      </segment>
      <segment id="189-5">
        <source xml:space="preserve"> Alternatively, multiple-dose reclosable containers can be used, in which case it is typical to include a preservative in the composition.</source>
      </segment>
      <segment id="189-6">
        <source xml:space="preserve"> By way of example only, formulations for parenteral injection may be presented in unit dosage form, which include, but are not limited to ampoules, or in multi-dose containers, with an added preservative.</source>
      </segment>
    </unit>
    <unit id="190">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="190-0">
        <source xml:space="preserve">Toxicity and therapeutic efficacy of such therapeutic regimens can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD<ph id="ph1"/>50<ph id="ph2"/> (the dose lethal to 50% of the population) and the ED<ph id="ph3"/>50<ph id="ph4"/> (the dose therapeutically effective in 50% of the population).</source>
      </segment>
      <segment id="190-1">
        <source xml:space="preserve"> The dose ratio between the toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD<ph id="ph5"/>50<ph id="ph6"/> and ED<ph id="ph7"/>50<ph id="ph8"/>.</source>
      </segment>
      <segment id="190-2">
        <source xml:space="preserve"> Compounds exhibiting high therapeutic indices are preferred.</source>
      </segment>
      <segment id="190-3">
        <source xml:space="preserve"> The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in human.</source>
      </segment>
      <segment id="190-4">
        <source xml:space="preserve"> The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<ph id="ph9"/>50<ph id="ph10"/> with minimal toxicity.</source>
      </segment>
      <segment id="190-5">
        <source xml:space="preserve"> The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.</source>
      </segment>
    </unit>
    <unit id="191">
      <segment id="191">
        <source xml:space="preserve">Combination Treatments</source>
      </segment>
    </unit>
    <unit id="192">
      <segment id="192-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides and pharmaceutical compositions may also be used in combination with other therapeutic agents that are selected for their therapeutic value for the condition to be treated.</source>
      </segment>
      <segment id="192-1">
        <source xml:space="preserve"> The modified FGF-1 polypeptides and pharmaceutical compositions may also be used in combination with other therapeutic agents that are selected for their therapeutic value for treating the vesicant injury.</source>
      </segment>
      <segment id="192-2">
        <source xml:space="preserve"> Such agents do not have to be administered in the same pharmaceutical composition, and may, because of different physical and chemical characteristics, have to be administered by different routes.</source>
      </segment>
      <segment id="192-3">
        <source xml:space="preserve"> The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the clinician.</source>
      </segment>
      <segment id="192-4">
        <source xml:space="preserve"> The initial administration can be made according to established protocols recognized in the field, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the clinician.</source>
      </segment>
    </unit>
    <unit id="193">
      <segment id="193-0">
        <source xml:space="preserve">The particular choice of these optional additional agents used will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol.</source>
      </segment>
      <segment id="193-1">
        <source xml:space="preserve"> The agents may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the disease, disorder, or condition, the condition of the patient, and the actual choice of agents used.</source>
      </segment>
      <segment id="193-2">
        <source xml:space="preserve"> The determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment protocol, is well within the knowledge of the physician after evaluation of the disease being treated and the condition of the patient.</source>
      </segment>
    </unit>
    <unit id="194">
      <segment id="194-0">
        <source xml:space="preserve">The pharmaceutical agents which make up the combination therapy disclosed herein may be a combined dosage form or in separate dosage forms intended for substantially simultaneous administration.</source>
      </segment>
      <segment id="194-1">
        <source xml:space="preserve"> The pharmaceutical agents that make up the combination therapy may also be administered sequentially, with either therapeutic compound being administered by a regimen calling for two-step administration.</source>
      </segment>
      <segment id="194-2">
        <source xml:space="preserve"> The two-step administration regimen may call for sequential administration of the active agents or spaced-apart administration of the separate active agents.</source>
      </segment>
      <segment id="194-3">
        <source xml:space="preserve"> The time period between the multiple administration steps may range from, a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent.</source>
      </segment>
      <segment id="194-4">
        <source xml:space="preserve"> Circadian variation of the target molecule concentration may also determine the optimal dose interval.</source>
      </segment>
    </unit>
    <unit id="195">
      <segment id="195-0">
        <source xml:space="preserve">Therapeutically-effective dosages can vary when the drugs are used in treatment combinations.</source>
      </segment>
      <segment id="195-1">
        <source xml:space="preserve"> Methods for experimentally determining therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens are described in the literature.</source>
      </segment>
      <segment id="195-2">
        <source xml:space="preserve"> For example, the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects, has been described extensively in the literature.</source>
      </segment>
      <segment id="195-3">
        <source xml:space="preserve"> Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.</source>
      </segment>
    </unit>
    <unit id="196">
      <segment id="196">
        <source xml:space="preserve">For example, the modified may be incorporated into formulations that contain other active ingredients such as steroids, antibiotics, anti-inflammatories, cytokines such as IL-1 or analogs of IL-1, or antagonists of cytokines such as inhibitors of IL-17.</source>
      </segment>
    </unit>
    <unit id="197">
      <segment id="197">
        <source xml:space="preserve">Other exemplary cytokines include, but are not limited to, interleukins (e.g., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-1α, IL-1β, and IL-1 RA), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), oncostatin M, erythropoietin, leukemia inhibitory factor (LIF), interferons, B7.1 (also known as CD80), B7.2 (also known as B70, CD86), TNF family members (TNF-α, TNF-β, LT-β, CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, Trail), and migration inhibitory factor MIF.</source>
      </segment>
    </unit>
    <unit id="198">
      <segment id="198-0">
        <source xml:space="preserve">Combinations or pharmaceutical compositions described herein may be administered in immunosuppressive therapy to reduce, inhibit, or prevent activity of the immune system.</source>
      </segment>
      <segment id="198-1">
        <source xml:space="preserve"> Immunosuppressive therapy is clinically used to:</source>
      </segment>
      <segment id="198-2">
        <source xml:space="preserve"> prevent the rejection of transplanted organs and tissues; treatment of autoimmune diseases or diseases that are most likely of autoimmune origin; and treatment of some other non-autoimmune inflammatory diseases.</source>
      </segment>
    </unit>
    <unit id="199">
      <segment id="199">
        <source xml:space="preserve">The modified FGF-1 polypeptides and pharmaceutical compositions described herein may be administered with one or more anti-inflammatory agent including, but not limited to, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (glucocorticoids).</source>
      </segment>
    </unit>
    <unit id="200">
      <segment id="200-0">
        <source xml:space="preserve">NSAIDs include, but are not limited to:</source>
      </segment>
      <segment id="200-1">
        <source xml:space="preserve"> aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, fluorobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, and COX-2 specific inhibitors (such as, but not limited to, celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib, lumiracoxib, CS-502, JTE-522, L-745,337 and NS398).</source>
      </segment>
    </unit>
    <unit id="201">
      <segment id="201-0">
        <source xml:space="preserve">Corticosteroids, include, but are not limited to:</source>
      </segment>
      <segment id="201-1">
        <source xml:space="preserve"> betamethasone, prednisone, alclometasone, aldosterone, amcinonide, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, cortivazol, deflazacort, deoxycorticosterone, desonide, desoximetasone, desoxycortone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluprednidene, fluticasone, formocortal, halcinonide, halometasone, hydrocortisone/cortisol, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone butyrate, loteprednol, medrysone, meprednisone, methylprednisolone, methylprednisolone aceponate, mometasone furoate, paramethasone, prednicarbate, prednisone/prednisolone, rimexolone, tixocortol, triamcinolone, and ulobetasol.</source>
      </segment>
    </unit>
    <unit id="202">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0027" w:id="228"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="228"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="202">
        <source xml:space="preserve">Other agents used as anti-inflammatories include those disclosed in <ph id="ph1"/>U.S. patent publication 2005/0227929<ph id="ph2"/>.</source>
      </segment>
    </unit>
    <unit id="203">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph11">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph12">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph13">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph14">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph15">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph16">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph17">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph18">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph19">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph20">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph21">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph22">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph23">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph24">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph25">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph26">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph27">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph28">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph29">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph30">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph31">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph32">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph33">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph34">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph35">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph36">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph37">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph38">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph39">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph40">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph41">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph42">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph43">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph44">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph45">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph46">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph47">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph48">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph49">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph50">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph51">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph52">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="203-0">
        <source xml:space="preserve">Some commercially available anti-inflammatories include, but are not limited to:</source>
      </segment>
      <segment id="203-1">
        <source xml:space="preserve"> Arthrotec<ph id="ph1"/>®<ph id="ph2"/> (diclofenac and misoprostol), Asacol<ph id="ph3"/>®<ph id="ph4"/>(5-aminosalicyclic acid), Salofalk<ph id="ph5"/>®<ph id="ph6"/> (5-aminosalicyclic acid), Auralgan<ph id="ph7"/>®<ph id="ph8"/> (antipyrine and benzocaine), Azulfidine<ph id="ph9"/>®<ph id="ph10"/> (sulfasalazine), Daypro<ph id="ph11"/>®<ph id="ph12"/> (oxaprozin), Lodine<ph id="ph13"/>®<ph id="ph14"/>(etodolac), Ponstan<ph id="ph15"/>®<ph id="ph16"/> (mefenamic acid), Solumedrol<ph id="ph17"/>®<ph id="ph18"/> (methylprednisolone), Bayer<ph id="ph19"/>®<ph id="ph20"/>(aspirin), Bufferin<ph id="ph21"/>®<ph id="ph22"/> (aspirin), Indocin<ph id="ph23"/>®<ph id="ph24"/> (indomethacin), Vioxx<ph id="ph25"/>®<ph id="ph26"/> (rofecoxib), Celebrex<ph id="ph27"/>®<ph id="ph28"/> (celecoxib), Bextra<ph id="ph29"/>®<ph id="ph30"/> (valdecoxib), Arcoxia<ph id="ph31"/>®<ph id="ph32"/> (etoricoxib), Prexige<ph id="ph33"/>®<ph id="ph34"/> (lumiracoxib), Advil<ph id="ph35"/>®<ph id="ph36"/>, Motrin<ph id="ph37"/>®<ph id="ph38"/> (ibuprofen), Voltaren<ph id="ph39"/>®<ph id="ph40"/>(diclofenac), Orudis<ph id="ph41"/>®<ph id="ph42"/>(ketoprofen), Mobic<ph id="ph43"/>®<ph id="ph44"/>(meloxicam), Relafen<ph id="ph45"/>®<ph id="ph46"/> (nabumetone), Aleve<ph id="ph47"/>®<ph id="ph48"/>, Naprosyn<ph id="ph49"/>®<ph id="ph50"/> (naproxen), Feldene<ph id="ph51"/>®<ph id="ph52"/> (piroxicam).</source>
      </segment>
    </unit>
    <unit id="204">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0028" w:id="231"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="231"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0029" w:id="232"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="232"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph9">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph10">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="204-0">
        <source xml:space="preserve">Compositions described herein may be administered with leukotriene receptor antagonists including, but are not limited to, BAY u9773 (see <ph id="ph1"/>EP 00791576; published 27 Aug 1997<ph id="ph2"/>), DUO-LT (<ph id="ph3"/>Tsuji et al, Org.</source>
      </segment>
      <segment id="204-1">
        <source xml:space="preserve"> Biomol.</source>
      </segment>
      <segment id="204-2">
        <source xml:space="preserve"> Chem., 1, 3139-3141, 2003<ph id="ph4"/>), zafirlukast (Accolate<ph id="ph5"/>®<ph id="ph6"/>), montelukast (Singulair<ph id="ph7"/>®<ph id="ph8"/>), prankulast (Onon<ph id="ph9"/>®<ph id="ph10"/>), and derivatives or analogs thereof.</source>
      </segment>
    </unit>
    <unit id="205">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0030" w:id="234"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="234"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="205-0">
        <source xml:space="preserve">The modified FGF-1 polypeptides and pharmaceutical compositions described herein may be administered with one or more Rho kinase inhibitors.</source>
      </segment>
      <segment id="205-1">
        <source xml:space="preserve"> The modified FGF-1 polypeptides and pharmaceutical compositions described herein may be administered with one or more additional growth factors, including, but not limited to epidermal growth factor (EGF) and nerve growth factor (NGF).</source>
      </segment>
      <segment id="205-2">
        <source xml:space="preserve"> <ph id="ph1"/>See, e.g.,<ph id="ph2"/> see <ph id="ph3"/>Joyce et al. (2009) Invest Ophthalmol.</source>
      </segment>
      <segment id="205-3">
        <source xml:space="preserve"> Vis Sci. 50:2116-2122<ph id="ph4"/>, vascular endothelial growth factor (VEGF), transforming growth factor alpha and beta (TGF-alpha and TFG-beta), platelet-derived endothelial growth factor (PD-ECGF), platelet-derived growth factor (PDGF), tumor necrosis factor alpha (TNF-alpha), hepatocyte growth factor (HGF), insulin like growth factor (IGF), erythropoietin, colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte/macrophage CSF (GM-CSF) and nitric oxidcsynthase (NOS).</source>
      </segment>
    </unit>
    <unit id="206">
      <segment id="206">
        <source xml:space="preserve">Kits/Articles of Manufacture</source>
      </segment>
    </unit>
    <unit id="207">
      <segment id="207-0">
        <source xml:space="preserve">For use in the therapeutic applications described herein, kits and articles of manufacture are also provided herein.</source>
      </segment>
      <segment id="207-1">
        <source xml:space="preserve"> Such kits can include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) including one of the separate elements to be used in a method described herein.</source>
      </segment>
      <segment id="207-2">
        <source xml:space="preserve"> Suitable containers include, for example, bottles, vials, syringes, and test tubes.</source>
      </segment>
      <segment id="207-3">
        <source xml:space="preserve"> The containers can be formed from a variety of materials such as glass or plastic.</source>
      </segment>
    </unit>
    <unit id="208">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0029" w:id="237"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="237"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0030" w:id="238"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="238"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="pcit0031" w:id="239"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="239"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="208-0">
        <source xml:space="preserve">The articles of manufacture provided herein contain packaging materials.</source>
      </segment>
      <segment id="208-1">
        <source xml:space="preserve"> Packaging materials for use in packaging pharmaceutical products include, e.g., <ph id="ph1"/>U.S.</source>
      </segment>
      <segment id="208-2">
        <source xml:space="preserve"> Patent Nos. 5,323,907<ph id="ph2"/>, <ph id="ph3"/>5,052,558<ph id="ph4"/> and <ph id="ph5"/>5,033,252<ph id="ph6"/>.</source>
      </segment>
      <segment id="208-3">
        <source xml:space="preserve"> Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.</source>
      </segment>
      <segment id="208-4">
        <source xml:space="preserve"> A wide array of ophthalmic formulations of the modified FGF-1 polypeptides and pharmaceutical compositions provided herein are contemplated as are a variety of treatments for any ocular disease, disorder, or condition that would benefit by administration of a modified FGF ore pharmaceutical composition described herein.</source>
      </segment>
    </unit>
    <unit id="209">
      <segment id="209-0">
        <source xml:space="preserve">For example, the container(s) can include a modified FGF such as a modified FGF-1 having a sequence of SEQ ID NO:</source>
      </segment>
      <segment id="209-1">
        <source xml:space="preserve"> 2.</source>
      </segment>
      <segment id="209-2">
        <source xml:space="preserve"> The container(s) optionally have a sterile access port.</source>
      </segment>
      <segment id="209-3">
        <source xml:space="preserve"> Such kits optionally comprising compounds with an identifying descriptions or labels or instructions relating to their use in the methods described herein.</source>
      </segment>
    </unit>
    <unit id="210">
      <segment id="210-0">
        <source xml:space="preserve">A kit typically may include one or more additional containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a modified FGF described herein.</source>
      </segment>
      <segment id="210-1">
        <source xml:space="preserve"> Non-limiting examples of such materials include, but not limited to, buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.</source>
      </segment>
      <segment id="210-2">
        <source xml:space="preserve"> A set of instructions will also typically be included.</source>
      </segment>
    </unit>
    <unit id="211">
      <segment id="211-0">
        <source xml:space="preserve">A label can be on or associated with the container.</source>
      </segment>
      <segment id="211-1">
        <source xml:space="preserve"> A label can be on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert.</source>
      </segment>
      <segment id="211-2">
        <source xml:space="preserve"> A label can be used to indicate that the contents are to be used for a specific therapeutic application.</source>
      </segment>
      <segment id="211-3">
        <source xml:space="preserve"> The label can also indicate directions for use of the contents, such as in the methods described herein.</source>
      </segment>
    </unit>
    <unit id="212">
      <segment id="212-0">
        <source xml:space="preserve">In certain embodiments, a modified FGF pharmaceutical composition can be presented in a pack or dispenser device which can contain one or more unit dosage forms containing a compound provided herein.</source>
      </segment>
      <segment id="212-1">
        <source xml:space="preserve"> The pack can for example contain metal or plastic foil, such as a blister pack.</source>
      </segment>
      <segment id="212-2">
        <source xml:space="preserve"> The pack or dispenser device can be accompanied by instructions for administration.</source>
      </segment>
      <segment id="212-3">
        <source xml:space="preserve"> The pack or dispenser can also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration.</source>
      </segment>
      <segment id="212-4">
        <source xml:space="preserve"> Such notice, for example, can be the labeling approved by the U.S.</source>
      </segment>
      <segment id="212-5">
        <source xml:space="preserve"> Food and Drug Administration for prescription drugs, or the approved product insert.</source>
      </segment>
      <segment id="212-6">
        <source xml:space="preserve"> Compositions containing a modified FGF provided herein formulated in a compatible pharmaceutical carrier can also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.</source>
      </segment>
    </unit>
    <unit id="213">
      <segment id="213">
        <source xml:space="preserve">EXAMPLES</source>
      </segment>
    </unit>
    <unit id="214">
      <segment id="214-0">
        <source xml:space="preserve">These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.</source>
      </segment>
      <segment id="214-1">
        <source xml:space="preserve"> The starting materials and reagents used in the examples described herein may be synthesized or can be obtained from commercial sources.</source>
      </segment>
    </unit>
    <unit id="215">
      <segment id="215-0">
        <source xml:space="preserve">Example 1:</source>
      </segment>
      <segment id="215-1">
        <source xml:space="preserve"> Exemplary Modified FGF-1 Polypeptide with an N-terminal methionine (N-Met) has similar activity as a version without the N-Met</source>
      </segment>
    </unit>
    <unit id="216">
      <segment id="216-0">
        <source xml:space="preserve">The study is directed towards modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="216-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) or SEQ ID NO:</source>
      </segment>
      <segment id="216-2">
        <source xml:space="preserve"> 205 (TTHX1001).</source>
      </segment>
      <segment id="216-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptides are generated using methods as described above in the Recombinant Techniques section.</source>
      </segment>
    </unit>
    <unit id="217">
      <segment id="217">
        <source xml:space="preserve">Experimental Methods and Results</source>
      </segment>
    </unit>
    <unit id="218">
      <segment id="218-0">
        <source xml:space="preserve">The biological activity of the test polypeptides are assessed in a NIH-3T3 cell proliferation assay.</source>
      </segment>
      <segment id="218-1">
        <source xml:space="preserve"> Results indicate no difference between the modified FGF-1 polypeptides of SEQ ID NO:</source>
      </segment>
      <segment id="218-2">
        <source xml:space="preserve"> 2 and SEQ ID NO:</source>
      </segment>
      <segment id="218-3">
        <source xml:space="preserve"> 205, in terms of effectivity in inducing proliferation of the fibroblast cells.</source>
      </segment>
    </unit>
    <unit id="219">
      <segment id="219-0">
        <source xml:space="preserve">Example 2:</source>
      </segment>
      <segment id="219-1">
        <source xml:space="preserve"> Effects of Modified FGF-1 Polypeptides on Human Corneal Endothelial Cell (HCEC) Proliferation</source>
      </segment>
    </unit>
    <unit id="220">
      <segment id="220-0">
        <source xml:space="preserve">The study is directed towards modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="220-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) or SEQ ID NO:</source>
      </segment>
      <segment id="220-2">
        <source xml:space="preserve"> 205 (TTHX1001).</source>
      </segment>
      <segment id="220-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptides are generated using methods as described above in the Recombinant Techniques section.</source>
      </segment>
    </unit>
    <unit id="221">
      <segment id="221">
        <source xml:space="preserve">Experimental Methods and Results</source>
      </segment>
    </unit>
    <unit id="222">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="222-0">
        <source xml:space="preserve">Primary cultures (passage 1) of human corneal endothelial cells from a healthy donor are seeded onto 24 well plates in the presence of fetal bovine serum (FBS, 8%) and 24 hours later treated with the varying concentrations of N-Met-TTHX1 114 (SEQ ID NO:</source>
      </segment>
      <segment id="222-1">
        <source xml:space="preserve"> 2), TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="222-2">
        <source xml:space="preserve"> 205), or wt-FGF-1 (SEQ ID NO:</source>
      </segment>
      <segment id="222-3">
        <source xml:space="preserve"> 1) in media with low (0.8%) FBS.</source>
      </segment>
      <segment id="222-4">
        <source xml:space="preserve"> The 8% FBS group serves as positive control.</source>
      </segment>
      <segment id="222-5">
        <source xml:space="preserve"> Results indicate that N-Met-TTHX1114 is more potent than TTHX1001 or wt-FGF-1 in stimulating human corneal epithelial cell proliferation and is dose responsive therein.</source>
      </segment>
      <segment id="222-6">
        <source xml:space="preserve"> The EC<ph id="ph1"/>50<ph id="ph2"/> of N-Met-TTHX1 114 is about 100-fold lower than the wt- FGF-1 or the other tested modified FGF-1 polypeptide (TTHX1001; SEQ ID NO:</source>
      </segment>
      <segment id="222-7">
        <source xml:space="preserve"> 205).</source>
      </segment>
    </unit>
    <unit id="223">
      <segment id="223-0">
        <source xml:space="preserve">Example 3:</source>
      </segment>
      <segment id="223-1">
        <source xml:space="preserve"> Nitrogen mustard induced injury of cornea</source>
      </segment>
    </unit>
    <unit id="224">
      <segment id="224-0">
        <source xml:space="preserve">The study is directed towards the effect of modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="224-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) on treatment of nitrogen mustard (NM) induced corneal injury.</source>
      </segment>
      <segment id="224-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptides are generated using methods as described above in the Recombinant Techniques section.</source>
      </segment>
    </unit>
    <unit id="225">
      <segment id="225">
        <source xml:space="preserve">Experimental Methods</source>
      </segment>
    </unit>
    <unit id="226">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="226-0">
        <source xml:space="preserve">A rabbit corneal organ culture model system was used to evaluate healing after exposure to NM.</source>
      </segment>
      <segment id="226-1">
        <source xml:space="preserve"> Rabbit eyes (8-12 weeks old) are obtained and corneas with 2-mm scleral rims are dissected from the eyes, placed epithelial-side down into a spot plate, and the concavities were filled with 558C molten agar (0.75%) in Dulbecco's modified Eagle's medium (DMEM).</source>
      </segment>
      <segment id="226-2">
        <source xml:space="preserve"> A non-limiting example of the set-up is shown in <ph id="ph1"/>Fig. 3.</source>
      </segment>
      <ignorable>
        <source xml:space="preserve"><ph id="ph2"/></source>
      </ignorable>
      <segment id="226-3">
        <source xml:space="preserve"> Once the solution is gelled, the corneas are inverted so that the epithelial layer is accessible.</source>
      </segment>
      <segment id="226-4">
        <source xml:space="preserve"> Cultures are placed in 60-mm diameter pyrex tissue culture dishes.</source>
      </segment>
      <segment id="226-5">
        <source xml:space="preserve"> High glucose DMEM is prepared containing 13MEM-NEAA (minimal essential medium non-essential amino acids), 13 RMPI 1640 Vitamin Solution, 13 antibiotic/antimycotic, ascorbic acid (0.45mM), and ciprofloxacin (10lg/ml).</source>
      </segment>
      <segment id="226-6">
        <source xml:space="preserve"> High glucose DMEM is added up to the scleral rims, leaving the corneas exposed to air.</source>
      </segment>
      <segment id="226-7">
        <source xml:space="preserve"> The dishes are placed in a 37 °C humidified incubator with 5% CO<ph id="ph3"/>2<ph id="ph4"/>.</source>
      </segment>
      <segment id="226-8">
        <source xml:space="preserve"> The epithelium of each culture is moistened with 500 µL medium, added dropwise onto the central cornea every 7 to 9 hours.</source>
      </segment>
      <segment id="226-9">
        <source xml:space="preserve"> The vesicating agent, NM, is added dropwise onto the central cornea.</source>
      </segment>
      <segment id="226-10">
        <source xml:space="preserve"> Cornea samples (peeled off their agar support) are either put epithelial side down in cryomolds containing Optimal Cutting Temperature (OCT, Tissue-Tek; Sakura, Torrance, CA, USA) compound and flash frozen for histology and immunofluorescence, or directly snap frozen for further protein analyses including Western blot and ADAM17 activity assays (InnoZyme TACE activity assay kit; Calbiochem, Billerica, MA, USA).</source>
      </segment>
    </unit>
    <unit id="227">
      <segment id="227-0">
        <source xml:space="preserve">NM is used to induce corneal injury.</source>
      </segment>
      <segment id="227-1">
        <source xml:space="preserve"> NM, in powdered solid form (catalog No. 122564; Sigma-Aldrich) is first dissolved in PBS to 100 mM, and then diluted with medium to 10 mM. Ten microliters are applied to deliver 100 nmol vesicant to the cornea.</source>
      </segment>
      <segment id="227-2">
        <source xml:space="preserve"> After applying NM onto the central corneas, the cultures are returned to the 37 °C incubator for 2 hours without removing the vesicant.</source>
      </segment>
      <segment id="227-3">
        <source xml:space="preserve"> After this incubation, contaminated medium is removed, and fresh medium is added to the central cornea until the level in the dish reached the top of the scleral rim.</source>
      </segment>
      <segment id="227-4">
        <source xml:space="preserve"> Control unexposed and exposed corneas are then returned to 37°C for a 22-hour incubation, being removed for only three short periods to add 20 µL medium to the exposed samples not receiving N-Met-TTHX1114 therapy, or to add 20 µL of N-Met-TTHX1114 as therapy to the central corneas.</source>
      </segment>
      <segment id="227-5">
        <source xml:space="preserve"> The first -met-TTHX1114 application is left on for 8 hours, the second for 9 hours, and the third for 5 hours.</source>
      </segment>
      <segment id="227-6">
        <source xml:space="preserve"> Thus, the length of the 2-hour exposure and the subsequent treatment is 24 hours in total.</source>
      </segment>
    </unit>
    <unit id="228">
      <segment id="228-0">
        <source xml:space="preserve">For experiments analyzing how fast NM exposure induced ADAM17, cultures are set up as described.</source>
      </segment>
      <segment id="228-1">
        <source xml:space="preserve"> For the shortest exposure time, the NM solution is applied to a cornea, then immediately washed off and the sample is put in protein isolation extraction buffer.</source>
      </segment>
      <segment id="228-2">
        <source xml:space="preserve"> This is repeated with two other corneas to collect three 0-minute exposures.</source>
      </segment>
      <segment id="228-3">
        <source xml:space="preserve"> For the 5- and 10- minute exposures, NM is added to the sets of three corneas accordingly, insuring none are accidentally under- or overexposed to NM.</source>
      </segment>
      <segment id="228-4">
        <source xml:space="preserve"> All corneas are extracted and processed for ADAM17 activity assays.</source>
      </segment>
    </unit>
    <unit id="229">
      <segment id="229-0">
        <source xml:space="preserve">The InnoZyme ADAM17/TACE Activity Kit (Calbiochem) is used to quantify the enzyme's activity from corneal extracts according to the vendor's provided protocol.</source>
      </segment>
      <segment id="229-1">
        <source xml:space="preserve"> Briefly, 400 µL wash buffer (from the InnoZyme kit) is applied to 96-well plates precoated with anti-human ADAM17 antibody, followed by two washes.</source>
      </segment>
      <segment id="229-2">
        <source xml:space="preserve"> Triplicate samples of corneal extracts and InnoZyme kit standards (100 µL) are each added to three sets of wells.</source>
      </segment>
      <segment id="229-3">
        <source xml:space="preserve"> Plates are sealed and incubated 1 hour with gentle shaking at room temperature.</source>
      </segment>
      <segment id="229-4">
        <source xml:space="preserve"> Then, plates are washed with 400 µL wash buffer five times.</source>
      </segment>
      <segment id="229-5">
        <source xml:space="preserve"> ADAM17 substrate supplied in the kit (100 µL) is added to each well and incubated for 5 hours at 37 °C.</source>
      </segment>
      <segment id="229-6">
        <source xml:space="preserve"> Fluorescence is measured at an excitation wavelength of 324 nm and an emission wavelength of 405 nm, and is reported as relative fluorescence units on graphs.</source>
      </segment>
      <segment id="229-7">
        <source xml:space="preserve"> For immunodetection of ADAM17, OCT-embedded sections on slides are first fixed in 20 °C methanol for 10 minutes.</source>
      </segment>
      <segment id="229-8">
        <source xml:space="preserve"> Nonspecific binding is blocked for 1 hour with 5% normal goat serum (NGS) in PBS with 0.05% Tween-20 (PBST).</source>
      </segment>
      <segment id="229-9">
        <source xml:space="preserve"> A mouse monoclonal antibody against the ectodomain (amino acids 18-671) of human ADAM 17 (5 µg/mL in 1.5% NGS, MAB9304; R&amp;D Systems, Minneapolis, MN, USA), which is found to detect only the active enzyme by immunofluorescence, is applied to the slides for a 1-hour incubation at room temperature, then the slides are washed three times for 10 minutes in PBST.</source>
      </segment>
      <segment id="229-10">
        <source xml:space="preserve"> For negative control slides, the same volume of PBST is applied to sections as that of primary antibody used on test sections, followed by the same wash volume.</source>
      </segment>
      <segment id="229-11">
        <source xml:space="preserve"> Goat anti-mouse IgG conjugated to AlexaFluor488 (1:1000; Invitrogen, Carlsbad, CA, USA) in 1.5% NGS is applied for 1 hour at room-temperature incubation.</source>
      </segment>
      <segment id="229-12">
        <source xml:space="preserve"> After washing with PBST three times for 5 minutes, 0.4 mg/mL DAPI is applied to sections for 5 minutes to counterstain the nuclei.</source>
      </segment>
      <segment id="229-13">
        <source xml:space="preserve"> Prolong Gold is used in cover slipping the slides.</source>
      </segment>
    </unit>
    <unit id="230">
      <segment id="230">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="231">
      <segment id="231">
        <source xml:space="preserve">Histopathology of NM Induced Injury in Corneal Organ Cultures</source>
      </segment>
    </unit>
    <unit id="232">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="232-0">
        <source xml:space="preserve">Injury inflicted by NM includes the following:</source>
      </segment>
      <segment id="232-1">
        <source xml:space="preserve"> (a) hyperplasia of the epithelial layer, which is apparent by the increase in the number and depth of epithelial cells pushing down into the stroma.</source>
      </segment>
      <segment id="232-2">
        <source xml:space="preserve"> This is referred to as downward hyperplasia.</source>
      </segment>
      <segment id="232-3">
        <source xml:space="preserve"> Unexposed (naïve) cornea shows some downward hyperplasia but it isn't as extensive as cornea exposed to NM; (b) basal cell nuclei rising up toward the top of the basal epithelial cells; and (c) epithelial-stromal separation.</source>
      </segment>
      <segment id="232-4">
        <source xml:space="preserve"> The histopathological effects are visible as early as four days post-exposure.</source>
      </segment>
      <segment id="232-5">
        <source xml:space="preserve"> An exemplary histopathological grading scheme for assessing the effects of NM induced corneal injury is shown in <ph id="ph1"/>Fig. 6.</source>
      </segment>
      <ignorable>
        <source xml:space="preserve"><ph id="ph2"/></source>
      </ignorable>
      <segment id="232-6">
        <source xml:space="preserve"> Histopathological grading is improved by treatment with N-Met-TTHX1114.</source>
      </segment>
      <segment id="232-7">
        <source xml:space="preserve"> The N-Met-TTHX1114 treated corneal sections exhibit lower score (indicative of lesser injury) compared to sections from untreated corneas.</source>
      </segment>
    </unit>
    <unit id="233">
      <segment id="233">
        <source xml:space="preserve">Treatment of NM exposed corneal cells with N-Met-TTHX1114 protects against injury</source>
      </segment>
    </unit>
    <unit id="234">
      <segment id="234-0">
        <source xml:space="preserve">Treatment of NM-exposed cornea with TTHX1114 protects the cornea from histopathological injury induced by NM.</source>
      </segment>
      <segment id="234-1">
        <source xml:space="preserve"> Following NM-exposure, the N-Met-TTHX1114 treated cornea does not exhibit downward hyperplasia.</source>
      </segment>
      <segment id="234-2">
        <source xml:space="preserve"> Further, epithelial-stromal separation is not visible in corneas treated with N-Met-TTHX1114.</source>
      </segment>
    </unit>
    <unit id="235">
      <segment id="235">
        <source xml:space="preserve">NM exposures reduces FGF-1 levels in rabbit cornea</source>
      </segment>
    </unit>
    <unit id="236">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="236-0">
        <source xml:space="preserve">Rabbit corneal sections, exposed to NM, are incubated with anti-FGF-1 antibodies.</source>
      </segment>
      <segment id="236-1">
        <source xml:space="preserve"> In exposed corneas, a reduction of FGF-1 level is observed, as shown in <ph id="ph1"/>Fig. 9.</source>
      </segment>
      <segment id="236-2">
        <source xml:space="preserve"><ph id="ph2"/> Corneal sections exposed to NM, 1 day (upper panel of <ph id="ph3"/>Fig. 9<ph id="ph4"/>), and 3 days (lower panel of <ph id="ph5"/>Fig. 9<ph id="ph6"/>) post-exposure, demonstrate enhanced suppression of FGF-1 compared to naïve corneal sections.</source>
      </segment>
    </unit>
    <unit id="237">
      <segment id="237">
        <source xml:space="preserve">NM exposures induces ADAM17 activation in rabbit cornea</source>
      </segment>
    </unit>
    <unit id="238">
      <segment id="238">
        <source xml:space="preserve">In NM exposed corneas, intense fluorescent signal is observed at the basement membrane zone where the ADAM17 enzyme would need to be positioned in order to degrade collagen XVII ADAM17 is not appreciably detected in unexposed corneas.</source>
      </segment>
    </unit>
    <unit id="239">
      <segment id="239">
        <source xml:space="preserve">N-Met-TTHX1114 treatment reduces NM exposure induced ADAM17 activation in rabbit cornea</source>
      </segment>
    </unit>
    <unit id="240">
      <segment id="240-0">
        <source xml:space="preserve">Upon treatment of corneas with TTH1114, ADAM17 fluorescent signal is attenuated in peripheral and central cornea.</source>
      </segment>
      <segment id="240-1">
        <source xml:space="preserve"> The attenuation or lack of ADAM17 fluorescent signal corresponds with better histologic appearance of the corneal epithelial-stromal junction.</source>
      </segment>
    </unit>
    <unit id="241">
      <segment id="241">
        <source xml:space="preserve">N-Met-TTHX1114 treatment ameliorates NM exposure induced suppression of corneal epithelial proliferation</source>
      </segment>
    </unit>
    <unit id="242">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0031" w:id="260"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="260"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0032" w:id="261"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="261"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="242-0">
        <source xml:space="preserve">Peripheral corneal epithelial layer stimulation is assessed by via EdU incorporation of corneal epithelial cells (CECs).</source>
      </segment>
      <segment id="242-1">
        <source xml:space="preserve"> Primary cultures of rabbit CECs are established using standard procedures, e.g., the procedure described by Kay et al. ( <ph id="ph1"/>Kay et al.</source>
      </segment>
      <segment id="242-2">
        <source xml:space="preserve"> Investigative ophthalmology &amp; visual science.</source>
      </segment>
      <segment id="242-3">
        <source xml:space="preserve"> 1993;34(3):663-72<ph id="ph2"/>; <ph id="ph3"/>Lee et al., Investigative ophthalmology &amp; visual science.</source>
      </segment>
      <segment id="242-4">
        <source xml:space="preserve"> 2009;50(5):2067-76<ph id="ph4"/>).</source>
      </segment>
      <segment id="242-5">
        <source xml:space="preserve"> The cells are exposed to NM for two hours.</source>
      </segment>
      <segment id="242-6">
        <source xml:space="preserve"> Proliferation assays are performed in 12-well plates using, e.g., a Click-IT assay kit (Life Technologies).</source>
      </segment>
      <segment id="242-7">
        <source xml:space="preserve"> Incorporation of EdU into corneal epithelial cells is an indicator of epithelial proliferation.</source>
      </segment>
      <segment id="242-8">
        <source xml:space="preserve"> The percentage corneal epithelial cells incorporating EdU are lower when treated with N-Met-TTHX1114, following NM-exposure, compared to untreated controls.</source>
      </segment>
    </unit>
    <unit id="243">
      <segment id="243-0">
        <source xml:space="preserve">Example 4:</source>
      </segment>
      <segment id="243-1">
        <source xml:space="preserve"> Sulfur mustard induced injury of corneal endothelial cells</source>
      </segment>
    </unit>
    <unit id="244">
      <segment id="244-0">
        <source xml:space="preserve">The study is directed towards the effect of modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="244-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) on treatment of sulfur mustard (SM) induced corneal injury.</source>
      </segment>
      <segment id="244-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptides are generated using methods as described above in the Recombinant Techniques section.</source>
      </segment>
    </unit>
    <unit id="245">
      <segment id="245">
        <source xml:space="preserve">Experimental methods</source>
      </segment>
    </unit>
    <unit id="246">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="246-0">
        <source xml:space="preserve">Rabbits are exposed to sulfur mustard in cohorts of 8 to 16 animals during a 4-month period.</source>
      </segment>
      <segment id="246-1">
        <source xml:space="preserve"> One day before exposure, a 4-in<ph id="ph1"/>2<ph id="ph2"/> region on each rabbit's back is clipped, and a fentanyl patch (25 µg/h) is placed anterior to the scapula.</source>
      </segment>
      <segment id="246-2">
        <source xml:space="preserve"> On the day of exposure, rabbits are anesthetized with an intramuscular administration of 15 mg/kg of ketamine and 7 mg/kg of xylazine, and physiological parameters are recorded.</source>
      </segment>
      <segment id="246-3">
        <source xml:space="preserve"> The corneas of anesthetized rabbits are exposed to SM vapor for 2.5 min.</source>
      </segment>
      <segment id="246-4">
        <source xml:space="preserve"> Two minutes after exposure, exposed eyes are gently rinsed with 10 mL sterile saline to flush residual agent.</source>
      </segment>
    </unit>
    <unit id="247">
      <segment id="247-0">
        <source xml:space="preserve">A first group of rabbits are euthanized 24 hours after exposure.</source>
      </segment>
      <segment id="247-1">
        <source xml:space="preserve"> Five minutes after euthanasia, 20 µL of a 0.1 mg/mL solution of AlexaFluor 488 (Life Technologies, Carlsbad, CA) dissolved in PBS (pH 7.4) is injected into the anterior chamber through a 30-gauge needle using a 100-µL Hamilton glass syringe (Hamilton Company, Reno, NV).</source>
      </segment>
      <segment id="247-2">
        <source xml:space="preserve"> After 10 minutes, corneas are excised and washed three times for 1 minute in 10 mL PBS.</source>
      </segment>
      <segment id="247-3">
        <source xml:space="preserve"> Corneas are transferred to 14-mL round-bottom tubes (Becton Dickinson, Franklin Lakes, NJ) with 100 µL PBS and incubated on ice in the dark with gentle agitation.</source>
      </segment>
      <segment id="247-4">
        <source xml:space="preserve"> After 30 minutes, supernatant is diluted 1:5 in PBS and analyzed for fluorescence on a Synergy MX fluorophotometer (Biotek, Winooski, VT) using an excitation wavelength of 488 ± 10 nm, emission wavelength of 524 ± 10 nm, and a gain of 50.</source>
      </segment>
      <segment id="247-5">
        <source xml:space="preserve"> Representative corneas are imaged with a blue diode and FITC filter set in a Versadoc MP 4000 (Bio-Rad Laboratories, Hercules, CA).</source>
      </segment>
    </unit>
    <unit id="248">
      <segment id="248-0">
        <source xml:space="preserve">The remaining rabbits are further divided into a test group, treated with N-Met-TTHX1114 at varying doses, and a sham control group, treated with control vehicle.</source>
      </segment>
      <segment id="248-1">
        <source xml:space="preserve"> The treatments are carried out for about two weeks.</source>
      </segment>
      <segment id="248-2">
        <source xml:space="preserve"> Rabbits are returned to cages and provided food and water ad libitum.</source>
      </segment>
      <segment id="248-3">
        <source xml:space="preserve"> Fentanyl patches are replaced after every 72 hours to manage discomfort through 6 days after the exposure and applied liberally thereafter as needed.</source>
      </segment>
      <segment id="248-4">
        <source xml:space="preserve"> Animals are monitored daily for signs of pain and distress.</source>
      </segment>
      <segment id="248-5">
        <source xml:space="preserve"> Corneal injury is clinically evaluated on a regular basis using pachymetry, fluorescein exclusion assays, and slit-lamp evaluations.</source>
      </segment>
    </unit>
    <unit id="249">
      <segment id="249">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="250">
      <segment id="250">
        <source xml:space="preserve">Sulfur Mustard (SM) exposure causes corneal endothelial injury</source>
      </segment>
    </unit>
    <unit id="251">
      <segment id="251-0">
        <source xml:space="preserve">Corneas visualized at 370 nm by scanning electron microscopy (SEM) 24 hours after SM exposure exhibit a centripetal injury, with extensive loss of corneal endothelial cells (CECs) in the central cornea and increased retention toward the exposure margins.</source>
      </segment>
      <segment id="251-1">
        <source xml:space="preserve"> To obtain a more comprehensive overview of SM-induced changes in the corneal endothelium, the fine structure of the posterior cornea is evaluated by electron microscopy.</source>
      </segment>
      <segment id="251-2">
        <source xml:space="preserve"> Enface scanning electron micrographs of unexposed corneas reveals a continuous layer of polygonal cells of regular shape and size, with interdigitated borders, apical microvilli, and infrequent cilia.</source>
      </segment>
      <segment id="251-3">
        <source xml:space="preserve"> Within 24 hours of exposure, all corneal endothelia exhibit evidence of an acute lesion, with extensive central CEC loss and more diffuse vesication in the exposure penumbra.</source>
      </segment>
      <segment id="251-4">
        <source xml:space="preserve"> The CECs within the exposed region displays two general morphologies, namely, enlarged (highly attenuated) polymorphic cells and rounded or spindle-shaped cells.</source>
      </segment>
      <segment id="251-5">
        <source xml:space="preserve"> Most CECs exhibit atypical apical membrane morphologies and lack cell-to-cell interdigitations.</source>
      </segment>
      <segment id="251-6">
        <source xml:space="preserve"> In regions of CEC vesication, denuded Descemet's membrane (DM) is covered by a complex arbor of CEC lamellipodia and filopodia.</source>
      </segment>
      <segment id="251-7">
        <source xml:space="preserve"> The TEM imaging of corneal cross-sections confirmed the centripetal injury pattern, with CEC morphology progressively normalizing toward the injury margin.</source>
      </segment>
      <segment id="251-8">
        <source xml:space="preserve"> Denuded DM near the central lesion is infiltrated by extensively arborized cellular processes.</source>
      </segment>
      <segment id="251-9">
        <source xml:space="preserve"> At more distal regions, overlapping cellular processes with loss of junctional complexes is common, suggestive of a motile population.</source>
      </segment>
      <segment id="251-10">
        <source xml:space="preserve"> The rounded CEC population observed by SEM is found exclusively overlying polymorphic endothelium and display signs of necrosis or apoptosis.</source>
      </segment>
    </unit>
    <unit id="252">
      <segment id="252">
        <source xml:space="preserve">Treatment with N-Met-TTHX1114 resolves corneal endothelial injuries</source>
      </segment>
    </unit>
    <unit id="253">
      <segment id="253-0">
        <source xml:space="preserve">Eight weeks after exposure, endothelial cell morphology and structure are compared between test group (also referred to as resolved eyes) and sham control group (which later develops MGK).</source>
      </segment>
      <segment id="253-1">
        <source xml:space="preserve"> Resolved eyes are distinguished by the absence of characteristic MGK sequelae during clinical evaluations such as corneal erosions, neovascularization, or corneal haze and had corneal thicknesses that are statistically indistinguishable from sham-exposed controls by 6 weeks.</source>
      </segment>
      <segment id="253-2">
        <source xml:space="preserve"> Enface scanning micrographs of resolved eyes are found to be strikingly similar to sham-exposed controls, with a well-organized monolayer of polygonal cells.</source>
      </segment>
      <segment id="253-3">
        <source xml:space="preserve"> The average CEC size is increased in resolved eyes compared with control corneas; otherwise, resolved corneas do not exhibit significant variability across the posterior surface.</source>
      </segment>
      <segment id="253-4">
        <source xml:space="preserve"> In contrast, the sham-control treated rabbits with MGK endothelia reveal extensive variability in cell shape and cell size among animals, indicative of a dynamic injury process.</source>
      </segment>
      <segment id="253-5">
        <source xml:space="preserve"> Focal variability in endothelial morphology is routinely observed in individual corneas, with some regions exhibiting enlarged but mosaic CECs and other regions displaying significant disorganization, with variable degrees of apical blebbing, areas showing denuded DM, and clearly delineated cell boundaries lacking.</source>
      </segment>
      <segment id="253-6">
        <source xml:space="preserve"> These phenomena are not observed in the N-Met-TTHX1114 treated resolved endothelium.</source>
      </segment>
      <segment id="253-7">
        <source xml:space="preserve"> Transmission Electron Microscope images of N-Met-TTHX1 114 treated resolved corneas are very similar to naïve endothelium.</source>
      </segment>
      <segment id="253-8">
        <source xml:space="preserve"> In contrast, sham-control treated endothelium with MGK pathology exhibit diffusive thickening of the posterior DM, consistent with either edema and/or the deposition of a retrocorneal fibrous membrane.</source>
      </segment>
      <segment id="253-9">
        <source xml:space="preserve"> The MGK corneas also exhibit extensive markers of CEC stress or injury, including cytoplasmic rarefication, excessive vacuolization, and swollen endoplasmic reticuli.</source>
      </segment>
      <segment id="253-10">
        <source xml:space="preserve"> There is a high frequency of overlapping cell processes, similar to 24-hour images and suggestive of an ongoing attempt to repopulate recently denuded DM.</source>
      </segment>
    </unit>
    <unit id="254">
      <segment id="254-0">
        <source xml:space="preserve">Example 5:</source>
      </segment>
      <segment id="254-1">
        <source xml:space="preserve"> Modified FGF-1 (N-Met-TTHX1114) is effective in wound healing</source>
      </segment>
    </unit>
    <unit id="255">
      <segment id="255-0">
        <source xml:space="preserve">This study is directed towards the effect of a modified FGF-1 polypeptide comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="255-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) on rate of wound healing.</source>
      </segment>
    </unit>
    <unit id="256">
      <segment id="256">
        <source xml:space="preserve">Experimental Methods</source>
      </segment>
    </unit>
    <unit id="257">
      <segment id="257">
        <source xml:space="preserve">Female C57BL/Ks-db/db diabetic mice, 11 weeks old, are obtained from Jackson Laboratories, and housed in sterile microisolator boxes with sterile water and bedding and are kept in a semi-barrier quarantine facility.</source>
      </segment>
    </unit>
    <unit id="258">
      <segment id="258">
        <source xml:space="preserve">Skin organ culture</source>
      </segment>
    </unit>
    <unit id="259">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="259-0">
        <source xml:space="preserve">Skin biopsy specimens from healing impaired mice are cultured in suitable culture medium.</source>
      </segment>
      <segment id="259-1">
        <source xml:space="preserve"> Briefly, tissue samples are incubated at 37 °C in DMEM (Gibco) medium supplemented with 0.25% heat-inactivated bovine serum (Gibco).</source>
      </segment>
      <segment id="259-2">
        <source xml:space="preserve"> The skin specimens are treated daily for 2 days or 3 days with 0, 1, 10, and 100 µg/mL N-Met-TTHX1114.</source>
      </segment>
      <segment id="259-3">
        <source xml:space="preserve"> The tissue samples are then labeled for 24 hours with 4 µCi of [methyl-<ph id="ph1"/>3<ph id="ph2"/>H]thymidine (from a stock solution containing 20 Ci/mmol; New England Biolabs).</source>
      </segment>
      <segment id="259-4">
        <source xml:space="preserve"> After thymidine labeling, the skin specimens are washed, solubilized, and assayed for radioactivity count.</source>
      </segment>
    </unit>
    <unit id="260">
      <segment id="260">
        <source xml:space="preserve">Wound-closure model</source>
      </segment>
    </unit>
    <unit id="261">
      <segment id="261-0">
        <source xml:space="preserve">Mice are anesthetized with intraperitoneal injections of 110 mg ketamine and 9 mg xylazine per kg of body weight.</source>
      </segment>
      <segment id="261-1">
        <source xml:space="preserve"> The mid-back and thoracic skin is shaved and disinfected with a 2% chlorhexidine surgical scrub followed by a 70% ethanol.</source>
      </segment>
    </unit>
    <unit id="262">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="262-0">
        <source xml:space="preserve">A template 1.6 cm in diameter is used to mark a 2.0-cm<ph id="ph1"/>2<ph id="ph2"/> circle on the mid-dorsal area, and a single full-thickness wound is created by blunt excision with sterile curved iris scissors.</source>
      </segment>
      <segment id="262-1">
        <source xml:space="preserve"> Wound areas typically increase to approximately 2.3 cm<ph id="ph3"/>2<ph id="ph4"/> soon after injury, presumably because of contraction of the dermis along the wound perimeter.</source>
      </segment>
      <segment id="262-2">
        <source xml:space="preserve"> All surgical and subsequent healing analysis procedures are performed in a laminar flow hood using a full aseptic techniques.</source>
      </segment>
      <segment id="262-3">
        <source xml:space="preserve"> Filtersterili zed growth factors, at varying doses, and corresponding vehicle control solutions are applied topically, on days 0, 3, and 7 after injury.</source>
      </segment>
      <segment id="262-4">
        <source xml:space="preserve"> The wounds are covered with a semitransparent Bioclusive dressing for protection, maintenance of a moist environment, and prevention of crust formation.</source>
      </segment>
      <segment id="262-5">
        <source xml:space="preserve"> Wound fluid samples are taken at day 10 after injury and cultured for aerobic and anaerobic microorganisms.</source>
      </segment>
      <segment id="262-6">
        <source xml:space="preserve"> Animals from cultures that exhibit more than 50 colonies per wound are excluded from the study analysis.</source>
      </segment>
      <segment id="262-7">
        <source xml:space="preserve"> Prevention of even mild or subclinical infection results in a consistent maximal healing impairment, thus providing a large wound-healing window for evaluation of treatment effects.</source>
      </segment>
    </unit>
    <unit id="263">
      <segment id="263">
        <source xml:space="preserve">Healing analysis</source>
      </segment>
    </unit>
    <unit id="264">
      <segment id="264">
        <source xml:space="preserve">Wound appearances are recorded photographically, and their perimeters are traced onto sterile glass slides applied directly to the exposed wound surfaces after prewetting with a drop of sterile physiologic saline.</source>
      </segment>
    </unit>
    <unit id="265">
      <segment id="265-0">
        <source xml:space="preserve">Measurements are made immediately after wounding and twice weekly thereafter until the wounds are completely closed.</source>
      </segment>
      <segment id="265-1">
        <source xml:space="preserve"> Wound areas and perimeters are determined from the glass-slide tracings using suitable computerized image analysis (e.g., using Presage C V-6; Advanced Imaging Concepts, Princeton, NJ).</source>
      </segment>
      <segment id="265-2">
        <source xml:space="preserve"> Statistical significances of differences between groups are evaluated using an unpaired two-tailed Student t test.</source>
      </segment>
      <segment id="265-3">
        <source xml:space="preserve"> Healing expressed as a decrease in percent initial area is converted to linear ingrowth from the wound edges by dividing the difference in wound areas by the average wound perimeters at sequential time intervals.</source>
      </segment>
      <segment id="265-4">
        <source xml:space="preserve"> Total ingrowth at a specific time is the sum of the incremental ingrowth distances up until that time.</source>
      </segment>
      <segment id="265-5">
        <source xml:space="preserve"> This transformation linearizes closure as a function of time, thereby allowing expression of healing as kinetic rates that are constant over time.</source>
      </segment>
      <segment id="265-6">
        <source xml:space="preserve"> Wounds are considered fully healed when moist granulation tissue is no longer apparent, indicating a functional epidermal water-permeability barrier.</source>
      </segment>
    </unit>
    <unit id="266">
      <segment id="266">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="267">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="267-0">
        <source xml:space="preserve">Skin biopsy specimens, from the healing impaired mice, incorporates [methyl-<ph id="ph1"/>3<ph id="ph2"/>H] thymidine in response to daily doses of N-Met-TTHX1 114.</source>
      </segment>
      <segment id="267-1">
        <source xml:space="preserve"> The cells within the skin respond mitogenically to N-Met-TTHX1114 in a dose-dependent manner.</source>
      </segment>
      <segment id="267-2">
        <source xml:space="preserve"> Thus, N-Met-TTHX111 induces DNA synthesis in skin organ cultures.</source>
      </segment>
    </unit>
    <unit id="268">
      <segment id="268-0">
        <source xml:space="preserve">Further, full-thickness dermal excisional wounds, about 1.6 cm in diameter, close substantially faster in responses of doses of N-Met-TTHX1 114, applied during the first week following wound initiation, compared to treatment with control vehicle.</source>
      </segment>
      <segment id="268-1">
        <source xml:space="preserve"> Thus, N-Met-TTHX1114 accelerates wound closure.</source>
      </segment>
    </unit>
    <unit id="269">
      <segment id="269-0">
        <source xml:space="preserve">Moreover, gross appearance and mean size of vehicle and N-Met-TTHX1 114 treated wounds differ significantly.</source>
      </segment>
      <segment id="269-1">
        <source xml:space="preserve"> The N-Met-TTHX1114 treated wounds show signs of neovascularization, such as visible reddening and leakage of serous fluids, as early as 3 days following treatment.</source>
      </segment>
      <segment id="269-2">
        <source xml:space="preserve"> In contract, the wounds receiving control vehicle contain little or no visible serous fluids and substantially less apparent signs of neoangiogenesis.</source>
      </segment>
    </unit>
    <unit id="270">
      <segment id="270-0">
        <source xml:space="preserve">Example 6:</source>
      </segment>
      <segment id="270-1">
        <source xml:space="preserve"> Treatment of herpetic keratopathy using a modified FGF-1 polypeptides (N-Met-TTHX1114 or TTHX-1114)</source>
      </segment>
    </unit>
    <unit id="271">
      <segment id="271-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptide comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="271-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) or SEQ ID NO:</source>
      </segment>
      <segment id="271-2">
        <source xml:space="preserve"> 205 (TTHX1001) for the treatment of herpetic keratopathy.</source>
      </segment>
    </unit>
    <unit id="272">
      <segment id="272">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="273">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="273-0">
        <source xml:space="preserve">A group of patients with herpetic keratopathy is selected for this study.</source>
      </segment>
      <segment id="273-1">
        <source xml:space="preserve"> The patients are divided into three subgroups.</source>
      </segment>
      <segment id="273-2">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml (<ph id="ph1"/>i.e., 5<ph id="ph2"/> µg/ml) of N-met TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="273-3">
        <source xml:space="preserve"> 2) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="273-4">
        <source xml:space="preserve"> Patients in the second sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml (<ph id="ph3"/>i.e., 5<ph id="ph4"/> µg/ml) of TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="273-5">
        <source xml:space="preserve"> 205) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="273-6">
        <source xml:space="preserve"> Patients in the third sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="273-7">
        <source xml:space="preserve"> 2) or the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="273-8">
        <source xml:space="preserve"> 205) but is otherwise identical to what is administered to the first and the second sub-group.</source>
      </segment>
      <segment id="273-9">
        <source xml:space="preserve"> For all three subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="273-10">
        <source xml:space="preserve"> The N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="273-11">
        <source xml:space="preserve"> 2) containing ophthalmic formulation, the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="273-12">
        <source xml:space="preserve"> 205) containing ophthalmic formulation, and the sham ophthalmic formulation are administered, respectively to patients in the first, second, and the third sub-group, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="274">
      <segment id="274">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="275">
      <segment id="275-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulation containing the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="275-1">
        <source xml:space="preserve"> 2) and the ophthalmic formulation containing the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="275-2">
        <source xml:space="preserve"> 205) results in healing of the herpetic corneal ulcer within about 14 days in majority of the patients belonging to the first and the second sub-groups, along with reduction in the duration of pain and inflammation.</source>
      </segment>
      <segment id="275-3">
        <source xml:space="preserve"> Furthermore, eyes of patients in the first and the second sub-groups, treated respectively with the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="275-4">
        <source xml:space="preserve"> 2) containing ophthalmic formulation and the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="275-5">
        <source xml:space="preserve"> 205) containing ophthalmic formulation have less corneal haze and scarring than patients in the third sub-group, who were treated with the sham.</source>
      </segment>
    </unit>
    <unit id="276">
      <segment id="276-0">
        <source xml:space="preserve">Example 7:</source>
      </segment>
      <segment id="276-1">
        <source xml:space="preserve"> Treatment of chronic herpetic keratopathy using a modified FGF-1 polypeptides (N-Met-TTHX1114 or TTHX-1001)</source>
      </segment>
    </unit>
    <unit id="277">
      <segment id="277-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptide comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="277-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) or SEQ ID NO:</source>
      </segment>
      <segment id="277-2">
        <source xml:space="preserve"> 205 (TTHX1001) for the treatment of chronic herpetic keratopathy.</source>
      </segment>
    </unit>
    <unit id="278">
      <segment id="278">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="279">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="279-0">
        <source xml:space="preserve">A group of patients with chronic herpetic keratopathy is selected for this study.</source>
      </segment>
      <segment id="279-1">
        <source xml:space="preserve"> The patients are divided into three subgroups.</source>
      </segment>
      <segment id="279-2">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml <ph id="ph1"/>(i.e., 5<ph id="ph2"/> µg/ml) of N-Met-TTHX1 114 (SEQ ID NO:</source>
      </segment>
      <segment id="279-3">
        <source xml:space="preserve"> 2) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="279-4">
        <source xml:space="preserve"> Patients in the second sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml (<ph id="ph3"/>i.e., 5<ph id="ph4"/> µg/ml) of TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="279-5">
        <source xml:space="preserve"> 205) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="279-6">
        <source xml:space="preserve"> Patients in the third sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="279-7">
        <source xml:space="preserve"> 2) or the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="279-8">
        <source xml:space="preserve"> 205) but is otherwise identical to what is administered to the first and the second sub-group.</source>
      </segment>
      <segment id="279-9">
        <source xml:space="preserve"> For all three subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="279-10">
        <source xml:space="preserve"> The N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="279-11">
        <source xml:space="preserve"> 2) containing ophthalmic formulation, the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="279-12">
        <source xml:space="preserve"> 205) containing ophthalmic formulation, and the sham ophthalmic formulation are administered, respectively to patients in the first, second, and the third sub-group, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="280">
      <segment id="280">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="281">
      <segment id="281-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulation containing the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="281-1">
        <source xml:space="preserve"> 2) and the ophthalmic formulation containing the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="281-2">
        <source xml:space="preserve"> 205) result in healing of corneal ulcer in majority of the patients belonging to the first and the second sub-groups, along with reduction in of pain and inflammation.</source>
      </segment>
      <segment id="281-3">
        <source xml:space="preserve"> Furthermore, eyes of patients in the first and the second sub-groups, treated respectively with the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="281-4">
        <source xml:space="preserve"> 2) containing ophthalmic formulation and the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="281-5">
        <source xml:space="preserve"> 205) containing ophthalmic formulation, have less corneal opacity haze and scarring than patients in the third sub-group, who are treated with the sham.</source>
      </segment>
    </unit>
    <unit id="282">
      <segment id="282-0">
        <source xml:space="preserve">Example 8:</source>
      </segment>
      <segment id="282-1">
        <source xml:space="preserve"> Treatment of neurotrophic keratopathy using modified FGF-1 polypeptides (N-Met-TTHX1114 or TTHX-1001)</source>
      </segment>
    </unit>
    <unit id="283">
      <segment id="283-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptide comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="283-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) or SEQ ID NO:</source>
      </segment>
      <segment id="283-2">
        <source xml:space="preserve"> 205 (TTHX1001) for the treatment of neurotrophic keratopathy secondary to herpes infection.</source>
      </segment>
    </unit>
    <unit id="284">
      <segment id="284">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="285">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="285-0">
        <source xml:space="preserve">A group of patients with neurotrophic keratopathy is selected for this study.</source>
      </segment>
      <segment id="285-1">
        <source xml:space="preserve"> The patients are divided into three subgroups.</source>
      </segment>
      <segment id="285-2">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml <ph id="ph1"/>(i.e., 5<ph id="ph2"/> µg/ml) of N-Met-TTHX1 114 (SEQ ID NO:</source>
      </segment>
      <segment id="285-3">
        <source xml:space="preserve"> 2) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="285-4">
        <source xml:space="preserve"> Patients in the second sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml (<ph id="ph3"/>i.e.,<ph id="ph4"/> 5 µg/ml) of TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="285-5">
        <source xml:space="preserve"> 205) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="285-6">
        <source xml:space="preserve"> Patients in the third sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="285-7">
        <source xml:space="preserve"> 2) or the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="285-8">
        <source xml:space="preserve"> 205) but is otherwise identical to what is administered to the first and the second sub-group.</source>
      </segment>
      <segment id="285-9">
        <source xml:space="preserve"> For all three subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="285-10">
        <source xml:space="preserve"> The N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="285-11">
        <source xml:space="preserve"> 2) containing ophthalmic formulation, the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="285-12">
        <source xml:space="preserve"> 205) containing ophthalmic formulation, and the sham ophthalmic formulation are administered, respectively to patients in the first, second, and the third sub-group, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="286">
      <segment id="286">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="287">
      <segment id="287-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulation containing the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="287-1">
        <source xml:space="preserve"> 2) and the ophthalmic formulation containing the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="287-2">
        <source xml:space="preserve"> 205) result in healing of corneal ulcer in majority of the patients belonging to the first and the second sub-groups, along with reduction in of pain and inflammation.</source>
      </segment>
      <segment id="287-3">
        <source xml:space="preserve"> Furthermore, eyes of patients in the first and the second sub-groups, treated respectively with the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="287-4">
        <source xml:space="preserve"> 2) containing ophthalmic formulation and the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="287-5">
        <source xml:space="preserve"> 205) containing ophthalmic formulation, have less corneal opacity haze and scarring than patients in the third sub-group, who are treated with the sham.</source>
      </segment>
    </unit>
    <unit id="288">
      <segment id="288-0">
        <source xml:space="preserve">Example 9:</source>
      </segment>
      <segment id="288-1">
        <source xml:space="preserve"> Treatment of recurrent herpetic keratopathy and the suppression of reactivation of latent virus using modified FGF-1 polypeptides (N-met-TTHX1114 or TTHX1001)</source>
      </segment>
    </unit>
    <unit id="289">
      <segment id="289-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="289-1">
        <source xml:space="preserve"> 2 (N-Met-TTHX1114) or SEQ ID NO:</source>
      </segment>
      <segment id="289-2">
        <source xml:space="preserve"> 205 (TTHX1001) for the treatment of neurotrophic keratopathy secondary to herpes infection.</source>
      </segment>
    </unit>
    <unit id="290">
      <segment id="290">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="291">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="291-0">
        <source xml:space="preserve">A group of patients with recurrent keratopathy is selected for this study.</source>
      </segment>
      <segment id="291-1">
        <source xml:space="preserve"> The patients have experienced at least one episode of herpetic keratopathy.</source>
      </segment>
      <segment id="291-2">
        <source xml:space="preserve"> For treatment of recurrent herpetic keratopathy and the suppression of reactivation of latent virus, the patients are divided into three subgroups.</source>
      </segment>
      <segment id="291-3">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 50 pg/ml to about 500 pg/ml (<ph id="ph1"/>i.e., 5<ph id="ph2"/> µg/ml) of N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="291-4">
        <source xml:space="preserve"> 2) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="291-5">
        <source xml:space="preserve"> Patients in the second sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 50 pg/ml to 500 pg/ml (<ph id="ph3"/>i.e., 5<ph id="ph4"/> µg/ml) of TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="291-6">
        <source xml:space="preserve"> 205) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="291-7">
        <source xml:space="preserve"> Patients in the third sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="291-8">
        <source xml:space="preserve"> 2) or the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="291-9">
        <source xml:space="preserve"> 205) but is otherwise identical to what is administered to the first and the second sub-group.</source>
      </segment>
      <segment id="291-10">
        <source xml:space="preserve"> For all three subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="291-11">
        <source xml:space="preserve"> The N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="291-12">
        <source xml:space="preserve"> 2) containing ophthalmic formulation, the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="291-13">
        <source xml:space="preserve"> 205) containing ophthalmic formulation, and the sham ophthalmic formulation are administered, respectively to patients in the first, second, and the third sub-group, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="292">
      <segment id="292">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="293">
      <segment id="293-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulations containing the N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="293-1">
        <source xml:space="preserve"> 2) and the ophthalmic formulation containing the TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="293-2">
        <source xml:space="preserve"> 205) increase the disease free interval and reduces the severity of the reactivated virus lesions, with patients receiving the modified FGF-1 having a longer period of time without recurrent disease than patients in the third sub-group, who are treated with the sham.</source>
      </segment>
    </unit>
    <unit id="294">
      <segment id="294-0">
        <source xml:space="preserve">Example 10:</source>
      </segment>
      <segment id="294-1">
        <source xml:space="preserve"> Effects of Modified FGF-1 Polypeptides on Human Corneal Endothelial Cell (HCEC) Proliferation</source>
      </segment>
    </unit>
    <unit id="295">
      <segment id="295-0">
        <source xml:space="preserve">The study is directed towards modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="295-1">
        <source xml:space="preserve"> 206 (TTHX1114) or SEQ ID NO:</source>
      </segment>
      <segment id="295-2">
        <source xml:space="preserve"> 205 (TTHX1001).</source>
      </segment>
      <segment id="295-3">
        <source xml:space="preserve"> The modified FGF-1 polypeptides are generated using methods as described above in the Recombinant Techniques section.</source>
      </segment>
    </unit>
    <unit id="296">
      <segment id="296">
        <source xml:space="preserve">Experimental Methods and Results</source>
      </segment>
    </unit>
    <unit id="297">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="297-0">
        <source xml:space="preserve">Primary cultures (passage 1) of human corneal endothelial cells from a healthy donor are seeded onto 24 well plates in the presence of fetal bovine serum (FBS, 8%) and 24 hours later treated with the varying concentrations of TTHX1 114 (SEQ ID NO:</source>
      </segment>
      <segment id="297-1">
        <source xml:space="preserve"> 206), TTHX1001 (SEQ ID NO:</source>
      </segment>
      <segment id="297-2">
        <source xml:space="preserve"> 205), or wt-FGF-1 (SEQ ID NO:</source>
      </segment>
      <segment id="297-3">
        <source xml:space="preserve"> 1) in media with low (0.8%) FBS.</source>
      </segment>
      <segment id="297-4">
        <source xml:space="preserve"> The 8% FBS group serves as positive control.</source>
      </segment>
      <segment id="297-5">
        <source xml:space="preserve"> Results indicated that TTHX1114 was more potent than TTHX1001 or wt-FGF-1 in stimulating human corneal epithelial cell proliferation and was dose responsive therein.</source>
      </segment>
      <segment id="297-6">
        <source xml:space="preserve"> The EC<ph id="ph1"/>50<ph id="ph2"/> of TTHX1114 was about 100-fold lower than the wt- FGF-1 or the other tested modified FGF-1 polypeptide (TTHX1001; SEQ ID NO:</source>
      </segment>
      <segment id="297-7">
        <source xml:space="preserve"> 205), as illustrated in <ph id="ph3"/>Fig. 2.</source>
      </segment>
    </unit>
    <unit id="298">
      <segment id="298-0">
        <source xml:space="preserve">Example 11:</source>
      </segment>
      <segment id="298-1">
        <source xml:space="preserve"> Nitrogen mustard induced injury of cornea</source>
      </segment>
    </unit>
    <unit id="299">
      <segment id="299-0">
        <source xml:space="preserve">The study is directed towards the effect of modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="299-1">
        <source xml:space="preserve"> 206 (TTHX1114) on treatment of nitrogen mustard (NM) induced corneal injury.</source>
      </segment>
      <segment id="299-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptides were generated using methods as described above in the Recombinant Techniques section.</source>
      </segment>
    </unit>
    <unit id="300">
      <segment id="300">
        <source xml:space="preserve">Experimental Methods</source>
      </segment>
    </unit>
    <unit id="301">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="subscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="301-0">
        <source xml:space="preserve">A rabbit corneal organ culture model system was used to evaluate healing after exposure to NM.</source>
      </segment>
      <segment id="301-1">
        <source xml:space="preserve"> Rabbit eyes (8-12 weeks old) were obtained and corneas with 2-mm scleral rims were dissected from the eyes, placed epithelial-side down into a spot plate, and the concavities were filled with 558C molten agar (0.75%) in Dulbecco's modified Eagle's medium (DMEM).</source>
      </segment>
      <segment id="301-2">
        <source xml:space="preserve"> A non-limiting example of the sett-up is shown in <ph id="ph1"/>Fig. 3.</source>
      </segment>
      <ignorable>
        <source xml:space="preserve"><ph id="ph2"/></source>
      </ignorable>
      <segment id="301-3">
        <source xml:space="preserve"> Once the solution gelled, the corneas were inverted so that the epithelial layer was accessible.</source>
      </segment>
      <segment id="301-4">
        <source xml:space="preserve"> Cultures were placed in 60-mmdiameter pyrex tissue culture dishes.</source>
      </segment>
      <segment id="301-5">
        <source xml:space="preserve"> High glucose DMEM was prepared containing 13MEM-NEAA (minimal essential medium non-essential amino acids), 13 RMPI 1640 Vitamin Solution, 13 antibiotic/antimycotic, ascorbic acid (0.45mM), and ciprofloxacin (10 µg/ml).</source>
      </segment>
      <segment id="301-6">
        <source xml:space="preserve"> High glucose DMEM was added up to the scleral rims, leaving the corneas exposed to air.</source>
      </segment>
      <segment id="301-7">
        <source xml:space="preserve"> The dishes were placed in a 37 °C humidified incubator with 5% CO<ph id="ph3"/>2<ph id="ph4"/>.</source>
      </segment>
      <segment id="301-8">
        <source xml:space="preserve"> The epithelium of each culture was moistened with 500 µL medium, added dropwise onto the central cornea every 7 to 9 hours.</source>
      </segment>
      <segment id="301-9">
        <source xml:space="preserve"> The vesicating agent, NM, was added dropwise onto the central cornea.</source>
      </segment>
      <segment id="301-10">
        <source xml:space="preserve"> Cornea samples (peeled off their agar support) were either put epithelial side down in cryomolds containing Optimal Cutting Temperature (OCT, Tissue-Tek; Sakura, Torrance, CA, USA) compound and flash frozen for histology and immunofluorescence, or directly snap frozen for further protein analyses including Western blot and ADAM17 activity assays (InnoZyme TACE activity assay kit; Calbiochem, Billerica, MA, USA).</source>
      </segment>
    </unit>
    <unit id="302">
      <segment id="302-0">
        <source xml:space="preserve">NM was used to induce corneal injury.</source>
      </segment>
      <segment id="302-1">
        <source xml:space="preserve"> NM, in powdered solid form (catalog No. 122564; Sigma-Aldrich) was first dissolved in PBS to 100 mM, and then diluted with medium to 10 mM. Ten microliters were applied to deliver 100 nmol vesicant to the cornea.</source>
      </segment>
      <segment id="302-2">
        <source xml:space="preserve"> After applying NM onto the central corneas, the cultures were returned to the 37 °C incubator for 2 hours without removing the vesicant.</source>
      </segment>
      <segment id="302-3">
        <source xml:space="preserve"> After this incubation, contaminated medium was removed, and fresh medium was added to the central cornea until the level in the dish reached the top of the scleral rim.</source>
      </segment>
      <segment id="302-4">
        <source xml:space="preserve"> Control unexposed and exposed corneas were then returned to 37°C for a 22-hour incubation, being removed for only three short periods to add 20 µL medium to the exposed samples not receiving TTHX1114 therapy, or to add 20 µL of TTHX1 114 as therapy to the central corneas.</source>
      </segment>
      <segment id="302-5">
        <source xml:space="preserve"> The first TTHX1114 application was left on for 8 hours, the second for 9 hours, and the third for 5 hours.</source>
      </segment>
      <segment id="302-6">
        <source xml:space="preserve"> Thus, the length of the 2-hour exposure and the subsequent treatment was 24 hours in total.</source>
      </segment>
    </unit>
    <unit id="303">
      <segment id="303-0">
        <source xml:space="preserve">For experiments analyzing how fast NM exposure induced ADAM17, cultures were set up as described.</source>
      </segment>
      <segment id="303-1">
        <source xml:space="preserve"> For the shortest exposure time, the NM solution was applied to a cornea, then immediately washed off and the sample was put in protein isolation extraction buffer.</source>
      </segment>
      <segment id="303-2">
        <source xml:space="preserve"> This was repeated with two other corneas to collect three 0-minute exposures.</source>
      </segment>
      <segment id="303-3">
        <source xml:space="preserve"> For the 5- and 10- minute exposures, NM was added to the sets of three corneas accordingly, insuring none were accidentally under- or overexposed to NM.</source>
      </segment>
      <segment id="303-4">
        <source xml:space="preserve"> All corneas were extracted and processed for ADAM17 activity assays.</source>
      </segment>
    </unit>
    <unit id="304">
      <segment id="304-0">
        <source xml:space="preserve">The InnoZyme ADAM17/TACE Activity Kit (Calbiochem) was used to quantify the enzyme's activity from corneal extracts according to the vendor's provided protocol.</source>
      </segment>
      <segment id="304-1">
        <source xml:space="preserve"> Briefly, 400 µL wash buffer (from the InnoZyme kit) was applied to 96-well plates precoated with anti-human ADAM17 antibody, followed by two washes.</source>
      </segment>
      <segment id="304-2">
        <source xml:space="preserve"> Triplicate samples of corneal extracts and InnoZyme kit standards (100 µL) were each added to three sets of wells.</source>
      </segment>
      <segment id="304-3">
        <source xml:space="preserve"> Plates were sealed and incubated 1 hour with gentle shaking at room temperature.</source>
      </segment>
      <segment id="304-4">
        <source xml:space="preserve"> Then, plates were washed with 400 µL wash buffer five times.</source>
      </segment>
      <segment id="304-5">
        <source xml:space="preserve"> ADAM17 substrate supplied in the kit (100 µL) was added to each well and incubated for 5 hours at 37 °C.</source>
      </segment>
      <segment id="304-6">
        <source xml:space="preserve"> Fluorescence was measured at an excitation wavelength of 324 nm and an emission wavelength of 405 nm, and was reported as relative fluorescence units on graphs.</source>
      </segment>
      <segment id="304-7">
        <source xml:space="preserve"> For immunodetection of ADAM17, OCT-embedded sections on slides were first fixed in 208C methanol for 10 minutes.</source>
      </segment>
      <segment id="304-8">
        <source xml:space="preserve"> Nonspecific binding was blocked for 1 hour with 5% normal goat serum (NGS) in PBS with 0.05% Tween-20 (PBST).</source>
      </segment>
      <segment id="304-9">
        <source xml:space="preserve"> A mouse monoclonal antibody against the ectodomain (amino acids 18-671) of human ADAM 17 (5 µg/mL in 1.5% NGS, MAB9304; R&amp;D Systems, Minneapolis, MN, USA), which was found to detect only the active enzyme by immunofluorescence, was applied to the slides for a 1-hour incubation at room temperature, then the slides were washed three times for 10 minutes in PBST.</source>
      </segment>
      <segment id="304-10">
        <source xml:space="preserve"> For negative control slides, the same volume of PBST was applied to sections as that of primary antibody used on test sections, followed by the same wash volume.</source>
      </segment>
      <segment id="304-11">
        <source xml:space="preserve"> Goat anti-mouse IgG conjugated to AlexaFluor488 (1:1000; Invitrogen, Carlsbad, CA, USA) in 1.5% NGS was applied for 1 hour at room-temperature incubation.</source>
      </segment>
      <segment id="304-12">
        <source xml:space="preserve"> After washing with PBST three times for 5 minutes, 0.4 mg/mL DAPI was applied to sections for 5 minutes to counterstain the nuclei.</source>
      </segment>
      <segment id="304-13">
        <source xml:space="preserve"> Prolong Gold was used in cover slipping the slides.</source>
      </segment>
    </unit>
    <unit id="305">
      <segment id="305">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="306">
      <segment id="306">
        <source xml:space="preserve">Histopathology of NM Induced Injury in Corneal Organ Cultures</source>
      </segment>
    </unit>
    <unit id="307">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="307-0">
        <source xml:space="preserve">Injury inflicted by NM included the following:</source>
      </segment>
      <segment id="307-1">
        <source xml:space="preserve"> (a) hyperplasia of the epithelial layer, which was apparent by the increase in the number and depth of epithelial cells pushing down into the stroma.</source>
      </segment>
      <segment id="307-2">
        <source xml:space="preserve"> This is referred to as downward hyperplasia.</source>
      </segment>
      <segment id="307-3">
        <source xml:space="preserve"> Unexposed (naïve) cornea (<ph id="ph1"/>Fig. 4,<ph id="ph2"/> lower panel) also showed some downward hyperplasia but it wasn't as extensive as cornea exposed to NM (<ph id="ph3"/>Fig. 4<ph id="ph4"/>, upper panel); (b) basal cell nuclei rising up toward the top of the basal epithelial cells; and (c) epithelial-stromal separation.</source>
      </segment>
      <segment id="307-4">
        <source xml:space="preserve"> The histopathological effects were visible as early as four days post-exposure.</source>
      </segment>
    </unit>
    <unit id="308">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="308">
        <source xml:space="preserve">An exemplary histopathological grading scheme for assessing the effects of NM induced corneal injury is shown in <ph id="ph1"/>Fig. 6<ph id="ph2"/>, and NM induced histopathological grading of corneal and stromal injuries is also illustrated in the plot of <ph id="ph3"/>Fig. 7<ph id="ph4"/>.</source>
      </segment>
    </unit>
    <unit id="309">
      <segment id="309">
        <source xml:space="preserve">Treatment of NM exposed corneal cells with TTHX1114 protects against injury</source>
      </segment>
    </unit>
    <unit id="310">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph8">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="310-0">
        <source xml:space="preserve">Treatment of NM-exposed cornea with TTHX1114 protected the cornea from histopathological injury induced by NM.</source>
      </segment>
      <segment id="310-1">
        <source xml:space="preserve"> As seen in <ph id="ph1"/>Fig. 5<ph id="ph2"/>, on day 4 following NM-exposure, the TTHX1114 treated cornea did not exhibit downward hyperplasia (compare upper and lower panels of <ph id="ph3"/>Fig. 5<ph id="ph4"/>).</source>
      </segment>
      <segment id="310-2">
        <source xml:space="preserve"> Further, epithelial-stromal separation, as seen in upper panel of <ph id="ph5"/>Fig. 4<ph id="ph6"/>, was not visible in corneas treated with TTHX1114 (day 6, lower panel, <ph id="ph7"/>Fig. 5<ph id="ph8"/>).</source>
      </segment>
    </unit>
    <unit id="311">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="311-0">
        <source xml:space="preserve">Histopathological grading of NM induced injury was also found to be reduced in corneas treated with TTHX1114.</source>
      </segment>
      <segment id="311-1">
        <source xml:space="preserve"> The results are shown in <ph id="ph1"/>Fig. 8.</source>
      </segment>
    </unit>
    <unit id="312">
      <segment id="312">
        <source xml:space="preserve">TTHX1114 protects NM exposures reduces FGF-1 levels in rabbit cornea</source>
      </segment>
    </unit>
    <unit id="313">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="313-0">
        <source xml:space="preserve">Rabbit corneal sections, exposed to NM, were incubated with anti-FGF-1 antibodies.</source>
      </segment>
      <segment id="313-1">
        <source xml:space="preserve"> In exposed corneas, a reduction of FGF-1 level was observed, as shown in <ph id="ph1"/>Fig. 9.</source>
      </segment>
      <segment id="313-2">
        <source xml:space="preserve"><ph id="ph2"/> Corneal sections exposed to NM, 1 day (upper panel of <ph id="ph3"/>Fig. 9<ph id="ph4"/>), and 3 days (lower panel of <ph id="ph5"/>Fig. 9<ph id="ph6"/>) post-exposure, demonstrated enhanced suppression of FGF-1 compared to naïve corneal sections.</source>
      </segment>
    </unit>
    <unit id="314">
      <segment id="314">
        <source xml:space="preserve">NM exposures induces ADAM17 activation in rabbit cornea</source>
      </segment>
    </unit>
    <unit id="315">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="315-0">
        <source xml:space="preserve">In NM exposed corneas, intense fluorescent signal was observed at the basement membrane zone where the ADAM17 enzyme would need to be positioned in order to degrade collagen XVII (upper panel of <ph id="ph1"/>Fig. 10B<ph id="ph2"/> showing ADAM17 immunofluorescence results on days 1, 4, and 6 post-exposure).</source>
      </segment>
      <segment id="315-1">
        <source xml:space="preserve"> ADAM17 was not appreciably detected in unexposed corneas (<ph id="ph3"/>Fig. 10A<ph id="ph4"/>).</source>
      </segment>
    </unit>
    <unit id="316">
      <segment id="316">
        <source xml:space="preserve">TTHX1114 treatment reduces NM exposure induced ADAM17 activation in rabbit cornea</source>
      </segment>
    </unit>
    <unit id="317">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="317-0">
        <source xml:space="preserve">Upon treatment of corneas with TTH1114, ADAM17 fluorescent signal was attenuated in peripheral and central cornea (lower panel <ph id="ph1"/>Fig. 10B<ph id="ph2"/>).</source>
      </segment>
      <segment id="317-1">
        <source xml:space="preserve"> The attenuation or lack of ADAM17 fluorescent signal corresponded with better histologic appearance of the corneal epithelial-stromal junction.</source>
      </segment>
    </unit>
    <unit id="318">
      <segment id="318">
        <source xml:space="preserve">TTHX1114 treatment ameliorates NM exposure induced suppression of corneal epithelial proliferation</source>
      </segment>
    </unit>
    <unit id="319">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0033" w:id="305"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="305"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph3">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkStart w:name="ncit0034" w:id="306"&gt;&lt;/w:bookmarkStart &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph4">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:bookmarkEnd w:id="306"&gt;&lt;/w:bookmarkEnd &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph5">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph6">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
        <data id="ph7">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:b&gt;&lt;/w:b &gt;&lt;w:bCs&gt;&lt;/w:bCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
      </originalData>
      <segment id="319-0">
        <source xml:space="preserve">Peripheral corneal epithelial layer was stimulation was assessed by via EdU incorporation of corneal epithelial cells (CECs).</source>
      </segment>
      <segment id="319-1">
        <source xml:space="preserve"> Primary cultures of rabbit CECs were established using standard procedures, e.g., the procedure described by Kay et al. ( <ph id="ph1"/>Kay et al.</source>
      </segment>
      <segment id="319-2">
        <source xml:space="preserve"> Investigative ophthalmology &amp; visual science.</source>
      </segment>
      <segment id="319-3">
        <source xml:space="preserve"> 1993;34(3):663-72<ph id="ph2"/>; <ph id="ph3"/>Lee et al., Investigative ophthalmology &amp; visual science.</source>
      </segment>
      <segment id="319-4">
        <source xml:space="preserve"> 2009;50(5):2067-76<ph id="ph4"/>).</source>
      </segment>
      <segment id="319-5">
        <source xml:space="preserve"> The cells are exposed to NM for two hours.</source>
      </segment>
      <segment id="319-6">
        <source xml:space="preserve"> Proliferation assays were performed in 12-well plates using, <ph id="ph5"/>e.g<ph id="ph6"/>., a Click-IT assay kit (Life Technologies).</source>
      </segment>
      <segment id="319-7">
        <source xml:space="preserve"> Incorporation of EdU into corneal epithelial cells were assessed as an indicator of epithelial proliferation.</source>
      </segment>
      <segment id="319-8">
        <source xml:space="preserve"> The percentage corneal epithelial cells incorporating EdU were lower when treated with TTHX1114, following NM-exposure, as seen in <ph id="ph7"/>Fig. 11.</source>
      </segment>
    </unit>
    <unit id="320">
      <segment id="320-0">
        <source xml:space="preserve">Example 12:</source>
      </segment>
      <segment id="320-1">
        <source xml:space="preserve"> Sulfur mustard induced injury of corneal endothelial cells</source>
      </segment>
    </unit>
    <unit id="321">
      <segment id="321-0">
        <source xml:space="preserve">The study is directed towards the effect of modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="321-1">
        <source xml:space="preserve"> 206 (TTHX1114) on treatment of sulfur mustard (SM) induced corneal injury.</source>
      </segment>
      <segment id="321-2">
        <source xml:space="preserve"> The modified FGF-1 polypeptides are generated using methods as described above in the Recombinant Techniques section.</source>
      </segment>
    </unit>
    <unit id="322">
      <segment id="322">
        <source xml:space="preserve">Experimental methods</source>
      </segment>
    </unit>
    <unit id="323">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;w:vertAlign w:val="superscript"&gt;&lt;/w:vertAlign &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="323-0">
        <source xml:space="preserve">Rabbits are exposed in cohorts of 8 to 16 animals during a 4-month period.</source>
      </segment>
      <segment id="323-1">
        <source xml:space="preserve"> One day before exposure, a 4-in<ph id="ph1"/>2<ph id="ph2"/> region on each rabbit's back is clipped, and a fentanyl patch (25 µg/h) is placed anterior to the scapula.</source>
      </segment>
      <segment id="323-2">
        <source xml:space="preserve"> On the day of exposure, rabbits are anesthetized with an intramuscular administration of 15 mg/kg of ketamine and 7 mg/kg of xylazine, and physiological parameters are recorded.</source>
      </segment>
      <segment id="323-3">
        <source xml:space="preserve"> The corneas of anesthetized rabbits are exposed to SM vapor for 2.5 min using a vapor cup delivery system as previously described.</source>
      </segment>
      <segment id="323-4">
        <source xml:space="preserve"> Two minutes after exposure, exposed eyes are gently rinsed with 10 mL sterile saline to flush residual agent.</source>
      </segment>
    </unit>
    <unit id="324">
      <segment id="324-0">
        <source xml:space="preserve">A first group of rabbits are euthanized 24 hours after exposure.</source>
      </segment>
      <segment id="324-1">
        <source xml:space="preserve"> Five minutes after euthanasia, 20 µL of a 0.1 mg/mL solution of AlexaFluor 488 (Life Technologies, Carlsbad, CA) dissolved in PBS (pH 7.4) is injected into the anterior chamber through a 30-gauge needle using a 100-µL Hamilton glass syringe (Hamilton Company, Reno, NV).</source>
      </segment>
      <segment id="324-2">
        <source xml:space="preserve"> After 10 minutes, corneas are excised and washed three times for 1 minute in 10 mL PBS.</source>
      </segment>
      <segment id="324-3">
        <source xml:space="preserve"> Corneas are transferred to 14-mL round-bottom tubes (Becton Dickinson, Franklin Lakes, NJ) with 100 µL PBS and incubated on ice in the dark with gentle agitation.</source>
      </segment>
      <segment id="324-4">
        <source xml:space="preserve"> After 30 minutes, supernatant is diluted 1:5 in PBS and analyzed for fluorescence on a Synergy MX fluorophotometer (Biotek, Winooski, VT) using an excitation wavelength of 488 ± 10 nm, emission wavelength of 524 ± 10 nm, and a gain of 50.</source>
      </segment>
      <segment id="324-5">
        <source xml:space="preserve"> Representative corneas are imaged with a blue diode and FITC filter set in a Versadoc MP 4000 (Bio-Rad Laboratories, Hercules, CA).</source>
      </segment>
    </unit>
    <unit id="325">
      <segment id="325-0">
        <source xml:space="preserve">The remaining rabbits are further divided into a test group, treated with TTHX1114 at varying doses, and a sham control group, treated with control vehicle.</source>
      </segment>
      <segment id="325-1">
        <source xml:space="preserve"> The treatments are carried out for about two weeks.</source>
      </segment>
      <segment id="325-2">
        <source xml:space="preserve"> Rabbits are returned to cages and provided food and water ad libitum.</source>
      </segment>
      <segment id="325-3">
        <source xml:space="preserve"> Fentanyl patches are replaced after every 72 hours to manage discomfort through 6 days after the exposure and applied liberally thereafter as needed.</source>
      </segment>
      <segment id="325-4">
        <source xml:space="preserve"> Animals are monitored daily for signs of pain and distress.</source>
      </segment>
      <segment id="325-5">
        <source xml:space="preserve"> Corneal injury is clinically evaluated on a regular basis using pachymetry, fluorescein exclusion assays, and slit-lamp evaluations.</source>
      </segment>
    </unit>
    <unit id="326">
      <segment id="326">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="327">
      <segment id="327">
        <source xml:space="preserve">Sulfur Mustard (SM) exposure causes corneal endothelial injury</source>
      </segment>
    </unit>
    <unit id="328">
      <segment id="328-0">
        <source xml:space="preserve">Corneas visualized at 370 nm by SEM 24 hours after SM exposure exhibit a centripetal injury, with extensive loss of corneal endothelial cells (CECs) in the central cornea and increased retention toward the exposure margins.</source>
      </segment>
      <segment id="328-1">
        <source xml:space="preserve"> To obtain a more comprehensive overview of SM-induced changes in the corneal endothelium, the fine structure of the posterior cornea is evaluated by electron microscopy.</source>
      </segment>
      <segment id="328-2">
        <source xml:space="preserve"> Enface scanning electron micrographs of sham-exposed corneas reveals a continuous layer of polygonal cells of regular shape and size, with interdigitated borders, apical microvilli, and infrequent cilia.</source>
      </segment>
      <segment id="328-3">
        <source xml:space="preserve"> Within 24 hours of exposure, all corneal endothelia exhibit evidence of an acute lesion, with extensive central CEC loss and more diffuse vesication in the exposure penumbra.</source>
      </segment>
      <segment id="328-4">
        <source xml:space="preserve"> The CECs within the exposed region displayed two general morphologies, namely, enlarged (highly attenuated) polymorphic cells and rounded or spindle-shaped cells.</source>
      </segment>
      <segment id="328-5">
        <source xml:space="preserve"> Most CECs exhibit atypical apical membrane morphologies and lack cell-to-cell interdigitations.</source>
      </segment>
      <segment id="328-6">
        <source xml:space="preserve"> In regions of CEC vesication, denuded Descemet's membrane (DM) is covered by a complex arbor of CEC lamellipodia and filopodia.</source>
      </segment>
      <segment id="328-7">
        <source xml:space="preserve"> The TEM imaging of corneal cross-sections confirmed the centripetal injury pattern, with CEC morphology progressively normalizing toward the injury margin.</source>
      </segment>
      <segment id="328-8">
        <source xml:space="preserve"> Denuded DM near the central lesion is infiltrated by extensively arborized cellular processes.</source>
      </segment>
      <segment id="328-9">
        <source xml:space="preserve"> At more distal regions, overlapping cellular processes with loss of junctional complexes is common, suggestive of a motile population.</source>
      </segment>
      <segment id="328-10">
        <source xml:space="preserve"> The rounded CEC population observed by SEM is found exclusively overlying polymorphic endothelium and display signs of necrosis or apoptosis.</source>
      </segment>
    </unit>
    <unit id="329">
      <segment id="329">
        <source xml:space="preserve">Treatment with TTHX1114 resolves corneal endothelial injuries</source>
      </segment>
    </unit>
    <unit id="330">
      <segment id="330-0">
        <source xml:space="preserve">Eight weeks after exposure, endothelial cell morphology and structure are compared between test group (also referred to as resolved) and sham control group (which later develops MGK).</source>
      </segment>
      <segment id="330-1">
        <source xml:space="preserve"> Resolved eyes are distinguished by the absence of characteristic MGK sequelae during clinical evaluations such as corneal erosions, neovascularization, or corneal haze and had corneal thicknesses that are statistically indistinguishable from sham-exposed controls by 6 weeks.</source>
      </segment>
      <segment id="330-2">
        <source xml:space="preserve"> Enface scanning micrographs of resolved eyes are found to be strikingly similar to sham-exposed controls, with a well-organized monolayer of polygonal cells.</source>
      </segment>
      <segment id="330-3">
        <source xml:space="preserve"> The average CEC size is increased in resolved eyes compared with control corneas; otherwise, resolved corneas do not exhibit significant variability across the posterior surface.</source>
      </segment>
      <segment id="330-4">
        <source xml:space="preserve"> In contrast, the sham-control treated rabbits with MGK endothelia reveal extensive variability in cell shape and cell size among animals, indicative of a dynamic injury process.</source>
      </segment>
      <segment id="330-5">
        <source xml:space="preserve"> Focal variability in endothelial morphology is routinely observed in individual corneas, with some regions exhibiting enlarged but mosaic CECs and other regions displaying significant disorganization, with variable degrees of apical blebbing, areas showing denuded DM, and clearly delineated cell boundaries lacking.</source>
      </segment>
      <segment id="330-6">
        <source xml:space="preserve"> These phenomena are not observed in the TTHX1114 treated resolved enodthelium.</source>
      </segment>
      <segment id="330-7">
        <source xml:space="preserve"> Transmission Electron Microscope images of TTHX1 114 treated resolved corneas is very similar to naïve endothelium.</source>
      </segment>
      <segment id="330-8">
        <source xml:space="preserve"> In contrast, sham-control treated endothelium with MGK pathology exhibit diffusive thickening of the posterior DM, consistent with either edema and/or the deposition of a retrocorneal fibrous membrane.</source>
      </segment>
      <segment id="330-9">
        <source xml:space="preserve"> The MGK corneas also exhibit extensive markers of CEC stress or injury, including cytoplasmic rarefication, excessive vacuolization, and swollen endoplasmic reticuli.</source>
      </segment>
      <segment id="330-10">
        <source xml:space="preserve"> There is a high frequency of overlapping cell processes, similar to 24-hour images and suggestive of an ongoing attempt to repopulate recently denuded DM.</source>
      </segment>
    </unit>
    <unit id="331">
      <segment id="331-0">
        <source xml:space="preserve">Example 13:</source>
      </segment>
      <segment id="331-1">
        <source xml:space="preserve"> Treatment of herpetic keratopathy using a modified FGF-1 polypeptide (TTHX1114)</source>
      </segment>
    </unit>
    <unit id="332">
      <segment id="332-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptide comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="332-1">
        <source xml:space="preserve"> 206 (TTHX1114) for the treatment of herpetic keratopathy.</source>
      </segment>
    </unit>
    <unit id="333">
      <segment id="333">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="334">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="334-0">
        <source xml:space="preserve">A group of patients with herpetic keratopathy is selected for this study.</source>
      </segment>
      <segment id="334-1">
        <source xml:space="preserve"> The patients are divided into two subgroups.</source>
      </segment>
      <segment id="334-2">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml <ph id="ph1"/>(i.e., 5<ph id="ph2"/> µg/ml) of TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="334-3">
        <source xml:space="preserve"> 206) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="334-4">
        <source xml:space="preserve"> Patients in the second sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="334-5">
        <source xml:space="preserve"> 206) but is otherwise identical to what is administered to the first and the second sub-group.</source>
      </segment>
      <segment id="334-6">
        <source xml:space="preserve"> For both subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="334-7">
        <source xml:space="preserve"> The TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="334-8">
        <source xml:space="preserve"> 206) containing ophthalmic formulation and the sham ophthalmic formulation are administered, respectively to patients in the first and second sub-groups, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="335">
      <segment id="335">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="336">
      <segment id="336-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulation containing the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="336-1">
        <source xml:space="preserve"> 206) results in healing of the herpetic corneal ulcer within about 14 days in majority of the patients belonging to the first sub-group, along with reduction in the duration of pain and inflammation.</source>
      </segment>
      <segment id="336-2">
        <source xml:space="preserve"> Furthermore, eyes of patients in the first sub-group, treated with the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="336-3">
        <source xml:space="preserve"> 206) containing ophthalmic formulation have less corneal haze and scarring than patients in the third sub-group, who were treated with the sham.</source>
      </segment>
    </unit>
    <unit id="337">
      <segment id="337-0">
        <source xml:space="preserve">Example 14:</source>
      </segment>
      <segment id="337-1">
        <source xml:space="preserve"> Treatment of chronic herpetic keratopathy using a modified FGF-1 polypeptide (TTHX1114)</source>
      </segment>
    </unit>
    <unit id="338">
      <segment id="338-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptide comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="338-1">
        <source xml:space="preserve"> 206 (TTHX1114)</source>
      </segment>
    </unit>
    <unit id="339">
      <segment id="339">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="340">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="340-0">
        <source xml:space="preserve">A group of patients with chronic herpetic keratopathy is selected for this study.</source>
      </segment>
      <segment id="340-1">
        <source xml:space="preserve"> The patients are divided into two subgroups.</source>
      </segment>
      <segment id="340-2">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml <ph id="ph1"/>(i.e., 5<ph id="ph2"/> µg/ml) of N-Met-TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="340-3">
        <source xml:space="preserve"> 2) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="340-4">
        <source xml:space="preserve"> Patients in the second sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="340-5">
        <source xml:space="preserve"> 206) but is otherwise identical to what is administered to the first and the second sub-group.</source>
      </segment>
      <segment id="340-6">
        <source xml:space="preserve"> For both subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="340-7">
        <source xml:space="preserve"> The TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="340-8">
        <source xml:space="preserve"> 206) containing ophthalmic formulation and the sham ophthalmic formulation are administered, respectively to patients in the first and second sub-group, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="341">
      <segment id="341">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="342">
      <segment id="342-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulation containing the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="342-1">
        <source xml:space="preserve"> 206) result in healing of corneal ulcer in majority of the patients belonging to the first sub-group, along with reduction in of pain and inflammation.</source>
      </segment>
      <segment id="342-2">
        <source xml:space="preserve"> Furthermore, eyes of patients in the first sub-groups, treated with the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="342-3">
        <source xml:space="preserve"> 206) containing ophthalmic formulation have less corneal opacity haze and scarring than patients in the third sub-group, who are treated with the sham.</source>
      </segment>
    </unit>
    <unit id="343">
      <segment id="343-0">
        <source xml:space="preserve">Example 15:</source>
      </segment>
      <segment id="343-1">
        <source xml:space="preserve"> Treatment of neurotrophic keratopathy using a modified FGF-1 polypeptide (TTHX1114)</source>
      </segment>
    </unit>
    <unit id="344">
      <segment id="344-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptide comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="344-1">
        <source xml:space="preserve"> 206 (TTHX1114) for the treatment of neurotrophic keratopathy secondary to herpes infection.</source>
      </segment>
    </unit>
    <unit id="345">
      <segment id="345">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="346">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="346-0">
        <source xml:space="preserve">A group of patients with neurotrophic keratopathy is selected for this study.</source>
      </segment>
      <segment id="346-1">
        <source xml:space="preserve"> The patients are divided into two subgroups.</source>
      </segment>
      <segment id="346-2">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 500 pg/ml <ph id="ph1"/>(i.e., 5<ph id="ph2"/> µg/ml) of TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="346-3">
        <source xml:space="preserve"> 206) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="346-4">
        <source xml:space="preserve"> Patients in the second sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="346-5">
        <source xml:space="preserve"> 206) but is otherwise identical to what is administered to the first sub-group.</source>
      </segment>
      <segment id="346-6">
        <source xml:space="preserve"> For both subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="346-7">
        <source xml:space="preserve"> The TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="346-8">
        <source xml:space="preserve"> 206) containing ophthalmic formulation and the sham ophthalmic formulation are administered, respectively to patients in the first and the second sub-group, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="347">
      <segment id="347">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="348">
      <segment id="348-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulation containing the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="348-1">
        <source xml:space="preserve"> 206) results in healing of corneal ulcer in majority of the patients belonging to the first sub-group, along with reduction in of pain and inflammation.</source>
      </segment>
      <segment id="348-2">
        <source xml:space="preserve"> Furthermore, eyes of patients in the first sub-group, treated respectively with the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="348-3">
        <source xml:space="preserve"> 206) containing ophthalmic formulation, have less corneal opacity haze and scarring than patients in the third sub-group, who are treated with the sham.</source>
      </segment>
    </unit>
    <unit id="349">
      <segment id="349-0">
        <source xml:space="preserve">Example 16:</source>
      </segment>
      <segment id="349-1">
        <source xml:space="preserve"> Treatment of recurrent herpetic keratopathy and the suppression of reactivation of latent virus using a modified FGF-1 polypeptide (TTHX1114)</source>
      </segment>
    </unit>
    <unit id="350">
      <segment id="350-0">
        <source xml:space="preserve">This study is directed towards using a modified FGF-1 polypeptides comprising the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="350-1">
        <source xml:space="preserve"> 206 (TTHX1114) for the treatment of neurotrophic keratopathy secondary to herpes infection.</source>
      </segment>
    </unit>
    <unit id="351">
      <segment id="351">
        <source xml:space="preserve">Methods</source>
      </segment>
    </unit>
    <unit id="352">
      <originalData>
        <data id="ph1">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r w:rsidRPr="00BD7333"&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:i&gt;&lt;/w:i &gt;&lt;w:iCs&gt;&lt;/w:iCs &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;&lt;w:r&gt;&lt;w:rPr&gt;&lt;w:rFonts w:ascii="Courier New" w:hAnsi="Courier New"&gt;&lt;/w:rFonts &gt;&lt;w:szCs w:val="22"&gt;&lt;/w:szCs &gt;&lt;/w:rPr &gt;&lt;w:t xml:space="preserve"&gt;</data>
      </originalData>
      <segment id="352-0">
        <source xml:space="preserve">A group of patients with recurrent keratopathy is selected for this study.</source>
      </segment>
      <segment id="352-1">
        <source xml:space="preserve"> The patients have experienced at least one episode of herpetic keratopathy.</source>
      </segment>
      <segment id="352-2">
        <source xml:space="preserve"> For treatment of recurrent herpetic keratopathy and the suppression of reactivation of latent virus, the patients are divided into two subgroups.</source>
      </segment>
      <segment id="352-3">
        <source xml:space="preserve"> Patients in the first sub-group are administered, ocularly, an ophthalmic formulation, such as an eye drop, containing about 50 pg/ml to about 500 pg/ml <ph id="ph1"/>(i.e., 5<ph id="ph2"/> µg/ml) of TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="352-4">
        <source xml:space="preserve"> 206) formulated in phosphate buffered saline (at pH 7.2), 0.3% propylene glycol, 0.4% polyethylene glycol 400, and 0.05% hydroxypropyl guar.</source>
      </segment>
      <segment id="352-5">
        <source xml:space="preserve"> Patients in the third sub-group are administered, ocularly, a sham ophthalmic formulation that does not contain the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="352-6">
        <source xml:space="preserve"> 206) but is otherwise identical to what is administered to the first and the second sub-group.</source>
      </segment>
      <segment id="352-7">
        <source xml:space="preserve"> For both subgroups, the eye drop is either self-administered by the patient or administered by a nurse or a caregiver.</source>
      </segment>
      <segment id="352-8">
        <source xml:space="preserve"> The TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="352-9">
        <source xml:space="preserve"> 206) containing ophthalmic formulation and the sham ophthalmic formulation are administered, respectively to patients in the first and the second sub-group, twice daily for up to 30 days.</source>
      </segment>
    </unit>
    <unit id="353">
      <segment id="353">
        <source xml:space="preserve">Results</source>
      </segment>
    </unit>
    <unit id="354">
      <segment id="354-0">
        <source xml:space="preserve">It is observed that the ophthalmic formulation containing the TTHX1114 (SEQ ID NO:</source>
      </segment>
      <segment id="354-1">
        <source xml:space="preserve"> 206) increases the disease free interval and reduces the severity of the reactivated virus lesions, with patients receiving the modified FGF-1 having a longer period of time without recurrent disease than patients in the second sub-group, who are treated with the sham.</source>
      </segment>
    </unit>
    <unit id="355">
      <segment id="355">
        <source xml:space="preserve">SEQUENCES</source>
      </segment>
    </unit>
    <unit id="356">
      <segment id="356">
        <source xml:space="preserve">SEQUENCE</source>
      </segment>
    </unit>
    <unit id="357">
      <segment id="357">
        <source xml:space="preserve">No.</source>
      </segment>
    </unit>
    <unit id="358">
      <segment id="358">
        <source xml:space="preserve">MAECEITTFTALTEK</source>
      </segment>
    </unit>
    <unit id="359">
      <segment id="359">
        <source xml:space="preserve">ALTEK</source>
      </segment>
    </unit>
    <unit id="360">
      <segment id="360">
        <source xml:space="preserve">LTEK</source>
      </segment>
    </unit>
    <unit id="361">
      <segment id="361">
        <source xml:space="preserve">TEK</source>
      </segment>
    </unit>
    <unit id="362">
      <segment id="362">
        <source xml:space="preserve">EK</source>
      </segment>
    </unit>
    <unit id="363">
      <segment id="363">
        <source xml:space="preserve">K</source>
      </segment>
    </unit>
    <unit id="364">
      <segment id="364">
        <source xml:space="preserve">RIVENDICAZIONI</source>
      </segment>
    </unit>
    <unit id="365">
      <segment id="365-0">
        <source xml:space="preserve">1.</source>
      </segment>
      <segment id="365-1">
        <source xml:space="preserve"> A recombinant modified FGF-1 polypeptide comprising the sequence set forth as SEQ ID NO:</source>
      </segment>
      <segment id="365-2">
        <source xml:space="preserve"> 1 with (i) an N-terminal methionine residue positioned upstream to the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="365-3">
        <source xml:space="preserve"> 1, and (ii) at least the mutations:</source>
      </segment>
      <segment id="365-4">
        <source xml:space="preserve"> Cys16Ser, Ala66Cys, and Cys117Val with respect to the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="365-5">
        <source xml:space="preserve"> 1.</source>
      </segment>
    </unit>
    <unit id="366">
      <segment id="366-0">
        <source xml:space="preserve">2.</source>
      </segment>
      <segment id="366-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of claim 1, wherein the modified FGF-1 polypeptide further comprises at least one mutation selected from the group consisting of:</source>
      </segment>
      <segment id="366-2">
        <source xml:space="preserve"> Lys12Val and Pro134Val.</source>
      </segment>
    </unit>
    <unit id="367">
      <segment id="367-0">
        <source xml:space="preserve">3.</source>
      </segment>
      <segment id="367-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of claim 1 or 2, wherein the polypeptide further comprises an extension peptide positioned between the N-terminal methionine residue and the first residue of SEQ ID NO:</source>
      </segment>
      <segment id="367-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
    </unit>
    <unit id="368">
      <segment id="368-0">
        <source xml:space="preserve">4.</source>
      </segment>
      <segment id="368-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of claim 3, wherein the extension peptide comprises one or more amino acid residues of SEQ ID NO:</source>
      </segment>
      <segment id="368-2">
        <source xml:space="preserve"> 3.</source>
      </segment>
    </unit>
    <unit id="369">
      <segment id="369-0">
        <source xml:space="preserve">5.</source>
      </segment>
      <segment id="369-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of claim 4, wherein the extension peptide comprises any one of the sequences set forth in SEQ ID NOS. 4-8.</source>
      </segment>
    </unit>
    <unit id="370">
      <segment id="370-0">
        <source xml:space="preserve">6.</source>
      </segment>
      <segment id="370-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of any one of claims 1-5, wherein the modified FGF-1 polypeptide is the mature form of the polypeptide.</source>
      </segment>
    </unit>
    <unit id="371">
      <segment id="371-0">
        <source xml:space="preserve">7.</source>
      </segment>
      <segment id="371-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of any one of claims 1-6, wherein the polypeptide further comprises a truncation of one or more of the first five residues on SEQ ID NO:</source>
      </segment>
      <segment id="371-2">
        <source xml:space="preserve"> 1.</source>
      </segment>
    </unit>
    <unit id="372">
      <segment id="372-0">
        <source xml:space="preserve">8.</source>
      </segment>
      <segment id="372-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of any one of claims 1-7, wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NOS:</source>
      </segment>
      <segment id="372-2">
        <source xml:space="preserve"> 2, 14-18, 41-44, 118-141, and 207.</source>
      </segment>
    </unit>
    <unit id="373">
      <segment id="373-0">
        <source xml:space="preserve">9.</source>
      </segment>
      <segment id="373-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of claim 8, wherein the polypeptide comprises the sequence of SEQ ID NO:</source>
      </segment>
      <segment id="373-2">
        <source xml:space="preserve"> 2.</source>
      </segment>
    </unit>
    <unit id="374">
      <segment id="374-0">
        <source xml:space="preserve">10.</source>
      </segment>
      <segment id="374-1">
        <source xml:space="preserve"> A pharmaceutical composition comprising the recombinant polypeptide of any one of claims 1-9, wherein the pharmaceutical composition further comprises, optionally, a pharmaceutically acceptable carrier, excipient, diluent, or any combinations thereof.</source>
      </segment>
    </unit>
    <unit id="375">
      <segment id="375-0">
        <source xml:space="preserve">11.</source>
      </segment>
      <segment id="375-1">
        <source xml:space="preserve"> The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is a liquid ophthalmic formulation.</source>
      </segment>
    </unit>
    <unit id="376">
      <segment id="376-0">
        <source xml:space="preserve">12.</source>
      </segment>
      <segment id="376-1">
        <source xml:space="preserve"> The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is administered topically, using microneedle into the cornea, or intracamerally.</source>
      </segment>
    </unit>
    <unit id="377">
      <segment id="377-0">
        <source xml:space="preserve">13.</source>
      </segment>
      <segment id="377-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide of any one of claims 1-9, or the pharmaceutical composition of any one of claims 10-12, for use in treating or preventing at least one of:</source>
      </segment>
      <segment id="377-2">
        <source xml:space="preserve"> (i) a chemical or vesicant induced injury; (ii) a disease, disorder, or condition of the corneal endothelium; (iii) a long-term corneal endothelial injury; (iv) a corneal ulcer, and (v) a herpetic keratopathy.</source>
      </segment>
    </unit>
    <unit id="378">
      <segment id="378-0">
        <source xml:space="preserve">14.</source>
      </segment>
      <segment id="378-1">
        <source xml:space="preserve"> The recombinant modified FGF-1 polypeptide for the use according to claim 13, wherein the chemical or vesicant induced injury is an ocular injury or a skin injury.</source>
      </segment>
    </unit>
    <unit id="379">
      <segment id="379">
        <source xml:space="preserve">TRADUZIONE DELLE DIDASCALIE DELLE FIGURE </source>
      </segment>
    </unit>
    <unit id="380">
      <segment id="380">
        <source xml:space="preserve">Figura X</source>
      </segment>
    </unit>
    <unit id="381">
      <segment id="381">
        <source xml:space="preserve">Originale</source>
      </segment>
    </unit>
    <unit id="382">
      <segment id="382">
        <source xml:space="preserve">Traduzione</source>
      </segment>
    </unit>
    <unit id="383">
      <segment id="383">
        <source xml:space="preserve">Figura X</source>
      </segment>
    </unit>
    <unit id="384">
      <segment id="384">
        <source xml:space="preserve">Originale</source>
      </segment>
    </unit>
    <unit id="385">
      <segment id="385">
        <source xml:space="preserve">Traduzione</source>
      </segment>
    </unit>
  </file>
  <file original="/Volumes/SSD_1_ext/CODING/WeGentic/Weg-Translator-Tauri/weg-translator/Test.docx" id="2">
    <skeleton href="/Volumes/SSD_1_ext/CODING/WeGentic/Weg-Translator-Tauri/weg-translator/Test.docx.skl"/>
    <mda:metadata>
      <mda:metaGroup category="format">
        <mda:meta type="datatype">x-office</mda:meta>
      </mda:metaGroup>
      <mda:metaGroup category="document">
        <mda:meta type="original">word/header1.xml</mda:meta>
      </mda:metaGroup>
      <mda:metaGroup category="tool">
        <mda:meta type="tool-id">OpenXLIFF</mda:meta>
        <mda:meta type="tool-name">OpenXLIFF Filters</mda:meta>
        <mda:meta type="tool-version">4.8.0 20250802_1047</mda:meta>
      </mda:metaGroup>
      <mda:metaGroup category="PI">
        <mda:meta type="encoding">UTF-8</mda:meta>
      </mda:metaGroup>
    </mda:metadata>
    <unit id="0">
      <originalData>
        <data id="ph1">&lt;/w:txbxContent &gt;&lt;/v:textbox &gt;&lt;/v:shape &gt;&lt;/w:pict &gt;&lt;/mc:Fallback &gt;&lt;/mc:AlternateContent &gt;&lt;/w:r &gt;&lt;w:r w:rsidR="00861015"&gt;&lt;w:tab&gt;&lt;/w:tab &gt;&lt;/w:r &gt;&lt;w:r w:rsidR="00BB6886" w:rsidRPr="00BB6886"&gt;&lt;w:t&gt;</data>
        <data id="ph2">&lt;/w:t &gt;&lt;/w:r &gt;</data>
      </originalData>
      <ignorable>
        <source xml:space="preserve"><ph id="ph1"/></source>
      </ignorable>
      <segment id="0">
        <source xml:space="preserve">B179225</source>
      </segment>
      <ignorable>
        <source xml:space="preserve"><ph id="ph2"/></source>
      </ignorable>
    </unit>
  </file>
</xliff>